BRAF V600 Mutant Melanoma

MONDO:0005012 Pathograph 24 Show in embeddings browser cutaneous melanoma

BRAF V600-mutant melanoma is a molecularly defined subtype of cutaneous melanoma in which tumor cells carry an activating somatic substitution at BRAF codon 600. V600E is the dominant allele, followed by V600K; V600R and V600M are uncommon and have a smaller treatment-evidence base. Codon-600 mutants are class-I BRAF proteins that signal as RAS-independent active monomers, sustaining MEK-ERK output. The driver can initiate melanocytic proliferation, but experimental models show that BRAF V600E alone often produces benign hyperplasia or a growth-arrest barrier; cooperating lesions such as PTEN loss enable malignant and metastatic progression. Stage and exact allele matter clinically. Resectable disease is managed surgically, while immune-checkpoint therapy and combined BRAF/MEK inhibition are major systemic options in advanced disease. Acquired resistance commonly restores MAPK signaling or engages bypass and adaptive programs.

Ask OpenScientist

Ask a research question about BRAF V600 Mutant Melanoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
8
Pathophys.
1
Histopath.
3
Phenotypes
2
Hypotheses
4
Gaps
24
Pathograph
4
Genes
6
Medical Actions
3
Subtypes
2
Differentials
1
Datasets
6
Trials
5
Models
30
References
2
Deep Research
🏷

Classifications

ICD-O Morphology
Melanoma
Harrison's Part
ONCOLOGY HEMATOLOGY
🔗

Mappings

MONDO
MONDO:0005012 cutaneous melanoma
skos:narrowMatch MONDO
BRAF V600-mutant melanoma is a molecularly defined stratum of MONDO's cutaneous melanoma class, not the class itself: MONDO has no term for the BRAF V600E/K kinase-domain mutation stratum, so `disease_term` anchors to the parent term while this narrowMatch records that the entry is narrower than it. Required by design decisions section 3a for a promoted L4 biomarker stratum, which must never present bare parent-term reuse as an exact match; the parent term itself is claimed as an exactMatch by Cutaneous_Melanoma. Filing a MONDO NTR for this stratum is a tracked follow-up.
◆

Subtypes

3
BRAF V600E Melanoma
Melanoma carrying the somatic BRAF p.Val600Glu substitution. V600E was the dominant V600 allele in the cited molecular-testing cohort and has the deepest clinical-trial evidence base.
Show evidence (1 reference)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The molecular-testing cohort identifies V600E as the dominant V600 allele.
BRAF V600K Melanoma
Melanoma carrying the somatic BRAF p.Val600Lys substitution. V600K is less common than V600E but was included with V600E in the pivotal advanced and adjuvant BRAF/MEK trials represented here.
Show evidence (2 references)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The molecular-testing cohort identifies V600K as the second most common V600 allele.
PMID:31166680 SUPPORT Human Clinical
"Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors."
The pooled phase-III analysis directly includes V600E and V600K melanoma.
Rare BRAF V600 Melanoma
Melanoma carrying another codon-600 substitution, including V600R or V600M. These alleles activate the same codon hotspot but are uncommon, and evidence from V600E/K-dominant registration trials must not be generalized to every rare V600 allele without allele-specific assessment.
Show evidence (2 references)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The cohort directly documents the rare V600R and V600M alleles.
PMID:28592387 SUPPORT Human Clinical
"BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases"
COMBI-MB supplies limited prospective inclusion of non-E V600 alleles but not broad evidence for every rare allele.
◈

Mechanistic Hypotheses

2
Canonical BRAF V600 Melanoma Model
canonical_braf_v600_melanoma_model CANONICAL
Evidence balance 2 support
A somatic class-I BRAF codon-600 mutant drives RAS-independent MEK-ERK signaling and melanocyte proliferation. BRAF V600E alone can generate benign melanocytic hyperplasia or oncogene-induced arrest, so malignant progression requires additional permissive changes. PTEN loss is a experimentally established cooperating route that activates PI3K-AKT-mTOR survival signaling and permits invasive, metastatic melanoma.
Pathograph links
Somatic BRAF Codon-600 Driver -> Sustained MEK-ERK Signaling DIRECT Constitutive class-I BRAF kinase output activates the downstream MEK-ERK cascade without an upstream RAS requirement.
Somatic BRAF Codon-600 Driver -> Oncogene-Induced Melanocytic Growth-Arrest Barrier INDIRECT KNOWN INTERMEDIATES In melanocytes, BRAF V600E can initiate benign hyperplasia followed by a durable growth-arrest barrier. Intermediates: excessive oncogenic signaling; cellular senescence program
Sustained MEK-ERK Signaling -> MAPK-Dependent Melanocyte Proliferation and Survival DIRECT Sustained ERK output maintains cell-cycle progression and survival in BRAF-driven melanoma cells.
MAPK-Dependent Melanocyte Proliferation and Survival -> Cutaneous Melanoma INDIRECT KNOWN INTERMEDIATES MAPK-dependent expansion contributes to the cutaneous melanoma phenotype when cooperating progression barriers are overcome. Intermediates: clonal melanocyte expansion; escape from oncogene-induced growth arrest; malignant transformation
PTEN-Loss and PI3K-AKT-mTOR Cooperation -> Invasive and Metastatic Melanoma Progression INDIRECT KNOWN INTERMEDIATES In the conditional model, PTEN loss converts BRAF-initiated hyperplasia into rapidly penetrant metastatic melanoma. Intermediates: escape from growth arrest; enhanced tumor-cell survival; invasive clonal expansion
Show evidence (2 references)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The foundational functional study establishes mutant-BRAF kinase activation and transforming capacity.
PMID:19282848 SUPPORT Model Organism
"Expression of BRaf(V600E) combined with Pten tumor suppressor gene silencing elicited development of melanoma with 100% penetrance."
The conditional mouse model directly demonstrates cooperation between the driver and PTEN loss.
Acquired BRAF/MEK-Inhibitor Resistance Model
acquired_mapk_inhibitor_resistance_model CANONICAL
Evidence balance 2 support
MAPK-pathway inhibition selects for heterogeneous tumor-cell states and clones. Resistant disease can restore ERK output through secondary NRAS or MEK alterations and other MAPK routes, engage PI3K-AKT or receptor-kinase bypass signaling, or adopt reversible transcriptional and metabolic states. No single mechanism explains every progressing lesion.
Pathograph links
Acquired MAPK Reactivation and Adaptive Resistance -> Progressive Metastatic Disease INDIRECT KNOWN INTERMEDIATES Restored or bypass signaling permits renewed tumor growth during targeted therapy. Intermediates: restoration of tumor-cell proliferation; survival of drug-tolerant clones; expansion of resistant lesions
Show evidence (2 references)
PMID:23569304 SUPPORT Human Clinical
"Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions."
Serial human biopsies directly demonstrate MAPK reactivation at progression.
PMID:24610826 SUPPORT Other
"Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS."
The mechanistic review supports metabolic adaptation as one component of resistance, not a universal route.
?

Discussions and Knowledge Gaps

4
How much efficacy evidence can be generalized from V600E/K registration trials to rare V600R, V600M, V600D, or other codon-600 alleles?
KNOWLEDGE GAP OPEN interpretation_rare_v600_allele_actionability
Attached to
genetic#BRAF p.Val600Arg genetic#BRAF p.Val600Met
Molecular testing confirms that rare V600 alleles exist, but the pivotal adjuvant and metastatic trials are dominated by or restricted to V600E/K. COMBI-MB included a small V600D/K/R cohort, which is not enough to assume identical efficacy for every rare allele and disease stage.
Show evidence (1 reference)
PMID:28592387 SUPPORT Human Clinical
"BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases"
The small mixed-allele cohort makes the evidence boundary explicit.
Which patients with treatment-naive metastatic BRAF V600 melanoma should begin with checkpoint immunotherapy, targeted therapy, or a short planned targeted induction?
INTERPRETATION OPEN interpretation_first_line_systemic_sequence
Attached to
treatments#Immune Checkpoint Blockade treatments#Dabrafenib Plus Trametinib for Unresectable or Metastatic Disease treatments#Encorafenib Plus Binimetinib
DREAMseq and SECOMBIT support immunotherapy first for most enrolled patients, while current guidance still allows BRAF/MEK inhibition first in selected cases. Rapidly progressive symptomatic disease, brain metastases, prior adjuvant therapy, contraindications, and the limited feasibility of crossover make individual sequencing more nuanced than a universal rule.
Show evidence (2 references)
PMID:36166727 SUPPORT Human Clinical
"Crossover occurred in 52% of patients with documented disease progression."
Limited crossover feasibility is directly relevant to real sequencing decisions.
PMID:39709737 SUPPORT Other
"In stage IV melanoma with a BRAFV600 mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy, in selected cases."
Current guidance preserves a selected-case targeted-first option.
Can postoperative or on-treatment BRAF V600 ctDNA be used prospectively to start, intensify, de-escalate, or switch therapy?
KNOWLEDGE GAP OPEN gap_ctdna_guided_intervention
Attached to
biochemical#Plasma BRAF V600 Circulating Tumor DNA
COMBI-d, COMBI-MB, and COMBI-AD biomarker analyses show prognostic association and useful kinetics, but they did not validate a ctDNA-directed intervention strategy.
Show evidence (1 reference)
PMID:40250457 SUPPORT Human Clinical
"Additional studies using ctDNA measurements to guide therapeutic interventions might lead to improvements in the management of resected stage III melanoma."
The authors explicitly identify intervention-guiding validation as future work.
Which cooperating lesions and cell states are necessary and sufficient for BRAF V600-initiated human melanocytes to become invasive and metastatic?
HUMAN MODEL MISMATCH OPEN gap_human_progression_model_fidelity
Attached to
pathophysiology#PTEN-Loss and PI3K-AKT-mTOR Cooperation
Conditional mouse and zebrafish models establish multi-hit progression and provide tractable systems, but engineered germline or synchronous driver combinations do not reproduce the timing, UV background, clonal diversity, and immune history of every human tumor.
Show evidence (1 reference)
PMID:24148783 SUPPORT Model Organism
"Engineered zebrafish melanomas show an overall low mutation burden."
The model's low-burden, no-UV context exposes a clear mismatch with many human cutaneous melanomas.
⚙

Pathophysiology

8
Somatic BRAF Codon-600 Driver
A tumor-acquired missense substitution at BRAF codon 600 destabilizes the inactive kinase configuration. Codon-600 mutants constitute class-I BRAF: they are active without upstream RAS, signal as monomers, and differ mechanistically from class-II dimers and RAS-dependent class-III mutants.
Canonical BRAF V600 Melanoma Model
BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee.
protein serine/threonine kinase activity GO:0004674 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves increased protein serine/threonine kinase activity (GO:0004674). GO:0004674 is a molecular function from the Gene Ontology. ↑ INCREASED
Experimental models
NIH3T3 Mutant-BRAF Transformation Assay CELL LINE Tests kinase activation and transforming capacity conferred by melanoma-derived BRAF mutations.
Downstream
Sustained MEK-ERK Signaling Constitutive class-I BRAF kinase output activates the downstream MEK-ERK cascade without an upstream RAS requirement. Canonical BRAF V600 Melanoma Model
Oncogene-Induced Melanocytic Growth-Arrest Barrier In melanocytes, BRAF V600E can initiate benign hyperplasia followed by a durable growth-arrest barrier. Canonical BRAF V600 Melanoma Model
Show evidence (2 references)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The foundational study functionally establishes kinase activation and transformation.
PMID:28783719 SUPPORT In Vitro
"Activating BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and signal either as active monomers (class 1) or constitutively active dimers (class 2)."
The functional-classification study places V600 alleles in the RAS-independent monomeric class.
Sustained MEK-ERK Signaling
Constitutive mutant-BRAF output maintains the RAF-MEK-ERK cascade, which controls proliferative and survival programs in the melanocytic lineage. The pathway remains pharmacologically actionable because inhibition at both BRAF and MEK reduces pathway output and delays, but does not eliminate, resistance.
Canonical BRAF V600 Melanoma Model
ERK1 and ERK2 cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Xiphophorus Gordon-Kosswig-Anders backcross hybrid melanoma Xiphophorus maculatus x Xiphophorus hellerii partially recapitulates Ligand-independent Xmrk signalling drives the same Ras/Raf/MEK/ERK output that a BRAF codon-600 mutation produces, so the model reproduces the downstream node while entering the cascade one step further upstream.
Downstream
MAPK-Dependent Melanocyte Proliferation and Survival Sustained ERK output maintains cell-cycle progression and survival in BRAF-driven melanoma cells. Canonical BRAF V600 Melanoma Model
Show evidence (1 reference)
PMID:23569304 SUPPORT Human Clinical
"Vemurafenib inhibited MAPK signaling and cell-cycle progression."
Paired clinical biopsies show target-pathway suppression during BRAF inhibition.
MAPK-Dependent Melanocyte Proliferation and Survival
Persistent ERK signaling expands and sustains transformed melanocytes. This output is necessary but not always sufficient for invasive melanoma: experimental BRAF expression can stop at a benign hyperplasia, whereas additional survival and tumor-suppressor lesions permit progression.
Canonical BRAF V600 Melanoma Model
melanocyte CL:0000148 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves melanocyte (CL:0000148). CL:0000148 is a cell type from the Cell Ontology.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↓ DECREASED
skin of body UBERON:0002097 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in skin of body (UBERON:0002097). UBERON:0002097 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cutaneous Melanoma MAPK-dependent expansion contributes to the cutaneous melanoma phenotype when cooperating progression barriers are overcome. Canonical BRAF V600 Melanoma Model
Show evidence (1 reference)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The functional assay establishes proliferative transformation downstream of mutant BRAF.
Oncogene-Induced Melanocytic Growth-Arrest Barrier
Strong oncogenic BRAF signaling can evoke a senescence-like arrest rather than continuous malignant growth. This helps explain why BRAF V600E is found in benign melanocytic proliferations and why additional genetic or cell-state changes are required for invasive cancer.
melanocyte CL:0000148 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves melanocyte (CL:0000148). CL:0000148 is a cell type from the Cell Ontology.
cellular senescence GO:0090398 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cellular senescence (GO:0090398). GO:0090398 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:19282848 SUPPORT Model Organism
"Mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months."
The long-lived benign phenotype supports a progression barrier after driver activation.
PMID:22549727 SUPPORT In Vitro
"PTEN depletion abrogates BRAF(V600E)-induced senescence in human fibroblasts and melanocytes."
The human-cell experiment directly identifies BRAF-induced senescence and its escape after PTEN depletion.
PTEN-Loss and PI3K-AKT-mTOR Cooperation
Loss of PTEN provides a cooperating survival pathway that permits BRAF-initiated melanocytes to escape the benign growth-arrest state and progress. This is a validated experimental route rather than a claim that PTEN loss is obligatory in every human BRAF V600 melanoma.
Canonical BRAF V600 Melanoma Model
PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee.
intracellular signal transduction GO:0035556 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased intracellular signal transduction (GO:0035556). GO:0035556 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Invasive and Metastatic Melanoma Progression In the conditional model, PTEN loss converts BRAF-initiated hyperplasia into rapidly penetrant metastatic melanoma. Canonical BRAF V600 Melanoma Model
Show evidence (2 references)
PMID:19282848 SUPPORT Model Organism
"Expression of BRaf(V600E) combined with Pten tumor suppressor gene silencing elicited development of melanoma with 100% penetrance."
The conditional mouse experiment directly establishes cooperation.
PMID:22549727 SUPPORT In Vitro
"PI3K pathway activation serves as a rate-limiting event in this setting"
Human cells and contiguous nevus-melanoma specimens support PI3K-pathway escape from the BRAF-induced barrier.
Invasive and Metastatic Melanoma Progression
Melanoma progression entails invasion, regional or distant dissemination, and survival in metastatic sites. BRAF V600 is a driver and treatment biomarker, but it does not by itself define the anatomic pattern or stage; co-alterations, immune context, and tumor-cell state modify progression.
positive regulation of cell migration GO:0030335 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of cell migration (GO:0030335). GO:0030335 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Brain Metastases Advanced BRAF V600 melanoma can disseminate to the brain, although a unique BRAF-dependent brain-homing route is not established here.
Progressive Metastatic Disease Continued invasive growth and dissemination produce clinically progressive metastatic melanoma.
Show evidence (1 reference)
PMID:19282848 SUPPORT Model Organism
"with metastases observed in lymph nodes and lungs"
The Braf/Pten model directly establishes dissemination after cooperative transformation.
Immune-Checkpoint-Mediated Evasion
BRAF-mutant melanoma exists within an immune-responsive but suppressive microenvironment. BRAF inhibition can increase CD8-positive T-cell infiltration while also increasing PD-L1, creating a rationale for checkpoint blockade. Immune phenotype varies among tumors and is not determined by BRAF status alone.
CD8-positive, alpha-beta T cell CL:0000625 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves CD8-positive, alpha-beta T cell (CL:0000625). CL:0000625 is a cell type from the Cell Ontology.
negative regulation of T cell mediated immunity GO:0002710 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of T cell mediated immunity (GO:0002710). GO:0002710 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:24903021 SUPPORT Human Clinical
"BRAF inhibition results in a more favorable tumor microenvironment in patients, with an increase in CD8(+) T-cell infiltrate and a decrease in immunosuppressive cytokines."
Human paired observations support treatment-associated immune remodeling.
PMID:26091043 SUPPORT Human Clinical
"samples assigned a transcriptomic subclass enriched for immune gene expression"
TCGA shows clinically relevant immune heterogeneity across cutaneous melanoma.
Acquired MAPK Reactivation and Adaptive Resistance
Under BRAF- or BRAF/MEK-inhibitor selection, progressing lesions can restore ERK signaling through secondary NRAS or MAP2K1 alterations and other MAPK routes. Parallel PI3K-AKT signaling and reversible transcriptional or metabolic adaptation can also sustain drug-tolerant states. Resistance is therefore mechanistically heterogeneous.
Acquired BRAF/MEK-Inhibitor Resistance Model
ERK1 and ERK2 cascade GO:0070371 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased ERK1 and ERK2 cascade (GO:0070371). GO:0070371 is a biological process from the Gene Ontology. ↑ INCREASED response to xenobiotic stimulus GO:0009410 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to xenobiotic stimulus (GO:0009410). GO:0009410 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Progressive Metastatic Disease Restored or bypass signaling permits renewed tumor growth during targeted therapy. Acquired BRAF/MEK-Inhibitor Resistance Model
Show evidence (2 references)
PMID:23569304 SUPPORT Human Clinical
"Acquired resistance results primarily from MAPK reactivation driven by the appearance of secondary mutations in NRAS and MEK1 in subsets of patients."
Serial biopsies directly establish specific clinical resistance routes.
PMID:24610826 SUPPORT Other
"Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS."
The review supports adaptive metabolic plasticity as a candidate resistance component.
✶

Histopathology

1
Malignant Melanocytic Neoplasm OBLIGATE
Histopathology must establish melanoma in the cutaneous context before the BRAF V600 result is used to assign this molecular subtype. BRAF status does not replace morphologic diagnosis or staging.
Show evidence (1 reference)
PMID:39700658 SUPPORT Other
"If melanoma is suspected, a histopathological examination is always required."
The current interdisciplinary guideline makes histopathologic confirmation mandatory.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for BRAF V600 Mutant Melanoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Integument 1
Cutaneous Melanoma OBLIGATE HP:0012056 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cutaneous melanoma (HP:0012056). HP:0012056 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39700658 SUPPORT Other
"Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality."
The guideline establishes the cutaneous melanoma disease context.
Neoplasm 1
Progressive Metastatic Disease Neoplasm HP:0002664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neoplasm (HP:0002664). HP:0002664 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:23569304 SUPPORT Human Clinical
"Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions"
Serial biopsies directly tie resistant signaling to clinically progressive lesions.
Other 1
Brain Metastases Brain neoplasm HP:0030692 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Brain metastasis, annotated with Brain neoplasm (HP:0030692). HP:0030692 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28592387 SUPPORT Human Clinical
"44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response"
The molecularly selected phase-II trial directly documents the brain-metastatic phenotype and intracranial response.
🧬

Genetic Associations

4
BRAF p.Val600Glu (Somatic Activating Driver Mutation)
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (2 references)
PMID:12068308 SUPPORT Human Clinical
"All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%."
The foundational study identifies the dominant activating melanoma allele under historical numbering.
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The clinical testing cohort confirms dominance of the standardized V600E allele.
BRAF p.Val600Lys (Somatic Activating Driver Mutation)
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (2 references)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The molecular-testing cohort directly identifies the V600K fraction.
PMID:31166680 SUPPORT Human Clinical
"Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors."
The long-term phase-III analysis directly includes this allele.
BRAF p.Val600Arg (Somatic Activating Driver Mutation)
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (2 references)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The molecular-testing cohort directly documents V600R melanoma.
PMID:28592387 SUPPORT Human Clinical
"BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases"
A small prospective cohort included V600R, but this is not equivalent to the V600E/K evidence base.
BRAF p.Val600Met (Somatic Activating Driver Mutation)
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (1 reference)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The molecular-testing cohort directly documents V600M melanoma.
💊

Medical Actions

6
Surgical Excision of Resectable Cutaneous Melanoma
Category: Therapeutic Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Complete excision with a stage-appropriate margin is the foundation for resectable primary disease. Sentinel-node biopsy is a staging procedure in selected tumors and should not be described as having a proven survival benefit. Subsequent adjuvant treatment depends on stage, BRAF allele, risk, and patient context.
Target Phenotypes: Cutaneous melanoma HP:0012056 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Cutaneous melanoma (HP:0012056). HP:0012056 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39709737 SUPPORT Other
"Cutaneous melanomas are excised with one to two-centimeter safety margins."
The current interdisciplinary treatment guideline directly supports surgical excision.
Adjuvant Dabrafenib Plus Trametinib
Category: Therapeutic Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: dabrafenib CHEBI:75045 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dabrafenib (CHEBI:75045). CHEBI:75045 is a therapeutic agent from Chemical Entities of Biological Interest. trametinib CHEBI:75998 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses trametinib (CHEBI:75998). CHEBI:75998 is a therapeutic agent from Chemical Entities of Biological Interest.
Twelve months of dabrafenib plus trametinib is an adjuvant option after complete resection of high-risk stage-III BRAF V600E/K melanoma. Final COMBI-AD follow-up showed durable relapse-free and distant-metastasis-free benefit; the overall-survival comparison did not meet conventional statistical significance in the full population.
Mechanism Target:
INHIBITS Somatic BRAF Codon-600 Driver — Dabrafenib inhibits class-I mutant BRAF kinase activity.
Show evidence (1 reference)
clinicaltrials:NCT01682083 SUPPORT Human Clinical
"BRAF V600E/K mutation-positive, high-risk"
The registry directly defines the biomarker-selected adjuvant population.
INHIBITS Sustained MEK-ERK Signaling — Trametinib blocks MEK output downstream of mutant BRAF.
Show evidence (1 reference)
PMID:23569304 SUPPORT Human Clinical
"The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance."
Human resistance biopsies provide the mechanistic rationale for downstream MEK inhibition.
Show evidence (1 reference)
PMID:38899716 SUPPORT Human Clinical
"Relapse-free survival favored dabrafenib plus trametinib over placebo (hazard ratio for relapse or death, 0.52; 95% CI, 0.43 to 0.63)"
Final randomized phase-III follow-up directly supports durable adjuvant relapse prevention.
Dabrafenib Plus Trametinib for Unresectable or Metastatic Disease
Category: Therapeutic Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: dabrafenib CHEBI:75045 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dabrafenib (CHEBI:75045). CHEBI:75045 is a therapeutic agent from Chemical Entities of Biological Interest. trametinib CHEBI:75998 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses trametinib (CHEBI:75998). CHEBI:75998 is a therapeutic agent from Chemical Entities of Biological Interest.
Dual BRAF/MEK inhibition produces rapid responses in BRAF V600E/K unresectable or metastatic melanoma. Pooled COMBI-d/COMBI-v follow-up showed five-year survival in a subset, while COMBI-MB demonstrated intracranial activity with comparatively limited response duration.
Mechanism Target:
INHIBITS Somatic BRAF Codon-600 Driver — Dabrafenib directly inhibits the mutant BRAF kinase.
Show evidence (1 reference)
PMID:31166680 SUPPORT Human Clinical
"A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib"
The biomarker-selected phase-III trials directly evaluate the combination.
INHIBITS Sustained MEK-ERK Signaling — Trametinib suppresses pathway output downstream of BRAF.
Show evidence (1 reference)
PMID:23569304 SUPPORT Human Clinical
"The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance."
Resistance profiling supports dual-level MAPK blockade.
Show evidence (2 references)
PMID:31166680 SUPPORT Human Clinical
"34% (95% CI, 30 to 38) at 5 years"
Pooled phase-III follow-up directly reports long-term survival with the combination.
PMID:28592387 SUPPORT Human Clinical
"44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response"
COMBI-MB directly supports activity in brain-metastatic disease.
Vemurafenib Plus Cobimetinib
Category: Therapeutic Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: vemurafenib CHEBI:63637 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses vemurafenib (CHEBI:63637). CHEBI:63637 is a therapeutic agent from Chemical Entities of Biological Interest. cobimetinib CHEBI:90851 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses cobimetinib (CHEBI:90851). CHEBI:90851 is a therapeutic agent from Chemical Entities of Biological Interest.
Vemurafenib plus cobimetinib is a combined BRAF/MEK option for BRAF V600 advanced melanoma. Five-year coBRIM follow-up confirmed longer median progression-free and overall survival than vemurafenib alone, with regimen-specific toxicity and patient factors informing selection.
Mechanism Target:
INHIBITS Somatic BRAF Codon-600 Driver — Vemurafenib inhibits class-I mutant BRAF.
Show evidence (1 reference)
clinicaltrials:NCT01689519 SUPPORT Human Clinical
"previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma"
The registry directly defines the molecular population and BRAF-containing regimen.
INHIBITS Sustained MEK-ERK Signaling — Cobimetinib inhibits MEK downstream of mutant BRAF.
Show evidence (1 reference)
PMID:34158360 SUPPORT Human Clinical
"Median PFS was 12.6 months (95% CI, 9.5-14.8) with cobimetinib plus vemurafenib and 7.2 months (95% CI, 5.6-7.5) with placebo plus vemurafenib; 5-year PFS rates were 14% and 10%, respectively."
The randomized comparison demonstrates added benefit from dual pathway inhibition.
Show evidence (1 reference)
PMID:34158360 SUPPORT Human Clinical
"Median OS was 22.5 months (95% CI, 20.3-28.8) with cobimetinib plus vemurafenib and 17.4 months (95% CI, 15.0-19.8) with placebo plus vemurafenib; 5-year OS rates were 31% and 26%, respectively."
Extended randomized follow-up directly supports the combination.
Encorafenib Plus Binimetinib
Category: Therapeutic Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: encorafenib NCIT:C98283 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses encorafenib (NCIT:C98283). NCIT:C98283 is a therapeutic agent from the NCI Thesaurus. binimetinib CHEBI:145371 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses binimetinib (CHEBI:145371). CHEBI:145371 is a therapeutic agent from Chemical Entities of Biological Interest.
Encorafenib plus binimetinib is a combined BRAF/MEK option for locally advanced unresectable or metastatic BRAF V600E/K melanoma. The seven-year COLUMBUS analysis provides the longest phase-III follow-up among the represented targeted combinations.
Mechanism Target:
INHIBITS Somatic BRAF Codon-600 Driver — Encorafenib inhibits class-I mutant BRAF.
Show evidence (1 reference)
clinicaltrials:NCT01909453 SUPPORT Human Clinical
"This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation."
The registry directly supports the regimen and biomarker-selected population.
INHIBITS Sustained MEK-ERK Signaling — Binimetinib inhibits MEK downstream of mutant BRAF.
Show evidence (1 reference)
PMID:38723373 SUPPORT Human Clinical
"Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively."
Long-term phase-III follow-up directly supports durable pathway control in a subset.
Show evidence (1 reference)
PMID:38723373 SUPPORT Human Clinical
"Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively."
The randomized phase-III update directly reports long-term overall survival.
Immune Checkpoint Blockade
Category: Therapeutic Action: immunotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunotherapy (NCIT:C15262). NCIT:C15262 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunotherapy NCIT:C15262
Agent: nivolumab NCIT:C68814 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses nivolumab (NCIT:C68814). NCIT:C68814 is a therapeutic agent from the NCI Thesaurus. ipilimumab CHEBI:231679 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ipilimumab (CHEBI:231679). CHEBI:231679 is a therapeutic agent from Chemical Entities of Biological Interest.
PD-1-based therapy, alone or in combination with CTLA-4 or LAG-3 blockade, is a major systemic option regardless of BRAF status. In treatment-naive metastatic BRAF V600 melanoma, DREAMseq and SECOMBIT support beginning with nivolumab plus ipilimumab for most trial-eligible patients, while urgent disease control, contraindications, prior adjuvant therapy, toxicity, and patient preference can alter individual sequencing.
Mechanism Target:
INHIBITS Immune-Checkpoint-Mediated Evasion — Checkpoint antibodies release inhibitory signals that constrain antitumor T-cell activity.
Show evidence (1 reference)
PMID:24903021 SUPPORT Model Organism
"Administration of anti-PD1 or anti-PDL1 together with a BRAF inhibitor led to an enhanced response, significantly prolonging survival and slowing tumor growth"
The immunocompetent melanoma model directly demonstrates checkpoint-mediated immune constraint.
Show evidence (3 references)
PMID:36166727 SUPPORT Human Clinical
"The 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P = .010)."
The randomized phase-III sequencing trial directly supports immunotherapy-first survival for most enrolled patients.
PMID:38167503 SUPPORT Human Clinical
"These long-term survival outcomes confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma"
Four-year randomized phase-II follow-up independently supports the sequencing conclusion.
PMID:39709737 SUPPORT Other
"For first line treatment PD-1 antibodies alone or in combination with CTLA-4 or LAG-3 antibodies shall be considered."
The current guideline places checkpoint therapy among first-line systemic options.
🌍

Environmental Factors

1
Intermittent Ultraviolet-Exposure Context
exposure to ultraviolet radiation ECTO:0000006 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to ultraviolet radiation (ECTO:0000006). ECTO:0000006 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Ultraviolet exposure is a background cause of cutaneous melanoma, and one primary-tumor cohort found BRAF mutation enriched with intermittent sun exposure. This association does not establish that UV directly creates the BRAF V600 nucleotide change, nor does it make exposure necessary for this molecular subtype.
Show evidence (2 references)
PMID:25357015 SUPPORT Human Clinical
"trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)"
The observational association supports a UV-exposure context but not direct mutagenic attribution for BRAF V600.
PMID:19919630 SUPPORT Human Clinical
"The prevalence of BRAF V600E in AGN suggests that ultraviolet exposure is not essential for generating the mutation."
Detection in a nonsun-exposed site directly supports the caveat that UV is not required for the V600E event.
Mechanism Target:
PREDISPOSES Somatic BRAF Codon-600 Driver — Deliberately not TRIGGERS. Intermittent sun exposure is associated with this tumour type, but this entry's own evidence notes the BRAF V600E mutation arises in anatomically sun-shielded naevi too, so ultraviolet light is a risk context rather than the mutational cause. The mutation does not carry a UV signature.
Show evidence (1 reference)
PMID:25357015 SUPPORT Human Clinical
"trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)"
Reports intermittent sun exposure as a risk factor by odds ratio, an epidemiological association with the tumour rather than a demonstrated cause of the codon-600 mutation.
🔬

Biochemical Markers

3
Tumor BRAF V600 Variant Detection (REQUIRED_FOR_SUBTYPE_ASSIGNMENT)
Show evidence (2 references)
PMID:22536370 SUPPORT Human Clinical
"The SNaPshot melanoma screen can detect 43 point mutations in 6 genes relevant to targeted therapy in melanoma."
The clinical implementation study establishes multiplex tumor genotyping and allele resolution.
PMID:39700658 SUPPORT Other
"From stage IIB/C and higher, a mutation test is recommended, especially for the BRAF V600 mutation."
The current diagnostic guideline supports stage-appropriate BRAF V600 testing.
BRAF V600E VE1 Immunoreactivity (VARIABLE)
Show evidence (1 reference)
PMID:28424234 SUPPORT Human Clinical
"The antibody showed a sensitivity of 86.1% with a specificity of 96.9%."
The direct PCR-versus-VE1 comparison quantifies performance and supports screening rather than universal substitution.
Plasma BRAF V600 Circulating Tumor DNA (VARIABLE)
Show evidence (2 references)
PMID:33587894 SUPPORT Human Clinical
"ctDNA was detected in pretreatment samples from 320 (93%) of 345 patients (COMBI-d) and 34 (89%) of 38 patients (COMBI-MB)."
The large biomarker analysis directly quantifies baseline detectability in advanced disease.
PMID:40250457 SUPPORT Human Clinical
"ctDNA was detectable in 79 (13%) of 597 baseline samples."
The resected-stage-III analysis demonstrates much lower detection in the minimal-residual-disease setting.
🔬

Diagnosis

4
Clinicopathologic cutaneous melanoma diagnosis (REQUIRED)
A suspicious cutaneous lesion is evaluated clinically and with dermoscopy, then confirmed histopathologically. Molecular subtype assignment follows the melanoma diagnosis; a BRAF result alone cannot establish the tissue of origin or distinguish melanoma from another BRAF-mutant cancer.
Show evidence (2 references)
PMID:39700658 SUPPORT Other
"The diagnosis of melanoma can be made clinically and must always be confirmed by dermoscopy."
The guideline directly supports clinical and dermoscopic assessment.
PMID:39700658 SUPPORT Other
"If melanoma is suspected, a histopathological examination is always required."
The guideline directly requires pathologic confirmation.
Tumor BRAF V600 genotyping (REQUIRED_FOR_SUBTYPE_ASSIGNMENT)
A validated DNA assay should identify the exact tumor BRAF allele. Testing is especially relevant from stage IIB/C onward and before BRAF/MEK therapy. Broad sequencing can also separate V600 class-I disease from class-II or class-III non-V600 BRAF melanoma.
genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Results: Detection of a somatic BRAF codon-600 variant establishes the molecular subtype in confirmed cutaneous melanoma.
Show evidence (2 references)
PMID:39700658 SUPPORT Other
"From stage IIB/C and higher, a mutation test is recommended, especially for the BRAF V600 mutation."
The guideline supports stage-appropriate BRAF V600 testing.
PMID:22536370 SUPPORT Human Clinical
"The test utilizes the SNaPshot method (multiplex PCR, multiplex primer extension, and capillary electrophoresis)"
The clinical laboratory study validates a multi-allele tumor-genotyping approach.
VE1 immunohistochemistry as a V600E screen (COMPLEMENTARY)
VE1 staining can rapidly support V600E detection in suitable tissue, but imperfect sensitivity and allele specificity mean that it is not a complete substitute for molecular BRAF V600 testing.
Results: Positive tumor-cell VE1 staining supports V600E; discordant or clinically consequential negative results require molecular resolution.
Show evidence (1 reference)
PMID:28424234 SUPPORT Human Clinical
"The concordance rate between PCR and immunohistochemical BRAF status was 95.1%."
The direct method comparison supports complementary screening while leaving room for discordance.
Stage-directed body and brain imaging (STAGE_DEPENDENT)
From stage IIB/C, cross-sectional body imaging together with brain MRI is recommended for staging and surveillance planning. Imaging defines disease extent but does not determine BRAF status.
Show evidence (1 reference)
PMID:39700658 SUPPORT Other
"From stage IIB/C, whole-body examinations with computed tomography or positron emission tomography CT in combination with magnetic resonance imaging of the brain are recommended."
The guideline directly supplies the stage threshold and imaging combination.
📈

Progression

4
BRAF-initiated melanocytic hyperplasia with a growth-arrest barrier
Lineage-restricted Braf V600E expression can initiate benign melanocytic proliferation without spontaneous melanoma progression, demonstrating that the driver is not a complete malignant program by itself.
Show evidence (1 reference)
PMID:19282848 SUPPORT Model Organism
"Mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months."
The conditional model directly defines an initiated but progression-constrained phase.
Cooperative malignant and metastatic progression
Additional tumor-suppressor and survival-pathway changes can release the BRAF-initiated barrier. PTEN loss is one experimentally established route, producing rapid melanoma and lymph-node or lung metastasis in mice; human tumors remain more heterogeneous.
Show evidence (1 reference)
PMID:19282848 SUPPORT Model Organism
"with metastases observed in lymph nodes and lungs"
The model directly establishes metastatic progression after genetic cooperation.
Targeted response followed by molecularly heterogeneous resistance
BRAF inhibition suppresses ERK phosphorylation and tumor proliferation, but progressing lesions can restore MAPK signaling through secondary NRAS or MEK1 alterations. Other lesions may use different or non-genetic routes.
Show evidence (1 reference)
PMID:23569304 SUPPORT Human Clinical
"Acquired resistance results primarily from MAPK reactivation driven by the appearance of secondary mutations in NRAS and MEK1 in subsets of patients."
Serial pretreatment and progression biopsies directly define the resistant phase and its heterogeneity.
Brain-metastatic disease
Brain metastasis is a clinically important advanced phase. Targeted therapy can induce intracranial responses, but response durability remains limited, requiring integrated systemic and local treatment planning.
Show evidence (1 reference)
PMID:28592387 SUPPORT Human Clinical
"44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response"
The prospective phase-II trial directly characterizes treated brain-metastatic disease.
🌍

Epidemiology

3
Cohort-dependent BRAF mutation frequency
In a series of 106 primary cutaneous melanomas from western Turkey, 42.5% carried a BRAF mutation. This is a cohort proportion, not a population prevalence estimate; frequency varies with ancestry, melanoma subtype, anatomic site, age distribution, and testing strategy.
Show evidence (1 reference)
PMID:25357015 SUPPORT Human Clinical
"BRAF (42.5%), NRAS (15.1%), and CDKN2A (13.2%) were the 3 most common mutations."
The primary-cutaneous-melanoma cohort supplies an explicit BRAF proportion and denominator.
Younger-age, trunk, and intermittent-sun-exposure enrichment
The same 106-tumor cohort associated BRAF mutation with younger age, trunk location, superficial-spreading or nodular histology, and intermittent sun exposure. These are enrichments within one regional series rather than diagnostic criteria or proof that ultraviolet radiation directly creates the noncanonical BRAF c.1799T>A substitution.
Show evidence (1 reference)
PMID:25357015 SUPPORT Human Clinical
"younger age (OR = 2.7)"
The cohort directly quantifies the stated clinicopathologic associations.
V600 allele distribution in a molecular-testing cohort
Among BRAF V600-positive tumors in the first 150 melanomas tested by one multiplex assay, V600E accounted for 79%, V600K for 12%, V600R for 5%, and V600M for 4%. These percentages characterize that referral cohort and should not be treated as invariant population frequencies.
Show evidence (1 reference)
PMID:22536370 SUPPORT Human Clinical
"Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively."
The clinical molecular-testing study directly reports the within-V600 allele distribution.
🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from BRAF V600 Mutant Melanoma:

Non-V600 BRAF-Mutant Cutaneous Melanoma
Overlapping Features These tumors can share the same cutaneous histology but carry class-II or class-III BRAF alleles with different dimerization, RAS dependence, kinase activity, and expected sensitivity to RAF monomer inhibitors.
Distinguishing Features
  • Resolve the exact BRAF protein change rather than treating any BRAF mutation as V600 disease.
  • Class-I V600 mutants signal as RAS-independent monomers; class-II mutants signal as dimers and class-III mutants depend on activated RAS.
Show evidence (1 reference)
PMID:28783719 SUPPORT In Vitro
"We have thus defined three distinct functional classes of BRAF mutants in human tumours."
Functional classification directly distinguishes V600 class-I disease from non-V600 classes.
RAS-Mutant, NF1-Mutant, or Triple-Wild-Type Cutaneous Melanoma
Overlapping Features Cutaneous melanomas in these genomic classes can be histologically indistinguishable but lack the defining BRAF V600 driver and follow different targeted-treatment logic.
Distinguishing Features
  • Use tumor sequencing to assign the BRAF, RAS, NF1, or triple-wild-type genomic class.
  • Do not infer BRAF V600 status from morphology, age, site, or UV-exposure history.
Show evidence (1 reference)
PMID:26091043 SUPPORT Human Clinical
"We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type)."
TCGA directly establishes the major mutually informative genomic classes.
📊

Related Datasets

1
https://portal.gdc.cancer.gov/projects/TCGA-SKCM https://portal.gdc.cancer.gov/projects/TCGA-SKCM
Integrated DNA, RNA, and protein analysis of 333 primary or metastatic cutaneous melanomas from 331 patients. The study established BRAF, RAS, NF1, and triple-wild-type genomic classes and an immune-expression subclass associated with lymphocytic infiltration and survival.
human MULTI OMICS n=333
Conditions: Primary cutaneous melanoma Metastatic cutaneous melanoma
Findings
Cutaneous melanomas separated into mutant-BRAF, mutant-RAS, mutant-NF1, and triple-wild-type genomic classes.
"We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT."
Show evidence (1 reference)
PMID:26091043 SUPPORT Human Clinical
"We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type)."
The integrated cohort directly establishes the molecular-class framework.
PMID:26091043
Show evidence (1 reference)
PMID:26091043 SUPPORT Human Clinical
"We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients."
The publication directly defines the multi-omics cohort and sample count.
🔬

Clinical Trials

6
NCT01682083 PHASE_III COMPLETED
COMBI-AD randomized 870 patients with completely resected, high-risk stage-III BRAF V600E/K cutaneous melanoma to 12 months of dabrafenib plus trametinib or matched placebos. ClinicalTrials.gov listed COMPLETED status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT01682083 SUPPORT Human Clinical
"This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection."
The registry directly supports the trial design, disease stage, and regimen.
NCT02224781 PHASE_III ACTIVE_NOT_RECRUITING
DREAMseq compares nivolumab plus ipilimumab followed at progression by dabrafenib plus trametinib against the reverse sequence in unresectable stage-III or IV BRAF V600 melanoma. ClinicalTrials.gov listed 267 participants and ACTIVE_NOT_RECRUITING status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT02224781 SUPPORT Human Clinical
"This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains..."
The current registry directly supports the sequencing design and status.
NCT02631447 PHASE_II COMPLETED
SECOMBIT tested targeted-therapy-first, immunotherapy-first, and an eight-week targeted-therapy induction followed by immunotherapy in metastatic BRAF V600 melanoma. ClinicalTrials.gov listed 251 participants and COMPLETED status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT02631447 SUPPORT Human Clinical
"To evaluate the best sequencing approach with the combination of target agents (LGX818 plus MEK162) and the combination of immunomodulatory antibodies (ipilimumab plus nivolumab) in patients with metastatic melanoma and BRAF V600 mutation."
The registry directly supports the population, interventions, and sequencing objective.
NCT02039947 PHASE_II COMPLETED
COMBI-MB evaluated dabrafenib plus trametinib across symptomatic, asymptomatic, previously locally treated, and untreated BRAF V600 melanoma brain-metastasis cohorts. ClinicalTrials.gov listed 127 participants and COMPLETED status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT02039947 SUPPORT Human Clinical
"This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain."
The registry directly supports the intracranial trial design and completed status.
NCT01909453 PHASE_III COMPLETED
COLUMBUS compared encorafenib plus binimetinib with vemurafenib and encorafenib monotherapy in locally advanced unresectable or metastatic BRAF V600 melanoma. ClinicalTrials.gov listed 921 participants and COMPLETED status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT01909453 SUPPORT Human Clinical
"This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation."
The registry directly supports the design, molecular population, and interventions.
NCT01689519 PHASE_III COMPLETED
coBRIM compared vemurafenib plus cobimetinib with vemurafenib plus placebo in previously untreated, unresectable locally advanced or metastatic BRAF V600 melanoma. ClinicalTrials.gov listed 495 participants and COMPLETED status when checked on 2026-07-23.
Show evidence (1 reference)
clinicaltrials:NCT01689519 SUPPORT Human Clinical
"To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS),..."
The registry directly supports the phase-III comparator design and molecular eligibility.
🧫

Experimental Models

1
NIH3T3 Mutant-BRAF Transformation Assay CELL_LINE
Expression of melanoma-derived mutant BRAF proteins in NIH3T3 fibroblasts demonstrates elevated kinase activity and transforming capacity. This is a reductionist driver-function assay, not a melanocyte-lineage or immune-competent model of cutaneous melanoma.
Wild-type BRAF expression Melanoma-derived mutant BRAF expression
Organism
mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Cell source
NIH3T3 mouse fibroblast cell line
Culture
Two-dimensional transformed-focus and signaling assays after mutant-BRAF expression
Publication
PMID:12068308
Pathograph links
Somatic BRAF Codon-600 Driver Tests kinase activation and transforming capacity conferred by melanoma-derived BRAF mutations.
Show evidence (1 reference)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The original study directly states both functional readouts.
Findings
Melanoma-derived mutant BRAF proteins have elevated kinase activity and transform NIH3T3 cells.
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
Show evidence (1 reference)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The reductionist assay directly establishes oncogenic function.
Show evidence (1 reference)
PMID:12068308 SUPPORT In Vitro
"Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells."
The publication explicitly reports the NIH3T3 functional assay.
🐁

Animal Models

4
Melanocyte-specific conditional Braf(V600E), with or without Pten silencing Mus musculus
Conditional melanocyte-specific Braf V600E produces benign melanocytic hyperplasia without melanoma over prolonged observation. Adding Pten loss produces rapid, fully penetrant melanoma with lymph-node and lung metastases, modeling oncogene initiation, progression restraint, and PI3K-pathway cooperation.
Benign melanocytic hyperplasia with Braf V600E alone Rapid melanoma after combined Braf V600E and Pten loss Lymph-node and lung metastases
Species
Mus musculus
Genotype
Melanocyte-specific conditional Braf(V600E), with or without Pten silencing
Genes
BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:19282848 SUPPORT Model Organism
"Expression of BRaf(V600E) combined with Pten tumor suppressor gene silencing elicited development of melanoma with 100% penetrance."
The study directly defines the conditional cooperative model.
Syngeneic Braf(V600E)/Pten-null melanoma graft in immunocompetent mice Mus musculus
An immunocompetent syngeneic Braf V600E/Pten-null graft model reproduces increased intratumoral CD8-positive T-cell density after BRAF inhibition and permits testing of combined targeted and checkpoint therapy.
Syngeneic melanoma growth Increased CD8-positive tumor infiltration after BRAF inhibition Enhanced response to combined BRAF and PD-1 or PD-L1 blockade
Species
Mus musculus
Genotype
Syngeneic Braf(V600E)/Pten-null melanoma graft in immunocompetent mice
Genes
BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. PTEN hgnc:9588 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns PTEN (hgnc:9588). hgnc:9588 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:24903021 SUPPORT Model Organism
"we developed a BRAF(V600E)/Pten(-/-) syngeneic tumor graft immunocompetent mouse model"
The publication explicitly defines the immune-competent graft model.
Transgenic BRAF(V600E)-driven melanoma with cooperating germline drivers including p53 loss Danio rerio
Engineered zebrafish melanomas initiated by BRAF V600E with cooperating drivers model multi-hit tumorigenesis in the absence of ultraviolet exposure. Tumors have low overall mutation burden but remain genetically heterogeneous, which helps separate driver cooperation from UV-associated human mutational burden.
Variable melanoma onset and pathology Low mutation burden Genetically heterogeneous tumors
Species
Danio rerio
Genotype
Transgenic BRAF(V600E)-driven melanoma with cooperating germline drivers including p53 loss
Genes
BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee. TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:24148783 SUPPORT Model Organism
"Engineered zebrafish melanomas show an overall low mutation burden."
Exome sequencing directly characterizes the BRAF-driven zebrafish tumors.
Xiphophorus Gordon-Kosswig-Anders backcross hybrid melanoma
The oldest vertebrate melanoma model. Crossing a spotted X. maculatus platyfish to X. hellerii and backcrossing the F1 to the swordtail parent segregates the melanoma oncogene Xmrk away from the R/Diff locus that normally restrains it. Backcross progeny segregate into four Mendelian classes, and those inheriting Xmrk on an R/Diff-free background develop highly malignant melanoma. Xmrk encodes a constitutively active paralogue of the epidermal growth factor receptor whose dominant downstream output is the Ras/Raf/MAPK cascade. Because the driver sits upstream of RAF rather than in it, the model isolates the consequences of sustained MAPK flux from the identity of the mutation that produces it, and it was the system in which receptor tyrosine kinase/Ras/Raf/MAPK signalling was identified as the critical melanoma driver roughly a decade before that role was established in human tumours.
Spontaneous malignant melanoma in the Xmrk-carrying, R/Diff-free segregant class Melanoma malignancy grade tracking Xmrk expression level Progression from pigmented macromelanophore lesion to invasive melanoma
Species
Xiphophorus maculatus x Xiphophorus hellerii
Genotype
Backcross hybrid hemizygous for the Xmrk (Tu) locus and lacking the X. maculatus R/Diff tumour-suppressor allele
Background
X. maculatus Jp163A spotted-dorsal (Sd) x X. hellerii, F1 backcrossed to X. hellerii. The sibling Jp163B spotted-side (Sp) line is the Tu-carrying parent of three of the alternative hybrid models rather than of this classical cross; one of those, Sp-couchianus, is the primary UVB-inducible melanoma model and crosses Jp163B to X. couchianus (PMID:21143485).
Publication
PMID:2797166
Pathograph links
Sustained MEK-ERK Signaling partially recapitulates fidelity: moderate Ligand-independent Xmrk signalling drives the same Ras/Raf/MEK/ERK output that a BRAF codon-600 mutation produces, so the model reproduces the downstream node while entering the cascade one step further upstream.
Limitations: The fish carries no BRAF codon-600 mutation; the driver is an EGFR-family receptor tyrosine kinase, so the model cannot report on RAF-inhibitor binding, paradoxical RAF activation, or codon-600-specific allele biology. Xmrk also activates STAT5 and PI3K-AKT branches that a BRAF V600E melanocyte does not engage the same way, so MAPK-attributable effects must be separated from those before transferring inferences.
Readouts
Ras/Raf/MAPK pathway activation downstream of Xmrk
Signalling analyses of Xmrk-expressing melanocytes and fish melanomas identifying which downstream cascade carries the transforming signal.
Direction: INCREASED
Interpretation: MAPK is the dominant effector arm of the fish oncogene, which is what makes the model informative for the human MEK-ERK node.
Show evidence (1 reference)
PMID:38299666 SUPPORT Other
"The most important downstream signaling pathway activated by the Xmrk receptor tyrosine kinase is the Ras/Raf/MAPK pathway"
Identifies MAPK as the principal transducer of the Xmrk signal, the basis for mapping this model onto the MEK-ERK node.
Xmrk transcript level versus tumour malignancy grade
Comparison of oncogene expression against histological malignancy across hybrid tumours.
Direction: INCREASED
Interpretation: A dose relationship between driver expression and malignancy, the fish counterpart of MAPK output scaling with melanoma aggressiveness.
Show evidence (1 reference)
PMID:2797166 SUPPORT Model Organism
"We show that its level of expression correlates with the degree of malignancy of the tumour."
Reports the measured relationship between oncogene expression and tumour grade.
Show evidence (2 references)
PMID:2797166 SUPPORT Model Organism
"The Tu gene codes for a novel receptor tyrosine kinase which is closely related to the receptor for epidermal growth factor."
Places the fish driver in the EGFR receptor tyrosine kinase family, upstream of the same Ras/Raf/MEK/ERK cascade this node describes.
+ 1 more reference
Show evidence (2 references)
PMID:2797166 SUPPORT Model Organism
"Malignant melanoma in Xiphophorus fish hybrids is caused by the activity of a dominant oncogene Tu."
Establishes the hybrid fish as a genetically defined melanoma model and identifies the single dominant locus responsible.
PMID:38299666 SUPPORT Other
"backcross segregants that have inherited only R/Diff-free chromosomes develop highly malignant melanoma due to unobstructed activity of Tu"
Describes the segregation that produces melanoma-bearing animals in this cross, and the tumour-suppressor loss that permits it.
{ }

Source YAML

click to show 
name: BRAF V600 Mutant Melanoma
creation_date: '2026-01-26T02:55:13Z'
description: >-
  BRAF V600-mutant melanoma is a molecularly defined subtype of cutaneous
  melanoma in which tumor cells carry an activating somatic substitution at
  BRAF codon 600. V600E is the dominant allele, followed by V600K; V600R and
  V600M are uncommon and have a smaller treatment-evidence base. Codon-600
  mutants are class-I BRAF proteins that signal as RAS-independent active
  monomers, sustaining MEK-ERK output. The driver can initiate melanocytic
  proliferation, but experimental models show that BRAF V600E alone often
  produces benign hyperplasia or a growth-arrest barrier; cooperating lesions
  such as PTEN loss enable malignant and metastatic progression. Stage and
  exact allele matter clinically. Resectable disease is managed surgically,
  while immune-checkpoint therapy and combined BRAF/MEK inhibition are major
  systemic options in advanced disease. Acquired resistance commonly restores
  MAPK signaling or engages bypass and adaptive programs.
categories:
- Skin Cancer
- Molecularly-Defined Cancer
- Solid Tumor
- Oncogene-Driven Cancer
parents:
- cutaneous melanoma
synonyms:
- BRAF V600-positive cutaneous melanoma
- BRAF V600-mutated melanoma
- BRAF class-I mutant melanoma

epidemiology:
- name: Cohort-dependent BRAF mutation frequency
  description: >-
    In a series of 106 primary cutaneous melanomas from western Turkey, 42.5%
    carried a BRAF mutation. This is a cohort proportion, not a population
    prevalence estimate; frequency varies with ancestry, melanoma subtype,
    anatomic site, age distribution, and testing strategy.
  evidence:
  - reference: PMID:25357015
    reference_title: Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BRAF (42.5%), NRAS (15.1%), and CDKN2A (13.2%) were the 3 most common mutations.
    explanation: The primary-cutaneous-melanoma cohort supplies an explicit BRAF proportion and denominator.
- name: Younger-age, trunk, and intermittent-sun-exposure enrichment
  description: >-
    The same 106-tumor cohort associated BRAF mutation with younger age, trunk
    location, superficial-spreading or nodular histology, and intermittent sun
    exposure. These are enrichments within one regional series rather than
    diagnostic criteria or proof that ultraviolet radiation directly creates
    the noncanonical BRAF c.1799T>A substitution.
  evidence:
  - reference: PMID:25357015
    reference_title: Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: younger age (OR = 2.7)
    explanation: The cohort directly quantifies the stated clinicopathologic associations.
- name: V600 allele distribution in a molecular-testing cohort
  description: >-
    Among BRAF V600-positive tumors in the first 150 melanomas tested by one
    multiplex assay, V600E accounted for 79%, V600K for 12%, V600R for 5%, and
    V600M for 4%. These percentages characterize that referral cohort and should
    not be treated as invariant population frequencies.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The clinical molecular-testing study directly reports the within-V600 allele distribution.

has_subtypes:
- name: BRAF V600E Melanoma
  description: >-
    Melanoma carrying the somatic BRAF p.Val600Glu substitution. V600E was the
    dominant V600 allele in the cited molecular-testing cohort and has the
    deepest clinical-trial evidence base.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The molecular-testing cohort identifies V600E as the dominant V600 allele.
- name: BRAF V600K Melanoma
  description: >-
    Melanoma carrying the somatic BRAF p.Val600Lys substitution. V600K is less
    common than V600E but was included with V600E in the pivotal advanced and
    adjuvant BRAF/MEK trials represented here.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The molecular-testing cohort identifies V600K as the second most common V600 allele.
  - reference: PMID:31166680
    reference_title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients who have unresectable or metastatic melanoma with a BRAF V600E
      or V600K mutation have prolonged progression-free survival and overall
      survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.
    explanation: The pooled phase-III analysis directly includes V600E and V600K melanoma.
- name: Rare BRAF V600 Melanoma
  description: >-
    Melanoma carrying another codon-600 substitution, including V600R or V600M.
    These alleles activate the same codon hotspot but are uncommon, and evidence
    from V600E/K-dominant registration trials must not be generalized to every
    rare V600 allele without allele-specific assessment.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The cohort directly documents the rare V600R and V600M alleles.
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases
    explanation: COMBI-MB supplies limited prospective inclusion of non-E V600 alleles but not broad evidence for every rare allele.

environmental:
- name: Intermittent Ultraviolet-Exposure Context
  exposure_term:
    preferred_term: exposure to ultraviolet radiation
    term:
      id: ECTO:0000006
      label: exposure to ultraviolet radiation
  influences_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Deliberately not TRIGGERS. Intermittent sun exposure is associated with
      this tumour type, but this entry's own evidence notes the BRAF V600E
      mutation arises in anatomically sun-shielded naevi too, so ultraviolet
      light is a risk context rather than the mutational cause. The mutation
      does not carry a UV signature.
    evidence:
    - reference: PMID:25357015
      reference_title: "Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)"
      explanation: >-
        Reports intermittent sun exposure as a risk factor by odds ratio, an
        epidemiological association with the tumour rather than a demonstrated
        cause of the codon-600 mutation.
  description: >-
    Ultraviolet exposure is a background cause of cutaneous melanoma, and one
    primary-tumor cohort found BRAF mutation enriched with intermittent sun
    exposure. This association does not establish that UV directly creates the
    BRAF V600 nucleotide change, nor does it make exposure necessary for this
    molecular subtype.
  effect: Risk context for cutaneous melanomagenesis; molecular-subtype association is cohort dependent.
  evidence:
  - reference: PMID:25357015
    reference_title: Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)
    explanation: The observational association supports a UV-exposure context but not direct mutagenic attribution for BRAF V600.
  - reference: PMID:19919630
    reference_title: BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The prevalence of BRAF V600E in AGN suggests that ultraviolet exposure is not essential for generating the mutation.
    explanation: Detection in a nonsun-exposed site directly supports the caveat that UV is not required for the V600E event.

mechanistic_hypotheses:
- hypothesis_group_id: canonical_braf_v600_melanoma_model
  hypothesis_label: Canonical BRAF V600 Melanoma Model
  status: CANONICAL
  description: >-
    A somatic class-I BRAF codon-600 mutant drives RAS-independent MEK-ERK
    signaling and melanocyte proliferation. BRAF V600E alone can generate
    benign melanocytic hyperplasia or oncogene-induced arrest, so malignant
    progression requires additional permissive changes. PTEN loss is a
    experimentally established cooperating route that activates PI3K-AKT-mTOR
    survival signaling and permits invasive, metastatic melanoma.
  evidence:
  - reference: PMID:12068308
    reference_title: Mutations of the BRAF gene in human cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
    explanation: The foundational functional study establishes mutant-BRAF kinase activation and transforming capacity.
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression of BRaf(V600E) combined with Pten tumor suppressor gene
      silencing elicited development of melanoma with 100% penetrance.
    explanation: The conditional mouse model directly demonstrates cooperation between the driver and PTEN loss.
- hypothesis_group_id: acquired_mapk_inhibitor_resistance_model
  hypothesis_label: Acquired BRAF/MEK-Inhibitor Resistance Model
  status: CANONICAL
  description: >-
    MAPK-pathway inhibition selects for heterogeneous tumor-cell states and
    clones. Resistant disease can restore ERK output through secondary NRAS or
    MEK alterations and other MAPK routes, engage PI3K-AKT or receptor-kinase
    bypass signaling, or adopt reversible transcriptional and metabolic states.
    No single mechanism explains every progressing lesion.
  evidence:
  - reference: PMID:23569304
    reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acquired resistance to vemurafenib associated with reactivation of MAPK
      signaling as observed by elevated ERK1/2 phosphorylation levels in
      progressive lesions.
    explanation: Serial human biopsies directly demonstrate MAPK reactivation at progression.
  - reference: PMID:24610826
    reference_title: "Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS.
    explanation: The mechanistic review supports metabolic adaptation as one component of resistance, not a universal route.

pathophysiology:
- name: Somatic BRAF Codon-600 Driver
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    A tumor-acquired missense substitution at BRAF codon 600 destabilizes the
    inactive kinase configuration. Codon-600 mutants constitute class-I BRAF:
    they are active without upstream RAS, signal as monomers, and differ
    mechanistically from class-II dimers and RAS-dependent class-III mutants.
  genes:
  - preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  molecular_functions:
  - preferred_term: protein serine/threonine kinase activity
    modifier: INCREASED
    term:
      id: GO:0004674
      label: protein serine/threonine kinase activity
  evidence:
  - reference: PMID:12068308
    reference_title: Mutations of the BRAF gene in human cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
    explanation: The foundational study functionally establishes kinase activation and transformation.
  - reference: PMID:28783719
    reference_title: Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Activating BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and signal either as active monomers (class 1) or constitutively active dimers (class 2).
    explanation: The functional-classification study places V600 alleles in the RAS-independent monomeric class.
  downstream:
  - target: Sustained MEK-ERK Signaling
    causal_link_type: DIRECT
    description: Constitutive class-I BRAF kinase output activates the downstream MEK-ERK cascade without an upstream RAS requirement.
    hypothesis_groups:
    - canonical_braf_v600_melanoma_model
    evidence:
    - reference: PMID:12068308
      reference_title: Mutations of the BRAF gene in human cancer.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: RAS function is not required for the growth of cancer cell lines with the V599E mutation.
      explanation: The original codon-numbering study directly demonstrates RAS-independent growth.
  - target: Oncogene-Induced Melanocytic Growth-Arrest Barrier
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - excessive oncogenic signaling
    - cellular senescence program
    description: In melanocytes, BRAF V600E can initiate benign hyperplasia followed by a durable growth-arrest barrier.
    hypothesis_groups:
    - canonical_braf_v600_melanoma_model
    evidence:
    - reference: PMID:19282848
      reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months.
      explanation: Melanocyte-specific Braf V600E directly produced a nonprogressing benign state in mice.

- name: Sustained MEK-ERK Signaling
  role: central_effector
  biological_scale: MOLECULAR
  description: >-
    Constitutive mutant-BRAF output maintains the RAF-MEK-ERK cascade, which
    controls proliferative and survival programs in the melanocytic lineage.
    The pathway remains pharmacologically actionable because inhibition at both
    BRAF and MEK reduces pathway output and delays, but does not eliminate,
    resistance.
  biological_processes:
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  evidence:
  - reference: PMID:23569304
    reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Vemurafenib inhibited MAPK signaling and cell-cycle progression.
    explanation: Paired clinical biopsies show target-pathway suppression during BRAF inhibition.
  downstream:
  - target: MAPK-Dependent Melanocyte Proliferation and Survival
    causal_link_type: DIRECT
    description: Sustained ERK output maintains cell-cycle progression and survival in BRAF-driven melanoma cells.
    hypothesis_groups:
    - canonical_braf_v600_melanoma_model
    evidence:
    - reference: PMID:23569304
      reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: An association between the decrease in extracellular signal-related kinase (ERK) phosphorylation and objective response was observed in paired biopsies (n = 22; P = .013).
      explanation: Pharmacodynamic response links reduced ERK activity with reduced tumor growth.

- name: MAPK-Dependent Melanocyte Proliferation and Survival
  role: consequence
  biological_scale: CELLULAR
  description: >-
    Persistent ERK signaling expands and sustains transformed melanocytes.
    This output is necessary but not always sufficient for invasive melanoma:
    experimental BRAF expression can stop at a benign hyperplasia, whereas
    additional survival and tumor-suppressor lesions permit progression.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  locations:
  - preferred_term: skin of body
    term:
      id: UBERON:0002097
      label: skin of body
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:12068308
    reference_title: Mutations of the BRAF gene in human cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
    explanation: The functional assay establishes proliferative transformation downstream of mutant BRAF.
  downstream:
  - target: Cutaneous Melanoma
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - clonal melanocyte expansion
    - escape from oncogene-induced growth arrest
    - malignant transformation
    description: MAPK-dependent expansion contributes to the cutaneous melanoma phenotype when cooperating progression barriers are overcome.
    hypothesis_groups:
    - canonical_braf_v600_melanoma_model
    evidence:
    - reference: PMID:19282848
      reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: By contrast, expression of BRaf(V600E) combined with Pten tumor suppressor gene silencing elicited development of melanoma with 100% penetrance, short latency and with metastases observed in lymph nodes and lungs.
      explanation: The lineage-specific model directly links the driver-plus-cooperation state to melanoma formation.

- name: Oncogene-Induced Melanocytic Growth-Arrest Barrier
  role: regulatory
  biological_scale: CELLULAR
  description: >-
    Strong oncogenic BRAF signaling can evoke a senescence-like arrest rather
    than continuous malignant growth. This helps explain why BRAF V600E is
    found in benign melanocytic proliferations and why additional genetic or
    cell-state changes are required for invasive cancer.
  cell_types:
  - preferred_term: melanocyte
    term:
      id: CL:0000148
      label: melanocyte
  biological_processes:
  - preferred_term: cellular senescence
    modifier: INCREASED
    term:
      id: GO:0090398
      label: cellular senescence
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months.
    explanation: The long-lived benign phenotype supports a progression barrier after driver activation.
  - reference: PMID:22549727
    reference_title: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: PTEN depletion abrogates BRAF(V600E)-induced senescence in human fibroblasts and melanocytes.
    explanation: The human-cell experiment directly identifies BRAF-induced senescence and its escape after PTEN depletion.

- name: PTEN-Loss and PI3K-AKT-mTOR Cooperation
  role: modifier
  biological_scale: MOLECULAR
  description: >-
    Loss of PTEN provides a cooperating survival pathway that permits
    BRAF-initiated melanocytes to escape the benign growth-arrest state and
    progress. This is a validated experimental route rather than a claim that
    PTEN loss is obligatory in every human BRAF V600 melanoma.
  genes:
  - preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  biological_processes:
  - preferred_term: intracellular signal transduction
    modifier: INCREASED
    term:
      id: GO:0035556
      label: intracellular signal transduction
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression of BRaf(V600E) combined with Pten tumor suppressor gene
      silencing elicited development of melanoma with 100% penetrance.
    explanation: The conditional mouse experiment directly establishes cooperation.
  - reference: PMID:22549727
    reference_title: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: PI3K pathway activation serves as a rate-limiting event in this setting
    explanation: Human cells and contiguous nevus-melanoma specimens support PI3K-pathway escape from the BRAF-induced barrier.
  downstream:
  - target: Invasive and Metastatic Melanoma Progression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - escape from growth arrest
    - enhanced tumor-cell survival
    - invasive clonal expansion
    description: In the conditional model, PTEN loss converts BRAF-initiated hyperplasia into rapidly penetrant metastatic melanoma.
    hypothesis_groups:
    - canonical_braf_v600_melanoma_model
    evidence:
    - reference: PMID:19282848
      reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: with metastases observed in lymph nodes and lungs
      explanation: The same model directly demonstrates metastatic progression after genetic cooperation.

- name: Invasive and Metastatic Melanoma Progression
  role: consequence
  biological_scale: TISSUE
  description: >-
    Melanoma progression entails invasion, regional or distant dissemination,
    and survival in metastatic sites. BRAF V600 is a driver and treatment
    biomarker, but it does not by itself define the anatomic pattern or stage;
    co-alterations, immune context, and tumor-cell state modify progression.
  biological_processes:
  - preferred_term: positive regulation of cell migration
    modifier: INCREASED
    term:
      id: GO:0030335
      label: positive regulation of cell migration
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: with metastases observed in lymph nodes and lungs
    explanation: The Braf/Pten model directly establishes dissemination after cooperative transformation.
  downstream:
  - target: Brain Metastases
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - hematogenous dissemination
    - blood-brain barrier transit
    - intracranial colonization
    description: Advanced BRAF V600 melanoma can disseminate to the brain, although a unique BRAF-dependent brain-homing route is not established here.
    evidence:
    - reference: PMID:28592387
      reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Between Feb 28, 2014, and Aug 5, 2016, 125 patients were enrolled in the study
      explanation: The molecularly selected trial establishes the clinical phenotype but not a unique brain-tropism mechanism.
  - target: Progressive Metastatic Disease
    causal_link_type: DIRECT
    description: Continued invasive growth and dissemination produce clinically progressive metastatic melanoma.
    evidence:
    - reference: PMID:28592387
      reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The median duration of response was relatively short.
      explanation: The trial documents limited response durability in advanced brain-metastatic disease.

- name: Immune-Checkpoint-Mediated Evasion
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  role: modifier
  biological_scale: CELLULAR
  description: >-
    BRAF-mutant melanoma exists within an immune-responsive but suppressive
    microenvironment. BRAF inhibition can increase CD8-positive T-cell
    infiltration while also increasing PD-L1, creating a rationale for
    checkpoint blockade. Immune phenotype varies among tumors and is not
    determined by BRAF status alone.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  evidence:
  - reference: PMID:24903021
    reference_title: Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BRAF inhibition results in a more favorable tumor microenvironment in patients, with an increase in CD8(+) T-cell infiltrate and a decrease in immunosuppressive cytokines.
    explanation: Human paired observations support treatment-associated immune remodeling.
  - reference: PMID:26091043
    reference_title: Genomic Classification of Cutaneous Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: samples assigned a transcriptomic subclass enriched for immune gene expression
    explanation: TCGA shows clinically relevant immune heterogeneity across cutaneous melanoma.

- name: Acquired MAPK Reactivation and Adaptive Resistance
  role: consequence
  biological_scale: CELLULAR
  description: >-
    Under BRAF- or BRAF/MEK-inhibitor selection, progressing lesions can restore
    ERK signaling through secondary NRAS or MAP2K1 alterations and other MAPK
    routes. Parallel PI3K-AKT signaling and reversible transcriptional or
    metabolic adaptation can also sustain drug-tolerant states. Resistance is
    therefore mechanistically heterogeneous.
  biological_processes:
  - preferred_term: ERK1 and ERK2 cascade
    modifier: INCREASED
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: response to xenobiotic stimulus
    modifier: ABNORMAL
    term:
      id: GO:0009410
      label: response to xenobiotic stimulus
  evidence:
  - reference: PMID:23569304
    reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acquired resistance results primarily from MAPK reactivation driven by
      the appearance of secondary mutations in NRAS and MEK1 in subsets of patients.
    explanation: Serial biopsies directly establish specific clinical resistance routes.
  - reference: PMID:24610826
    reference_title: "Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS.
    explanation: The review supports adaptive metabolic plasticity as a candidate resistance component.
  downstream:
  - target: Progressive Metastatic Disease
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - restoration of tumor-cell proliferation
    - survival of drug-tolerant clones
    - expansion of resistant lesions
    description: Restored or bypass signaling permits renewed tumor growth during targeted therapy.
    hypothesis_groups:
    - acquired_mapk_inhibitor_resistance_model
    evidence:
    - reference: PMID:23569304
      reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions
      explanation: Progressive human lesions directly link restored MAPK output with acquired clinical resistance.

histopathology:
- name: Malignant Melanocytic Neoplasm
  finding_term:
    preferred_term: Melanocytic Neoplasm
    term:
      id: NCIT:C7058
      label: Melanocytic Neoplasm
  frequency: OBLIGATE
  description: >-
    Histopathology must establish melanoma in the cutaneous context before the
    BRAF V600 result is used to assign this molecular subtype. BRAF status does
    not replace morphologic diagnosis or staging.
  evidence:
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If melanoma is suspected, a histopathological examination is always required.
    explanation: The current interdisciplinary guideline makes histopathologic confirmation mandatory.

phenotypes:
- category: Neoplastic
  name: Cutaneous Melanoma
  frequency: OBLIGATE
  diagnostic: true
  description: >-
    A malignant melanoma arising in skin is the defining tumor phenotype for
    this entry. The BRAF V600 result subdivides cutaneous melanoma but does not
    substitute for its clinicopathologic diagnosis.
  phenotype_term:
    preferred_term: Cutaneous melanoma
    term:
      id: HP:0012056
      label: Cutaneous melanoma
  evidence:
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality.
    explanation: The guideline establishes the cutaneous melanoma disease context.
- category: Neoplastic
  name: Progressive Metastatic Disease
  description: >-
    Stage III or IV disease can progress through regional or distant tumor
    growth. During targeted therapy, molecularly heterogeneous resistant lesions
    can restore MAPK signaling and resume growth.
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: PMID:23569304
    reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions
    explanation: Serial biopsies directly tie resistant signaling to clinically progressive lesions.
- category: Neurologic
  name: Brain Metastases
  description: >-
    Intracranial metastasis is an important advanced-disease phenotype that
    changes local and systemic treatment planning. COMBI-MB established
    intracranial activity of dabrafenib plus trametinib, but responses were often
    less durable than needed.
  phenotype_term:
    preferred_term: Brain metastasis
    term:
      id: HP:0030692
      label: Brain neoplasm
  evidence:
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response
    explanation: The molecularly selected phase-II trial directly documents the brain-metastatic phenotype and intracranial response.

biochemical:
- name: Tumor BRAF V600 Variant Detection
  presence: REQUIRED_FOR_SUBTYPE_ASSIGNMENT
  notes: >-
    Detection of a somatic BRAF codon-600 variant in melanoma tissue defines
    this molecular subtype. The exact protein allele should be reported because
    registration-trial evidence is strongest for V600E and V600K.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The SNaPshot melanoma screen can detect 43 point mutations in 6 genes relevant to targeted therapy in melanoma.
    explanation: The clinical implementation study establishes multiplex tumor genotyping and allele resolution.
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: From stage IIB/C and higher, a mutation test is recommended, especially for the BRAF V600 mutation.
    explanation: The current diagnostic guideline supports stage-appropriate BRAF V600 testing.
- name: BRAF V600E VE1 Immunoreactivity
  presence: VARIABLE
  notes: >-
    VE1 immunohistochemistry can screen for the V600E protein, but it does not
    comprehensively identify all V600 alleles and showed imperfect sensitivity
    and specificity in the cited cohort. Molecular testing remains necessary
    when the result is discordant, negative despite clinical need, or when exact
    non-E allele resolution matters.
  evidence:
  - reference: PMID:28424234
    reference_title: "BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The antibody showed a sensitivity of 86.1% with a specificity of 96.9%.
    explanation: The direct PCR-versus-VE1 comparison quantifies performance and supports screening rather than universal substitution.
- name: Plasma BRAF V600 Circulating Tumor DNA
  presence: VARIABLE
  notes: >-
    BRAF V600-mutant circulating tumor DNA is frequently detectable in advanced
    disease and can carry prognostic information. Detectability is lower after
    resection, and intervention guided by ctDNA remains investigational rather
    than a replacement for tissue diagnosis or standard imaging.
  evidence:
  - reference: PMID:33587894
    reference_title: "Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ctDNA was detected in pretreatment samples from 320 (93%) of 345 patients (COMBI-d) and 34 (89%) of 38 patients (COMBI-MB).
    explanation: The large biomarker analysis directly quantifies baseline detectability in advanced disease.
  - reference: PMID:40250457
    reference_title: "Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ctDNA was detectable in 79 (13%) of 597 baseline samples.
    explanation: The resected-stage-III analysis demonstrates much lower detection in the minimal-residual-disease setting.

genetic:
- name: BRAF p.Val600Glu
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  association: Somatic Activating Driver Mutation
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    BRAF c.1799T>A (p.Val600Glu) is the dominant codon-600 allele and has the
    most extensive targeted-therapy evidence. Historical literature called the
    same residue V599E before sequence numbering was standardized.
  evidence:
  - reference: PMID:12068308
    reference_title: Mutations of the BRAF gene in human cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.
    explanation: The foundational study identifies the dominant activating melanoma allele under historical numbering.
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The clinical testing cohort confirms dominance of the standardized V600E allele.
- name: BRAF p.Val600Lys
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  association: Somatic Activating Driver Mutation
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    V600K is the second most common allele in the cited testing cohort and was
    explicitly eligible in pivotal BRAF/MEK trials.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The molecular-testing cohort directly identifies the V600K fraction.
  - reference: PMID:31166680
    reference_title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.
    explanation: The long-term phase-III analysis directly includes this allele.
- name: BRAF p.Val600Arg
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  association: Somatic Activating Driver Mutation
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    V600R is an uncommon codon-600 allele. It belongs in the molecular subtype,
    but its treatment evidence is smaller than that for V600E/K and should be
    assessed with exact-allele and regimen context.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The molecular-testing cohort directly documents V600R melanoma.
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases
    explanation: A small prospective cohort included V600R, but this is not equivalent to the V600E/K evidence base.
- name: BRAF p.Val600Met
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  association: Somatic Activating Driver Mutation
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  notes: >-
    V600M is a rare codon-600 allele documented in clinical molecular testing.
    It is included in the disease spectrum, while allele-specific therapeutic
    efficacy remains less certain than for V600E/K.
  evidence:
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively.
    explanation: The molecular-testing cohort directly documents V600M melanoma.

diagnosis:
- name: Clinicopathologic cutaneous melanoma diagnosis
  presence: REQUIRED
  description: >-
    A suspicious cutaneous lesion is evaluated clinically and with dermoscopy,
    then confirmed histopathologically. Molecular subtype assignment follows
    the melanoma diagnosis; a BRAF result alone cannot establish the tissue of
    origin or distinguish melanoma from another BRAF-mutant cancer.
  evidence:
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of melanoma can be made clinically and must always be confirmed by dermoscopy.
    explanation: The guideline directly supports clinical and dermoscopic assessment.
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: If melanoma is suspected, a histopathological examination is always required.
    explanation: The guideline directly requires pathologic confirmation.
- name: Tumor BRAF V600 genotyping
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  presence: REQUIRED_FOR_SUBTYPE_ASSIGNMENT
  description: >-
    A validated DNA assay should identify the exact tumor BRAF allele. Testing
    is especially relevant from stage IIB/C onward and before BRAF/MEK therapy.
    Broad sequencing can also separate V600 class-I disease from class-II or
    class-III non-V600 BRAF melanoma.
  results: Detection of a somatic BRAF codon-600 variant establishes the molecular subtype in confirmed cutaneous melanoma.
  evidence:
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: From stage IIB/C and higher, a mutation test is recommended, especially for the BRAF V600 mutation.
    explanation: The guideline supports stage-appropriate BRAF V600 testing.
  - reference: PMID:22536370
    reference_title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The test utilizes the SNaPshot method (multiplex PCR, multiplex primer extension, and capillary electrophoresis)
    explanation: The clinical laboratory study validates a multi-allele tumor-genotyping approach.
- name: VE1 immunohistochemistry as a V600E screen
  presence: COMPLEMENTARY
  description: >-
    VE1 staining can rapidly support V600E detection in suitable tissue, but
    imperfect sensitivity and allele specificity mean that it is not a complete
    substitute for molecular BRAF V600 testing.
  results: Positive tumor-cell VE1 staining supports V600E; discordant or clinically consequential negative results require molecular resolution.
  evidence:
  - reference: PMID:28424234
    reference_title: "BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The concordance rate between PCR and immunohistochemical BRAF status was 95.1%.
    explanation: The direct method comparison supports complementary screening while leaving room for discordance.
- name: Stage-directed body and brain imaging
  presence: STAGE_DEPENDENT
  description: >-
    From stage IIB/C, cross-sectional body imaging together with brain MRI is
    recommended for staging and surveillance planning. Imaging defines disease
    extent but does not determine BRAF status.
  evidence:
  - reference: PMID:39700658
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      From stage IIB/C, whole-body examinations with computed tomography or
      positron emission tomography CT in combination with magnetic resonance
      imaging of the brain are recommended.
    explanation: The guideline directly supplies the stage threshold and imaging combination.

differential_diagnoses:
- name: Non-V600 BRAF-Mutant Cutaneous Melanoma
  description: >-
    These tumors can share the same cutaneous histology but carry class-II or
    class-III BRAF alleles with different dimerization, RAS dependence, kinase
    activity, and expected sensitivity to RAF monomer inhibitors.
  distinguishing_features:
  - Resolve the exact BRAF protein change rather than treating any BRAF mutation as V600 disease.
  - Class-I V600 mutants signal as RAS-independent monomers; class-II mutants signal as dimers and class-III mutants depend on activated RAS.
  evidence:
  - reference: PMID:28783719
    reference_title: Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We have thus defined three distinct functional classes of BRAF mutants in human tumours.
    explanation: Functional classification directly distinguishes V600 class-I disease from non-V600 classes.
- name: RAS-Mutant, NF1-Mutant, or Triple-Wild-Type Cutaneous Melanoma
  description: >-
    Cutaneous melanomas in these genomic classes can be histologically
    indistinguishable but lack the defining BRAF V600 driver and follow
    different targeted-treatment logic.
  distinguishing_features:
  - Use tumor sequencing to assign the BRAF, RAS, NF1, or triple-wild-type genomic class.
  - Do not infer BRAF V600 status from morphology, age, site, or UV-exposure history.
  evidence:
  - reference: PMID:26091043
    reference_title: Genomic Classification of Cutaneous Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We establish a framework for genomic classification into one of four
      subtypes based on the pattern of the most prevalent significantly mutated
      genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type).
    explanation: TCGA directly establishes the major mutually informative genomic classes.

progression:
- phase: BRAF-initiated melanocytic hyperplasia with a growth-arrest barrier
  notes: >-
    Lineage-restricted Braf V600E expression can initiate benign melanocytic
    proliferation without spontaneous melanoma progression, demonstrating that
    the driver is not a complete malignant program by itself.
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Mice developed benign melanocytic hyperplasias that failed to progress to melanoma over 15-20 months.
    explanation: The conditional model directly defines an initiated but progression-constrained phase.
- phase: Cooperative malignant and metastatic progression
  notes: >-
    Additional tumor-suppressor and survival-pathway changes can release the
    BRAF-initiated barrier. PTEN loss is one experimentally established route,
    producing rapid melanoma and lymph-node or lung metastasis in mice; human
    tumors remain more heterogeneous.
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: with metastases observed in lymph nodes and lungs
    explanation: The model directly establishes metastatic progression after genetic cooperation.
- phase: Targeted response followed by molecularly heterogeneous resistance
  notes: >-
    BRAF inhibition suppresses ERK phosphorylation and tumor proliferation, but
    progressing lesions can restore MAPK signaling through secondary NRAS or
    MEK1 alterations. Other lesions may use different or non-genetic routes.
  evidence:
  - reference: PMID:23569304
    reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acquired resistance results primarily from MAPK reactivation driven by
      the appearance of secondary mutations in NRAS and MEK1 in subsets of patients.
    explanation: Serial pretreatment and progression biopsies directly define the resistant phase and its heterogeneity.
- phase: Brain-metastatic disease
  notes: >-
    Brain metastasis is a clinically important advanced phase. Targeted therapy
    can induce intracranial responses, but response durability remains limited,
    requiring integrated systemic and local treatment planning.
  evidence:
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response
    explanation: The prospective phase-II trial directly characterizes treated brain-metastatic disease.

treatments:
- name: Surgical Excision of Resectable Cutaneous Melanoma
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  description: >-
    Complete excision with a stage-appropriate margin is the foundation for
    resectable primary disease. Sentinel-node biopsy is a staging procedure in
    selected tumors and should not be described as having a proven survival
    benefit. Subsequent adjuvant treatment depends on stage, BRAF allele, risk,
    and patient context.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Cutaneous melanoma
    term:
      id: HP:0012056
      label: Cutaneous melanoma
  evidence:
  - reference: PMID:39709737
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Cutaneous melanomas are excised with one to two-centimeter safety margins.
    explanation: The current interdisciplinary treatment guideline directly supports surgical excision.

- name: Adjuvant Dabrafenib Plus Trametinib
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Twelve months of dabrafenib plus trametinib is an adjuvant option after
    complete resection of high-risk stage-III BRAF V600E/K melanoma. Final
    COMBI-AD follow-up showed durable relapse-free and distant-metastasis-free
    benefit; the overall-survival comparison did not meet conventional
    statistical significance in the full population.
  target_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    treatment_effect: INHIBITS
    description: Dabrafenib inhibits class-I mutant BRAF kinase activity.
    evidence:
    - reference: clinicaltrials:NCT01682083
      reference_title: "COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: BRAF V600E/K mutation-positive, high-risk
      explanation: The registry directly defines the biomarker-selected adjuvant population.
  - target: Sustained MEK-ERK Signaling
    treatment_effect: INHIBITS
    description: Trametinib blocks MEK output downstream of mutant BRAF.
    evidence:
    - reference: PMID:23569304
      reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance.
      explanation: Human resistance biopsies provide the mechanistic rationale for downstream MEK inhibition.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: dabrafenib
      term:
        id: CHEBI:75045
        label: dabrafenib
    - preferred_term: trametinib
      term:
        id: CHEBI:75998
        label: trametinib
  evidence:
  - reference: PMID:38899716
    reference_title: Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Relapse-free survival favored dabrafenib plus trametinib over placebo (hazard ratio for relapse or death, 0.52; 95% CI, 0.43 to 0.63)
    explanation: Final randomized phase-III follow-up directly supports durable adjuvant relapse prevention.

- name: Dabrafenib Plus Trametinib for Unresectable or Metastatic Disease
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Dual BRAF/MEK inhibition produces rapid responses in BRAF V600E/K
    unresectable or metastatic melanoma. Pooled COMBI-d/COMBI-v follow-up showed
    five-year survival in a subset, while COMBI-MB demonstrated intracranial
    activity with comparatively limited response duration.
  target_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    treatment_effect: INHIBITS
    description: Dabrafenib directly inhibits the mutant BRAF kinase.
    evidence:
    - reference: PMID:31166680
      reference_title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib
      explanation: The biomarker-selected phase-III trials directly evaluate the combination.
  - target: Sustained MEK-ERK Signaling
    treatment_effect: INHIBITS
    description: Trametinib suppresses pathway output downstream of BRAF.
    evidence:
    - reference: PMID:23569304
      reference_title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The data suggest that inhibition downstream of BRAF should help to overcome acquired resistance.
      explanation: Resistance profiling supports dual-level MAPK blockade.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: dabrafenib
      term:
        id: CHEBI:75045
        label: dabrafenib
    - preferred_term: trametinib
      term:
        id: CHEBI:75998
        label: trametinib
  evidence:
  - reference: PMID:31166680
    reference_title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 34% (95% CI, 30 to 38) at 5 years
    explanation: Pooled phase-III follow-up directly reports long-term survival with the combination.
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response
    explanation: COMBI-MB directly supports activity in brain-metastatic disease.

- name: Vemurafenib Plus Cobimetinib
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Vemurafenib plus cobimetinib is a combined BRAF/MEK option for BRAF V600
    advanced melanoma. Five-year coBRIM follow-up confirmed longer median
    progression-free and overall survival than vemurafenib alone, with
    regimen-specific toxicity and patient factors informing selection.
  target_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    treatment_effect: INHIBITS
    description: Vemurafenib inhibits class-I mutant BRAF.
    evidence:
    - reference: clinicaltrials:NCT01689519
      reference_title: "A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma
      explanation: The registry directly defines the molecular population and BRAF-containing regimen.
  - target: Sustained MEK-ERK Signaling
    treatment_effect: INHIBITS
    description: Cobimetinib inhibits MEK downstream of mutant BRAF.
    evidence:
    - reference: PMID:34158360
      reference_title: "5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Median PFS was 12.6 months (95% CI, 9.5-14.8) with cobimetinib plus vemurafenib and 7.2 months (95% CI, 5.6-7.5) with placebo plus vemurafenib; 5-year PFS rates were 14% and 10%, respectively.
      explanation: The randomized comparison demonstrates added benefit from dual pathway inhibition.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: vemurafenib
      term:
        id: CHEBI:63637
        label: vemurafenib
    - preferred_term: cobimetinib
      term:
        id: CHEBI:90851
        label: cobimetinib
  evidence:
  - reference: PMID:34158360
    reference_title: "5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Median OS was 22.5 months (95% CI, 20.3-28.8) with cobimetinib plus vemurafenib and 17.4 months (95% CI, 15.0-19.8) with placebo plus vemurafenib; 5-year OS rates were 31% and 26%, respectively.
    explanation: Extended randomized follow-up directly supports the combination.

- name: Encorafenib Plus Binimetinib
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    Encorafenib plus binimetinib is a combined BRAF/MEK option for locally
    advanced unresectable or metastatic BRAF V600E/K melanoma. The seven-year
    COLUMBUS analysis provides the longest phase-III follow-up among the
    represented targeted combinations.
  target_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    treatment_effect: INHIBITS
    description: Encorafenib inhibits class-I mutant BRAF.
    evidence:
    - reference: clinicaltrials:NCT01909453
      reference_title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation.
      explanation: The registry directly supports the regimen and biomarker-selected population.
  - target: Sustained MEK-ERK Signaling
    treatment_effect: INHIBITS
    description: Binimetinib inhibits MEK downstream of mutant BRAF.
    evidence:
    - reference: PMID:38723373
      reference_title: "COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively.
      explanation: Long-term phase-III follow-up directly supports durable pathway control in a subset.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: encorafenib
      term:
        id: NCIT:C98283
        label: Encorafenib
    - preferred_term: binimetinib
      term:
        id: CHEBI:145371
        label: binimetinib
  evidence:
  - reference: PMID:38723373
    reference_title: "COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seven-year PFS and OS rates (95 % CI) were 21.2 % (14.7-28.4 %) and 27.4 % (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4 % (2.1-14.0 %) and 18.2 % (12.8-24.3 %) in the vemurafenib arm, respectively.
    explanation: The randomized phase-III update directly reports long-term overall survival.

- name: Immune Checkpoint Blockade
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: >-
    PD-1-based therapy, alone or in combination with CTLA-4 or LAG-3 blockade,
    is a major systemic option regardless of BRAF status. In treatment-naive
    metastatic BRAF V600 melanoma, DREAMseq and SECOMBIT support beginning with
    nivolumab plus ipilimumab for most trial-eligible patients, while urgent
    disease control, contraindications, prior adjuvant therapy, toxicity, and
    patient preference can alter individual sequencing.
  target_mechanisms:
  - target: Immune-Checkpoint-Mediated Evasion
    treatment_effect: INHIBITS
    description: Checkpoint antibodies release inhibitory signals that constrain antitumor T-cell activity.
    evidence:
    - reference: PMID:24903021
      reference_title: Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Administration of anti-PD1 or anti-PDL1 together with a BRAF inhibitor led to an enhanced response, significantly prolonging survival and slowing tumor growth
      explanation: The immunocompetent melanoma model directly demonstrates checkpoint-mediated immune constraint.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
    therapeutic_agent:
    - preferred_term: nivolumab
      term:
        id: NCIT:C68814
        label: Nivolumab
    - preferred_term: ipilimumab
      term:
        id: CHEBI:231679
        label: ipilimumab
  evidence:
  - reference: PMID:36166727
    reference_title: "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The 2-year OS for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1) and arm B 51.5% (95% CI, 41.7 to 60.4; log-rank P = .010).
    explanation: The randomized phase-III sequencing trial directly supports immunotherapy-first survival for most enrolled patients.
  - reference: PMID:38167503
    reference_title: "Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These long-term survival outcomes confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma
    explanation: Four-year randomized phase-II follow-up independently supports the sequencing conclusion.
  - reference: PMID:39709737
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: For first line treatment PD-1 antibodies alone or in combination with CTLA-4 or LAG-3 antibodies shall be considered.
    explanation: The current guideline places checkpoint therapy among first-line systemic options.

clinical_trials:
- name: NCT01682083
  phase: PHASE_III
  status: COMPLETED
  description: >-
    COMBI-AD randomized 870 patients with completely resected, high-risk stage-III
    BRAF V600E/K cutaneous melanoma to 12 months of dabrafenib plus trametinib
    or matched placebos. ClinicalTrials.gov listed COMPLETED status when checked
    on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT01682083
    reference_title: "COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus 2 placebos in the adjuvant treatment of melanoma after surgical resection.
    explanation: The registry directly supports the trial design, disease stage, and regimen.
- name: NCT02224781
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    DREAMseq compares nivolumab plus ipilimumab followed at progression by
    dabrafenib plus trametinib against the reverse sequence in unresectable
    stage-III or IV BRAF V600 melanoma. ClinicalTrials.gov listed 267
    participants and ACTIVE_NOT_RECRUITING status when checked on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT02224781
    reference_title: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable).
    explanation: The current registry directly supports the sequencing design and status.
- name: NCT02631447
  phase: PHASE_II
  status: COMPLETED
  description: >-
    SECOMBIT tested targeted-therapy-first, immunotherapy-first, and an eight-week
    targeted-therapy induction followed by immunotherapy in metastatic BRAF V600
    melanoma. ClinicalTrials.gov listed 251 participants and COMPLETED status
    when checked on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT02631447
    reference_title: A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To evaluate the best sequencing approach with the combination of target agents (LGX818 plus MEK162) and the combination of immunomodulatory antibodies (ipilimumab plus nivolumab) in patients with metastatic melanoma and BRAF V600 mutation.
    explanation: The registry directly supports the population, interventions, and sequencing objective.
- name: NCT02039947
  phase: PHASE_II
  status: COMPLETED
  description: >-
    COMBI-MB evaluated dabrafenib plus trametinib across symptomatic,
    asymptomatic, previously locally treated, and untreated BRAF V600 melanoma
    brain-metastasis cohorts. ClinicalTrials.gov listed 127 participants and
    COMPLETED status when checked on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT02039947
    reference_title: "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain.
    explanation: The registry directly supports the intracranial trial design and completed status.
- name: NCT01909453
  phase: PHASE_III
  status: COMPLETED
  description: >-
    COLUMBUS compared encorafenib plus binimetinib with vemurafenib and
    encorafenib monotherapy in locally advanced unresectable or metastatic BRAF
    V600 melanoma. ClinicalTrials.gov listed 921 participants and COMPLETED
    status when checked on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT01909453
    reference_title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation.
    explanation: The registry directly supports the design, molecular population, and interventions.
- name: NCT01689519
  phase: PHASE_III
  status: COMPLETED
  description: >-
    coBRIM compared vemurafenib plus cobimetinib with vemurafenib plus placebo
    in previously untreated, unresectable locally advanced or metastatic BRAF
    V600 melanoma. ClinicalTrials.gov listed 495 participants and COMPLETED
    status when checked on 2026-07-23.
  evidence:
  - reference: clinicaltrials:NCT01689519
    reference_title: "A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.
    explanation: The registry directly supports the phase-III comparator design and molecular eligibility.

animal_models:
- species: Mus musculus
  genotype: Melanocyte-specific conditional Braf(V600E), with or without Pten silencing
  genes:
  - preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  - preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  description: >-
    Conditional melanocyte-specific Braf V600E produces benign melanocytic
    hyperplasia without melanoma over prolonged observation. Adding Pten loss
    produces rapid, fully penetrant melanoma with lymph-node and lung
    metastases, modeling oncogene initiation, progression restraint, and
    PI3K-pathway cooperation.
  associated_phenotypes:
  - Benign melanocytic hyperplasia with Braf V600E alone
  - Rapid melanoma after combined Braf V600E and Pten loss
  - Lymph-node and lung metastases
  evidence:
  - reference: PMID:19282848
    reference_title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Expression of BRaf(V600E) combined with Pten tumor suppressor gene
      silencing elicited development of melanoma with 100% penetrance.
    explanation: The study directly defines the conditional cooperative model.
- species: Mus musculus
  genotype: Syngeneic Braf(V600E)/Pten-null melanoma graft in immunocompetent mice
  genes:
  - preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  - preferred_term: PTEN
    term:
      id: hgnc:9588
      label: PTEN
  description: >-
    An immunocompetent syngeneic Braf V600E/Pten-null graft model reproduces
    increased intratumoral CD8-positive T-cell density after BRAF inhibition and
    permits testing of combined targeted and checkpoint therapy.
  associated_phenotypes:
  - Syngeneic melanoma growth
  - Increased CD8-positive tumor infiltration after BRAF inhibition
  - Enhanced response to combined BRAF and PD-1 or PD-L1 blockade
  evidence:
  - reference: PMID:24903021
    reference_title: Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: we developed a BRAF(V600E)/Pten(-/-) syngeneic tumor graft immunocompetent mouse model
    explanation: The publication explicitly defines the immune-competent graft model.
- species: Danio rerio
  genotype: Transgenic BRAF(V600E)-driven melanoma with cooperating germline drivers including p53 loss
  genes:
  - preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  description: >-
    Engineered zebrafish melanomas initiated by BRAF V600E with cooperating
    drivers model multi-hit tumorigenesis in the absence of ultraviolet
    exposure. Tumors have low overall mutation burden but remain genetically
    heterogeneous, which helps separate driver cooperation from UV-associated
    human mutational burden.
  associated_phenotypes:
  - Variable melanoma onset and pathology
  - Low mutation burden
  - Genetically heterogeneous tumors
  evidence:
  - reference: PMID:24148783
    reference_title: The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Engineered zebrafish melanomas show an overall low mutation burden.
    explanation: Exome sequencing directly characterizes the BRAF-driven zebrafish tumors.
- name: Xiphophorus Gordon-Kosswig-Anders backcross hybrid melanoma
  species: Xiphophorus maculatus x Xiphophorus hellerii
  genotype: >-
    Backcross hybrid hemizygous for the Xmrk (Tu) locus and lacking the
    X. maculatus R/Diff tumour-suppressor allele
  background: >-
    X. maculatus Jp163A spotted-dorsal (Sd) x X. hellerii, F1 backcrossed to
    X. hellerii. The sibling Jp163B spotted-side (Sp) line is the Tu-carrying
    parent of three of the alternative hybrid models rather than of this
    classical cross; one of those, Sp-couchianus, is the primary UVB-inducible
    melanoma model and crosses Jp163B to X. couchianus (PMID:21143485).
  publication: PMID:2797166
  description: >-
    The oldest vertebrate melanoma model. Crossing a spotted X. maculatus
    platyfish to X. hellerii and backcrossing the F1 to the swordtail parent
    segregates the melanoma oncogene Xmrk away from the R/Diff locus that
    normally restrains it. Backcross progeny segregate into four Mendelian
    classes, and those inheriting Xmrk on an R/Diff-free background develop
    highly malignant melanoma. Xmrk encodes a constitutively active paralogue of the
    epidermal growth factor receptor whose dominant downstream output is the
    Ras/Raf/MAPK cascade. Because the driver sits upstream of RAF rather than in
    it, the model isolates the consequences of sustained MAPK flux from the
    identity of the mutation that produces it, and it was the system in which
    receptor tyrosine kinase/Ras/Raf/MAPK signalling was identified as the
    critical melanoma driver roughly a decade before that role was established
    in human tumours.
  associated_phenotypes:
  - Spontaneous malignant melanoma in the Xmrk-carrying, R/Diff-free segregant class
  - Melanoma malignancy grade tracking Xmrk expression level
  - Progression from pigmented macromelanophore lesion to invasive melanoma
  evidence:
  - reference: PMID:2797166
    reference_title: Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Malignant melanoma in Xiphophorus fish hybrids is caused by the activity of a dominant oncogene Tu.
    explanation: >-
      Establishes the hybrid fish as a genetically defined melanoma model and
      identifies the single dominant locus responsible.
  - reference: PMID:38299666
    reference_title: Validity of Xiphophorus fish as models for human disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: backcross segregants that have inherited only R/Diff-free chromosomes develop highly malignant melanoma due to unobstructed activity of Tu
    explanation: >-
      Describes the segregation that produces melanoma-bearing animals in this
      cross, and the tumour-suppressor loss that permits it.
  modeled_mechanisms:
  - target: Sustained MEK-ERK Signaling
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Ligand-independent Xmrk signalling drives the same Ras/Raf/MEK/ERK output
      that a BRAF codon-600 mutation produces, so the model reproduces the
      downstream node while entering the cascade one step further upstream.
    limitations: >-
      The fish carries no BRAF codon-600 mutation; the driver is an
      EGFR-family receptor tyrosine kinase, so the model cannot report on
      RAF-inhibitor binding, paradoxical RAF activation, or codon-600-specific
      allele biology. Xmrk also activates STAT5 and PI3K-AKT branches that a
      BRAF V600E melanocyte does not engage the same way, so MAPK-attributable
      effects must be separated from those before transferring inferences.
    readouts:
    - name: Ras/Raf/MAPK pathway activation downstream of Xmrk
      target: Sustained MEK-ERK Signaling
      description: >-
        Signalling analyses of Xmrk-expressing melanocytes and fish melanomas
        identifying which downstream cascade carries the transforming signal.
      direction: INCREASED
      interpretation: >-
        MAPK is the dominant effector arm of the fish oncogene, which is what
        makes the model informative for the human MEK-ERK node.
      evidence:
      - reference: PMID:38299666
        reference_title: Validity of Xiphophorus fish as models for human disease.
        supports: SUPPORT
        evidence_source: OTHER
        snippet: The most important downstream signaling pathway activated by the Xmrk receptor tyrosine kinase is the Ras/Raf/MAPK pathway
        explanation: >-
          Identifies MAPK as the principal transducer of the Xmrk signal, the
          basis for mapping this model onto the MEK-ERK node.
    - name: Xmrk transcript level versus tumour malignancy grade
      target: Sustained MEK-ERK Signaling
      description: >-
        Comparison of oncogene expression against histological malignancy across
        hybrid tumours.
      direction: INCREASED
      interpretation: >-
        A dose relationship between driver expression and malignancy, the fish
        counterpart of MAPK output scaling with melanoma aggressiveness.
      evidence:
      - reference: PMID:2797166
        reference_title: Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: We show that its level of expression correlates with the degree of malignancy of the tumour.
        explanation: Reports the measured relationship between oncogene expression and tumour grade.
    evidence:
    - reference: PMID:2797166
      reference_title: Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The Tu gene codes for a novel receptor tyrosine kinase which is closely related to the receptor for epidermal growth factor.
      explanation: >-
        Places the fish driver in the EGFR receptor tyrosine kinase family,
        upstream of the same Ras/Raf/MEK/ERK cascade this node describes.
    - reference: PMID:38299666
      reference_title: Validity of Xiphophorus fish as models for human disease.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: studies of oncogenic Xmrk signaling predicted the role of the receptor tyrosine kinase/Ras/Raf/MAPK pathway as the critical driver for melanoma a decade before this was confirmed in humans
      explanation: >-
        States the predictive validity of this model for the human MAPK-driven
        melanoma mechanism.

experimental_models:
- name: NIH3T3 Mutant-BRAF Transformation Assay
  description: >-
    Expression of melanoma-derived mutant BRAF proteins in NIH3T3 fibroblasts
    demonstrates elevated kinase activity and transforming capacity. This is a
    reductionist driver-function assay, not a melanocyte-lineage or
    immune-competent model of cutaneous melanoma.
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  cell_source: NIH3T3 mouse fibroblast cell line
  culture_system: Two-dimensional transformed-focus and signaling assays after mutant-BRAF expression
  conditions:
  - Wild-type BRAF expression
  - Melanoma-derived mutant BRAF expression
  publication: PMID:12068308
  modeled_mechanisms:
  - target: Somatic BRAF Codon-600 Driver
    description: Tests kinase activation and transforming capacity conferred by melanoma-derived BRAF mutations.
    evidence:
    - reference: PMID:12068308
      reference_title: Mutations of the BRAF gene in human cancer.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
      explanation: The original study directly states both functional readouts.
  findings:
  - statement: Melanoma-derived mutant BRAF proteins have elevated kinase activity and transform NIH3T3 cells.
    supporting_text: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
    evidence:
    - reference: PMID:12068308
      reference_title: Mutations of the BRAF gene in human cancer.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
      explanation: The reductionist assay directly establishes oncogenic function.
  evidence:
  - reference: PMID:12068308
    reference_title: Mutations of the BRAF gene in human cancer.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.
    explanation: The publication explicitly reports the NIH3T3 functional assay.

datasets:
- accession: https://portal.gdc.cancer.gov/projects/TCGA-SKCM
  title: https://portal.gdc.cancer.gov/projects/TCGA-SKCM
  description: >-
    Integrated DNA, RNA, and protein analysis of 333 primary or metastatic
    cutaneous melanomas from 331 patients. The study established BRAF, RAS, NF1,
    and triple-wild-type genomic classes and an immune-expression subclass
    associated with lymphocytic infiltration and survival.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MULTI_OMICS
  sample_count: 333
  conditions:
  - Primary cutaneous melanoma
  - Metastatic cutaneous melanoma
  publication: PMID:26091043
  findings:
  - statement: Cutaneous melanomas separated into mutant-BRAF, mutant-RAS, mutant-NF1, and triple-wild-type genomic classes.
    supporting_text: >-
      We establish a framework for genomic classification into one of four
      subtypes based on the pattern of the most prevalent significantly mutated
      genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT.
    evidence:
    - reference: PMID:26091043
      reference_title: Genomic Classification of Cutaneous Melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We establish a framework for genomic classification into one of four
        subtypes based on the pattern of the most prevalent significantly mutated
        genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type).
      explanation: The integrated cohort directly establishes the molecular-class framework.
  evidence:
  - reference: PMID:26091043
    reference_title: Genomic Classification of Cutaneous Melanoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients.
    explanation: The publication directly defines the multi-omics cohort and sample count.

discussions:
- discussion_id: interpretation_rare_v600_allele_actionability
  prompt: >-
    How much efficacy evidence can be generalized from V600E/K registration
    trials to rare V600R, V600M, V600D, or other codon-600 alleles?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#BRAF p.Val600Arg
  - genetic#BRAF p.Val600Met
  rationale: >-
    Molecular testing confirms that rare V600 alleles exist, but the pivotal
    adjuvant and metastatic trials are dominated by or restricted to V600E/K.
    COMBI-MB included a small V600D/K/R cohort, which is not enough to assume
    identical efficacy for every rare allele and disease stage.
  evidence:
  - reference: PMID:28592387
    reference_title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: BRAFV600D/K/R-positive, asymptomatic melanoma brain metastases
    explanation: The small mixed-allele cohort makes the evidence boundary explicit.
- discussion_id: interpretation_first_line_systemic_sequence
  prompt: >-
    Which patients with treatment-naive metastatic BRAF V600 melanoma should
    begin with checkpoint immunotherapy, targeted therapy, or a short planned
    targeted induction?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - treatments#Immune Checkpoint Blockade
  - treatments#Dabrafenib Plus Trametinib for Unresectable or Metastatic Disease
  - treatments#Encorafenib Plus Binimetinib
  rationale: >-
    DREAMseq and SECOMBIT support immunotherapy first for most enrolled
    patients, while current guidance still allows BRAF/MEK inhibition first in
    selected cases. Rapidly progressive symptomatic disease, brain metastases,
    prior adjuvant therapy, contraindications, and the limited feasibility of
    crossover make individual sequencing more nuanced than a universal rule.
  evidence:
  - reference: PMID:36166727
    reference_title: "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Crossover occurred in 52% of patients with documented disease progression.
    explanation: Limited crossover feasibility is directly relevant to real sequencing decisions.
  - reference: PMID:39709737
    reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In stage IV melanoma with a BRAFV600 mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy, in selected cases.
    explanation: Current guidance preserves a selected-case targeted-first option.
- discussion_id: gap_ctdna_guided_intervention
  prompt: >-
    Can postoperative or on-treatment BRAF V600 ctDNA be used prospectively to
    start, intensify, de-escalate, or switch therapy?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - biochemical#Plasma BRAF V600 Circulating Tumor DNA
  rationale: >-
    COMBI-d, COMBI-MB, and COMBI-AD biomarker analyses show prognostic
    association and useful kinetics, but they did not validate a ctDNA-directed
    intervention strategy.
  evidence:
  - reference: PMID:40250457
    reference_title: "Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Additional studies using ctDNA measurements to guide therapeutic interventions might lead to improvements in the management of resected stage III melanoma.
    explanation: The authors explicitly identify intervention-guiding validation as future work.
- discussion_id: gap_human_progression_model_fidelity
  prompt: >-
    Which cooperating lesions and cell states are necessary and sufficient for
    BRAF V600-initiated human melanocytes to become invasive and metastatic?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#PTEN-Loss and PI3K-AKT-mTOR Cooperation
  rationale: >-
    Conditional mouse and zebrafish models establish multi-hit progression and
    provide tractable systems, but engineered germline or synchronous driver
    combinations do not reproduce the timing, UV background, clonal diversity,
    and immune history of every human tumor.
  evidence:
  - reference: PMID:24148783
    reference_title: The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Engineered zebrafish melanomas show an overall low mutation burden.
    explanation: The model's low-burden, no-UV context exposes a clear mismatch with many human cutaneous melanomas.

disease_term:
  preferred_term: cutaneous melanoma
  term:
    id: MONDO:0005012
    label: cutaneous melanoma
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0005012
      label: cutaneous melanoma
    mapping_predicate: skos:narrowMatch
    mapping_source: MONDO
    mapping_justification: >-
      BRAF V600-mutant melanoma is a molecularly defined stratum of MONDO's cutaneous melanoma
      class, not the class itself: MONDO has no term for the
      BRAF V600E/K kinase-domain mutation stratum, so `disease_term` anchors to the parent
      term while this narrowMatch records that the entry is narrower than it.
      Required by design decisions section 3a for a promoted L4 biomarker
      stratum, which must never present bare parent-term reuse as an exact
      match; the parent term itself is claimed as an exactMatch by
      Cutaneous_Melanoma. Filing a MONDO NTR for this stratum is a tracked
      follow-up.

classifications:
  icdo_morphology:
    classification_value: Melanoma
    evidence:
    - reference: PMID:39700658
      reference_title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality.
      explanation: The guideline establishes the melanoma morphology and cutaneous context.
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:26091043
      reference_title: Genomic Classification of Cutaneous Melanoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We describe the landscape of genomic alterations in cutaneous melanomas through DNA, RNA, and protein-based analysis of 333 primary and/or metastatic melanomas from 331 patients.
      explanation: The integrated cancer cohort supports oncology classification.
review_notes: >-
  MONDO does not provide a dedicated term for this exact molecular subtype, so
  disease_term binds the cutaneous melanoma parent. The entry deliberately
  excludes non-V600 BRAF melanoma and does not generalize cutaneous evidence to
  uveal, mucosal, or acral melanoma without site-specific support. Variant
  frequencies are cohort observations. Treatment assertions distinguish
  V600E/K registration evidence from the thinner rare-V600 evidence base.
  DREAMseq and SECOMBIT favor immunotherapy-first sequencing for most enrolled
  metastatic patients, while current guidance retains targeted-first treatment
  for selected cases. TCGA-SKCM is represented as a broad cutaneous-melanoma
  dataset rather than a pure BRAF V600-only cohort.

references:
- reference: clinicaltrials:NCT01682083
  title: "COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection"
- reference: clinicaltrials:NCT01689519
  title: "A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma"
- reference: clinicaltrials:NCT01909453
  title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- reference: clinicaltrials:NCT02039947
  title: "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain"
- reference: clinicaltrials:NCT02224781
  title: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
- reference: clinicaltrials:NCT02631447
  title: A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
- reference: PMID:12068308
  title: Mutations of the BRAF gene in human cancer.
- reference: PMID:19282848
  title: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
- reference: PMID:19919630
  title: BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
- reference: PMID:22536370
  title: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
- reference: PMID:22549727
  title: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
- reference: PMID:23569304
  title: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
- reference: PMID:24148783
  title: The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
- reference: PMID:24610826
  title: "Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation."
- reference: PMID:24903021
  title: Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
- reference: PMID:25357015
  title: Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
- reference: PMID:26091043
  title: Genomic Classification of Cutaneous Melanoma.
- reference: PMID:28424234
  title: "BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods."
- reference: PMID:28592387
  title: "Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial."
- reference: PMID:28783719
  title: Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
- reference: PMID:31166680
  title: Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
- reference: PMID:33587894
  title: "Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study."
- reference: PMID:34158360
  title: "5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study."
- reference: PMID:36166727
  title: "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134."
- reference: PMID:38167503
  title: "Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial."
- reference: PMID:38723373
  title: "COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma."
- reference: PMID:38899716
  title: Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
- reference: PMID:39700658
  title: "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024."
- reference: PMID:39709737
  title: "European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024."
- reference: PMID:40250457
  title: "Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial."
📚

References & Deep Research

References

30
clinicaltrials:NCT01682083
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
No top-level findings curated for this source.
clinicaltrials:NCT01689519
A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
No top-level findings curated for this source.
clinicaltrials:NCT01909453
A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
No top-level findings curated for this source.
clinicaltrials:NCT02039947
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
No top-level findings curated for this source.
clinicaltrials:NCT02224781
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
No top-level findings curated for this source.
clinicaltrials:NCT02631447
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
No top-level findings curated for this source.
PMID:12068308
Mutations of the BRAF gene in human cancer.
No top-level findings curated for this source.
PMID:19282848
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
No top-level findings curated for this source.
PMID:19919630
BRAF V600E mutation and the tumour suppressor IGFBP7 in atypical genital naevi.
No top-level findings curated for this source.
PMID:22536370
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.
No top-level findings curated for this source.
PMID:22549727
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
No top-level findings curated for this source.
PMID:23569304
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
No top-level findings curated for this source.
PMID:24148783
The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
No top-level findings curated for this source.
PMID:24610826
Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.
No top-level findings curated for this source.
PMID:24903021
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
No top-level findings curated for this source.
PMID:25357015
Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
No top-level findings curated for this source.
PMID:26091043
Genomic Classification of Cutaneous Melanoma.
No top-level findings curated for this source.
PMID:28424234
BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
No top-level findings curated for this source.
PMID:28592387
Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
No top-level findings curated for this source.
PMID:28783719
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
No top-level findings curated for this source.
PMID:31166680
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
No top-level findings curated for this source.
PMID:33587894
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
No top-level findings curated for this source.
PMID:34158360
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
No top-level findings curated for this source.
PMID:36166727
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
No top-level findings curated for this source.
PMID:38167503
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
No top-level findings curated for this source.
PMID:38723373
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
No top-level findings curated for this source.
PMID:38899716
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
No top-level findings curated for this source.
PMID:39700658
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
No top-level findings curated for this source.
PMID:39709737
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
No top-level findings curated for this source.
PMID:40250457
Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
No top-level findings curated for this source.

Deep Research

2
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 68 citations 2026-04-05T13:30:31.689756

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: BRAF V600 Mutant Melanoma
  • MONDO ID: (if available)
  • Category:

Research Objectives

Please provide a comprehensive research report on BRAF V600 Mutant Melanoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Disease Characteristics Research Report: BRAF V600–Mutant Melanoma

Target Disease

  • Disease name: BRAF V600–mutant cutaneous melanoma (localized, resectable, unresectable/metastatic) (marquezrodas2024seomgemclinicalguidelines pages 1-2, castellani2023brafmutationsin pages 1-2)
  • Category: Neoplastic disease (cutaneous malignant melanoma defined by oncogenic BRAF V600 driver mutation)
  • MONDO ID: Not identified in the retrieved primary/guideline sources in this run (marquezrodas2024seomgemclinicalguidelines pages 1-2, NCT02036086 chunk 2)
Disease label ICD-10 code MeSH term / ID Key molecular synonyms Staging system referenced Source (first author, year) Publication date URL / DOI
BRAF V600–mutant cutaneous melanoma C43 (malignant melanoma of skin) (hoejberg2016trendsinmelanoma pages 1-3) Melanoma / D008545 (NCT02036086 chunk 2) BRAFmut; BRAFV600mut; BRAFV600E/K (marquezrodas2024seomgemclinicalguidelines pages 1-2, ghate2018healthcareresourceutilization pages 1-5) AJCC 8th edition (marquezrodas2024seomgemclinicalguidelines pages 1-2, dixon2024primarycutaneousmelanoma—management pages 1-2) Márquez-Rodas, 2024; Hoejberg, 2016; ClinicalTrials.gov NCT02036086 (marquezrodas2024seomgemclinicalguidelines pages 1-2, NCT02036086 chunk 2, hoejberg2016trendsinmelanoma pages 1-3) May 2024; Jan 2016; trial record 2015 https://doi.org/10.1007/s12094-024-03497-2 ; https://doi.org/10.3109/0284186x.2015.1114677 ; NCT02036086
BRAF V600–mutant metastatic melanoma C43 (used for malignant melanoma of skin in registry-based melanoma coding; metastatic subset not separately coded in retrieved texts) (hoejberg2016trendsinmelanoma pages 1-3) Melanoma / D008545 (NCT02036086 chunk 2) BRAF-mutant melanoma; BRAFV600-mutant melanoma; BRAFV600E/K–mutant advanced or metastatic melanoma (dummer2026exploratoryanalysisof pages 20-21) AJCC 8th edition referenced in melanoma guidelines/management sources (marquezrodas2024seomgemclinicalguidelines pages 1-2, dixon2024primarycutaneousmelanoma—management pages 1-2) Dummer, 2026; Ghate, 2018; ClinicalTrials.gov NCT02036086 (dummer2026exploratoryanalysisof pages 20-21, ghate2018healthcareresourceutilization pages 1-5, NCT02036086 chunk 2) Jan 2026; Aug 2018; trial record 2015 https://doi.org/10.1158/1078-0432.ccr-25-3262 ; https://doi.org/10.1080/03007995.2018.1501351 ; NCT02036086

Table: This table summarizes the principal coded disease terms and naming conventions that can anchor a knowledge base entry for BRAF V600–mutant melanoma. It also notes the staging framework used in the retrieved guideline and trial sources.

1. Disease Information

Definition/overview. Cutaneous melanoma is a malignant neoplasm derived from melanocytes and is the skin-cancer subtype responsible for most skin cancer deaths due to metastatic potential (belloni2025treatmentrelatedadverseevents pages 1-2, frantz2020fromtankto pages 1-3). “BRAF V600–mutant melanoma” is a molecularly defined subset characterized by an activating missense substitution at BRAF codon 600 (most commonly V600E; also V600K/R/D/M), which constitutively activates MAPK signaling and enables use of BRAF/MEK targeted therapies (castellani2023brafmutationsin pages 1-2, castellani2023brafmutationsin pages 2-4).

Key identifiers and code systems (available in retrieved sources). Melanoma was operationalized as ICD-10 C43 in a Danish registry analysis (hoejberg2016trendsinmelanoma pages 1-3). A ClinicalTrials.gov record lists MeSH “Melanoma” (MeSH ID D008545) (NCT02036086 chunk 2).

Common synonyms/alternative names used in the literature. “Cutaneous melanoma,” “BRAF-mutant melanoma,” “BRAF V600E/K–mutant melanoma,” and shorthand “BRAFmut/BRAFV600mut” appear in clinical and review literature and guidelines (mohr2025updateonthe pages 2-3, marquezrodas2024seomgemclinicalguidelines pages 1-2, dummer2026exploratoryanalysisof pages 20-21).

Evidence source type. The evidence synthesized here is primarily aggregated disease-level knowledge (guidelines/reviews), augmented with randomized trials and observational/real-world cohorts (marquezrodas2024seomgemclinicalguidelines pages 1-2, bai2023dabrafenibplustrametinib pages 1-2, ascierto2024sequentialimmunotherapyand pages 1-2).

2. Etiology

Causal and mechanistic factors. Ultraviolet (UV) radiation (natural sunlight and artificial tanning) is consistently described as the leading environmental risk factor for melanoma development (florent2023brafv600mutatedmetastatic pages 1-2, mohr2025updateonthe pages 2-2). Molecularly, BRAF V600 mutations are common early driver events (including in nevi), but additional alterations are typically required for progression to melanoma (pelosi2024brafmutantmelanomasbiology pages 4-5, pelosi2024brafmutantmelanomasbiology pages 2-4).

Risk factors (environmental/host/genetic). Reported risks include high UV exposure, personal or family history of melanoma (florent2023brafv600mutatedmetastatic pages 1-2), and host pigmentation phenotypes (e.g., pale skin, freckles, light/red hair) associated with increased melanoma risk (castellani2023brafmutationsin pages 1-2). BRAF-mutant melanomas are reported to be more frequent in younger patients and those with intermittent (occasional) sun exposure compared with chronically sun-exposed individuals (castellani2023brafmutationsin pages 2-4). The V600K subtype is specifically linked to chronic sun damage/exposure (pelosi2024brafmutantmelanomasbiology pages 4-5, pelosi2024brafmutantmelanomasbiology pages 2-4).

Protective factors. Direct protective factors were not quantified in the retrieved melanoma/BRAF V600–specific sources; however, UV exposure is the leading modifiable driver, implying sun-protective behaviors as primary prevention (mohr2025updateonthe pages 2-2, manganelli2025skinphotodamageand pages 1-2).

Gene–environment interaction (current understanding). One mechanistic bridge between UV exposure and melanocyte biology is UV-triggered melanocortin signaling (e.g., α-MSH/MC1R → MITF via cAMP–PKA–CREB), linking environmental exposure to transcriptional programs that intersect with MAPK pathway biology (castellani2023brafmutationsin pages 4-6).

3. Phenotypes

3.1 Core clinical phenotypes (primary disease)

  • Primary cutaneous melanoma subtypes: superficial spreading melanoma (SSM) and nodular melanoma (NM) are the most common primary histologies (~70% and ~15%, respectively) (pelosi2024brafmutantmelanomasbiology pages 1-2). NM is described as particularly lethal and responsible for ~40% of melanoma deaths (pelosi2024brafmutantmelanomasbiology pages 1-2).
  • Progression pattern: SSM is described as having radial growth followed by vertical growth and metastatic potential; NM rapidly enters vertical growth phase and tends to be thicker (pelosi2024brafmutantmelanomasbiology pages 1-2).

Suggested HPO terms (examples). - Cutaneous neoplasm/skin lesion: HP:0008069 (abnormality of skin morphology) / HP:0008064 (skin neoplasm; if using disease-phenotype mapping) - Ulceration: HP:0001052 - Increased Breslow thickness / deep invasion: not a single canonical HPO term; can map via “invasive melanoma” phenotype ontology in cancer-specific vocabularies (not retrieved here)

3.2 Metastatic phenotypes and key sites

  • Brain metastases: brain metastases occur in ~40–50% of patients with cutaneous melanoma and are highlighted as a major clinical problem (ascierto2024sequencingofcheckpoint pages 1-2). In SECOMBIT, new brain metastases occurred in 23/69 (targeted-first), 11/69 (immunotherapy-first), and 9/68 (sandwich) (ascierto2024sequencingofcheckpoint pages 1-2).

Suggested HPO terms (examples). - Metastatic neoplasm: HP:0003002 - Lymph node metastasis: HP:0012735 - Brain metastasis: not a standard HPO term in all releases; often represented via “metastatic neoplasm of the brain” in oncology ontologies (mapping may require NCIt)

3.3 Treatment-related symptom phenotypes (toxicity burden)

A meta-analysis reported pooled toxicity prevalences for commonly used BRAF/MEK inhibitor regimens: - Vemurafenib: arthralgia 44% (95% CI 29–59%); rash 39% (95% CI 22–56%) (belloni2025treatmentrelatedadverseevents pages 1-2). - Dabrafenib + trametinib: fatigue 47% (95% CI 38–56%); pyrexia 40% (95% CI 26–54%) (belloni2025treatmentrelatedadverseevents pages 1-2).

Suggested HPO terms (examples). - Arthralgia: HP:0002829 - Rash: HP:0000988 - Pyrexia: HP:0001945 - Fatigue: HP:0012378

Quality of life (QoL). In the retrieved set, QoL evidence is largely indirect (treatment discontinuation/toxicity; patient narrative). A patient+oncologist perspective emphasizes long-term adverse effects and individualized decision-making over a decade-long course (finke2024brafv600emetastaticmelanoma pages 1-2).

4. Genetic/Molecular Information

4.1 Causal gene(s) and driver variants

  • Causal/driver gene: BRAF (HGNC:1097; OMIM *164757 referenced) (castellani2023brafmutationsin pages 2-4).
  • Variant spectrum and relative frequencies (melanoma): somatic BRAF variants occur in ~50% of melanomas; most are codon-600 substitutions. V600E accounts for ~70–88% of BRAF-positive melanomas; V600K ~10–20%; non-V600 ~11% (castellani2023brafmutationsin pages 2-4).

4.2 Functional consequences and pathways

  • MAPK activation: BRAFV600 (class I) is a RAS-independent activating mutant that constitutively activates the RAS/RAF/MEK/ERK cascade (shang2026brafinhibitorresistance pages 2-3, cosci2025molecularbasisof pages 2-4). V600E is described as a phosphomimetic with ~480-fold increased kinase activity and associated with increased cell growth (cosci2025molecularbasisof pages 2-4).

Suggested GO Biological Process terms (examples). - MAPK cascade: GO:0000165 - ERK1 and ERK2 cascade: GO:0070371 - Positive regulation of cell population proliferation: GO:0008284 - Epithelial to mesenchymal transition (phenotype switching analogue): GO:0001837

Suggested Cell Ontology (CL) terms (examples). - Melanocyte: CL:0000148 - Regulatory T cell (immune evasion context): CL:0000815 (supported by BRAF-driven Treg recruitment models in the broader literature base retrieved) (shang2026brafinhibitorresistance pages 2-3)

4.3 Co-mutations / modifiers and resistance biology

Co-altered pathways/genes frequently implicated include NRAS, NF1, PTEN, TP53, CDKN2A, TERT promoter, and regulators of melanoma state such as MITF (pelosi2024brafmutantmelanomasbiology pages 1-2, castellani2023brafmutationsin pages 11-12).

Mechanisms of resistance to BRAF-targeted therapy include: - Primary resistance in ~50% of treatment-naïve patients (reported) (castellani2023brafmutationsin pages 11-12). - Acquired resistance frequently via MAPK reactivation (~80% of BRAFi-resistant tumors) and/or PI3K/AKT/mTOR pathway activation (castellani2023brafmutationsin pages 11-12). - Adaptive resistance via loss of ERK negative feedback leading to RTK upregulation (e.g., PDGFRβ, EGFR) (castellani2023brafmutationsin pages 11-12). - Phenotype switching involving MITF-high melanocyte-like vs MITF-low mesenchymal invasive states (AXL/EGFR/TEAD programs; WNT5A/ROR2 axis) (castellani2023brafmutationsin pages 11-12).

5. Environmental Information

Primary environmental driver is UV radiation exposure (sunlight; indoor tanning), with UVA/UVB causing DNA damage, oxidative stress, inflammation, and immunosuppression (castellani2023brafmutationsin pages 1-2, manganelli2025skinphotodamageand pages 1-2). No infectious etiology is indicated in the retrieved sources.

6. Mechanism / Pathophysiology

Causal chain (simplified): UV-induced DNA damage and mutagenesis in melanocytes + acquisition of activating BRAFV600 mutation → constitutive MAPK/ERK signaling → melanocyte proliferation/survival and tumor initiation (often as nevi) → additional cooperating alterations (e.g., PTEN loss, TERT promoter) enable escape from senescence and progression → invasion/metastasis and microenvironmental remodeling → therapy response followed by adaptive/acquired resistance (MAPK reactivation, phenotype switching, RTK/PI3K bypass, autophagy) (castellani2023brafmutationsin pages 4-6, pelosi2024brafmutantmelanomasbiology pages 2-4, castellani2023brafmutationsin pages 11-12).

Immune involvement. The tumor microenvironment contributes to resistance via stromal and immune components; CAF and immune remodeling are emphasized in resistance reviews (florent2023brafv600mutatedmetastatic pages 1-2). The early immune-modulating effects of oncogenic BRAF (e.g., Treg recruitment) are also supported by retrieved experimental literature (shang2026brafinhibitorresistance pages 2-3).

7. Anatomical Structures Affected

  • Primary: skin (cutaneous melanoma; melanocytes in epidermal basal layer) (belloni2025treatmentrelatedadverseevents pages 1-2, saeed2024cutaneousoncologystrategies pages 1-2).
  • Regional spread: lymph nodes (stage III) and lymphatic drainage, with EV-based detection in exudative seroma after lymphadenectomy (garciasilva2019useofextracellular pages 1-2).
  • Distant metastases: brain is a common metastatic site (brain metastases in ~40–50% of cutaneous melanoma patients) (ascierto2024sequencingofcheckpoint pages 1-2).

Suggested UBERON terms (examples). - Skin: UBERON:0002097 - Lymph node: UBERON:0000029 - Brain: UBERON:0000955

8. Temporal Development

  • Onset: melanoma median age at diagnosis reported as ~57 years in an advanced melanoma treatment review (mohr2025updateonthe pages 2-2).
  • Progression: stage IV disease historically had poor survival (reported 6–12 months historically; improved with modern therapies) (finke2024brafv600emetastaticmelanoma pages 1-2).

9. Inheritance and Population

BRAF V600–mutant melanoma is predominantly somatic. Hereditary melanoma (~10% of cases) is reported to lack BRAF mutations, implying BRAF V600 melanomas are primarily sporadic (castellani2023brafmutationsin pages 2-4).

Burden statistics. Global Cancer Observatory (GCO) 2022: 331,647 new melanoma cases and 58,645 deaths (imani2024theevolutionof pages 1-2). A 2025 meta-analysis summary cites similar 2022 global estimates and projects ~510,000 new cases and ~96,000 deaths by 2040 (belloni2025treatmentrelatedadverseevents pages 1-2).

Survival statistics (general melanoma). Europe-wide 5-year survival is cited at ~85% (mohr2025updateonthe pages 2-2). A melanoma screening review reports 5-year survival in most European countries is 80–90% with country-level variation (czerw2024newscreeningmethods pages 2-3).

10. Diagnostics

Histopathology/biopsy. The SEOM-GEM guideline states suspicious lesions should be confirmed by excisional biopsy and staged per AJCC (marquezrodas2024seomgemclinicalguidelines pages 1-2).

IHC markers for melanoma. Recommended markers include S-100, SOX10, HMB-45, PRAME, MART-1 (marquezrodas2024seomgemclinicalguidelines pages 1-2).

Molecular testing for BRAF. SEOM-GEM: “Determination of BRAF V600 status is mandatory in patients with stage IV melanoma” (marquezrodas2024seomgemclinicalguidelines pages 1-2). In clinical trials and safety literature, BRAF V600 mutation detection has been performed using PCR-based assays, NGS, and Sanger sequencing (belloni2025treatmentrelatedadverseevents pages 7-8).

Liquid biopsy / circulating biomarkers. ctDNA (BRAF V600E) is described as prognostic and dynamic with treatment, and can detect emergent resistance mutations (NRAS, MAP2K1, AKT1, PIK3CA) (castellani2023brafmutationsin pages 17-18). Extracellular vesicle DNA from lymphatic drainage (exudative seroma) can detect BRAFV600E and was reported to correlate with relapse risk in stage III disease (garciasilva2019useofextracellular pages 1-2).

11. Outcome/Prognosis

Metastatic sequencing outcomes (SECOMBIT). 4-year OS differed by first-line sequencing: 46% (targeted→immunotherapy), 64% (immunotherapy→targeted), 59% (sandwich) (ascierto2024sequentialimmunotherapyand pages 1-2). Total PFS to second progression at 4 years was 29%, 55%, and 54% in Arms A/B/C, respectively (ascierto2024sequentialimmunotherapyand pages 1-2).

Brain-metastasis outcomes (SECOMBIT analysis). 60-month brain-metastases-free survival was 56% (targeted-first), 80% (immunotherapy-first; HR vs A 0.40), and 85% (sandwich; HR vs A 0.35) (ascierto2024sequencingofcheckpoint pages 1-2).

12. Treatment

12.1 Targeted therapy (BRAF/MEK inhibitors)

Approved combinations are widely used in advanced disease; guideline notes include vemurafenib+cobimetinib, dabrafenib+trametinib, and encorafenib+binimetinib (marquezrodas2024seomgemclinicalguidelines pages 4-5).

Adjuvant (stage III). SEOM-GEM notes COMBI-AD supports 1 year dabrafenib+trametinib as a standard adjuvant option for completely resected stage III BRAF-mutated melanoma (marquezrodas2024seomgemclinicalguidelines pages 4-5). In a large multicenter retrospective cohort (n=598), adjuvant dabrafenib+trametinib had longer RFS than adjuvant anti–PD-1 monotherapy: median RFS 51.0 vs 44.8 months; multivariable HR 0.58 (P=0.007); OS similar (multivariable HR 0.90) (bai2023dabrafenibplustrametinib pages 1-2).

MAXO suggestions (examples). - BRAF inhibitor therapy; MEK inhibitor therapy; combination targeted therapy (MAXO mapping not directly retrieved; recommended as action ontology entries).

12.2 Immunotherapy and sequencing (metastatic)

SECOMBIT provides prospective evidence supporting immunotherapy-first (ipilimumab+nivolumab) as preferred first-line sequencing for many patients with BRAF V600–mutant metastatic melanoma (ascierto2024sequentialimmunotherapyand pages 1-2). The NEJM Evidence analysis further supports immunotherapy-first or sandwich sequences for reducing brain metastasis risk (ascierto2024sequencingofcheckpoint pages 1-2).

12.3 Neoadjuvant (resectable stage III)

NeoTrio tested pembrolizumab alone vs addition of dabrafenib+trametinib sequentially or concurrently. - Abstract quote: “The pathological response rate was 55% (11/20; including six pathological complete responses (pCRs)) with pembrolizumab, 50% (10/20; three pCRs) with sequential therapy and 80% (16/20; ten pCRs) with concurrent therapy…” (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2). - 2-year outcomes: event-free survival 60%, 80%, 71% (pembro, sequential, concurrent) (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2). - Safety quote: “Treatment-related adverse events affected 75–100% of patients during neoadjuvant treatment, with seven early discontinuations (all in the concurrent arm).” (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2).

Visual evidence (NeoTrio survival curves). Kaplan–Meier curves and 12-/24-month landmark rates for EFS/RFS/OS are shown in Figure 2 (long2024neoadjuvantpembrolizumabdabrafenib media 7989da9e).

12.4 Adverse events (real-world relevance)

Pooled prevalence estimates: vemurafenib-associated arthralgia 44% and rash 39%; dabrafenib+trametinib-associated fatigue 47% and pyrexia 40% (belloni2025treatmentrelatedadverseevents pages 1-2).

13. Prevention

Primary prevention. UVR is the principal modifiable driver; a recent comprehensive photodamage review states UVR is the leading environmental factor and accounts for an estimated 60–70% of cutaneous melanoma cases (manganelli2025skinphotodamageand pages 1-2).

Secondary prevention/high-risk surveillance. A systematic review of interventions to increase skin self-examination (SSE) in high-risk individuals found low-certainty evidence that interventions improve SSE practice; no evidence of effects on melanoma mortality was identified (gooley2025clinicaleffectivenessof pages 1-2). A 2024 management review emphasizes lifelong regular skin checks and considering total-body photography in patients with many nevi (dixon2024primarycutaneousmelanoma—management pages 1-2).

14. Other Species / Natural Disease

No robust, BRAF V600–specific naturally occurring veterinary melanoma evidence was retrieved in this run; thus, cross-species “natural disease” mapping is incomplete.

15. Model Organisms

Murine models. A widely used inducible genetic model combines melanocyte-specific BRAFV600E with PTEN loss (Tyr::CreERT2; BrafV600E; Ptenfl/fl) for preclinical testing of targeted therapy and immunotherapy combinations (hooijkaas2012targetingbrafv600ein pages 1-2).

Zebrafish models. Zebrafish are used to model melanoma initiation, metastasis, remission, and relapse due to conserved pathways and optical accessibility (frantz2020fromtankto pages 1-3). Transgenic BRAFV600E zebrafish models show that BRAFV600E alone can generate nevi and needs cooperating lesions for melanoma, paralleling human biology (frantz2020fromtankto pages 1-3).

Expert opinions / guideline perspectives (authoritative sources)

  • SEOM-GEM guideline positions BRAF testing as mandatory in stage IV and provides evidence-based recommendations for adjuvant targeted therapy and systemic therapy selection, with explicit levels of evidence/grades (marquezrodas2024seomgemclinicalguidelines pages 1-2, marquezrodas2024seomgemclinicalguidelines pages 4-5).
  • SECOMBIT authors conclude their long-term data “confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma” (ascierto2024sequentialimmunotherapyand pages 1-2).

Notes on evidence gaps in this run

  • MONDO identifier and ICD-11 codes were not located in the retrieved texts.
  • Many primary statements here are supported by DOIs/URLs rather than PMIDs because PubMed identifiers were not present in the retrieved excerpts.
Study Setting Population Interventions / arms Key efficacy results with numbers Key safety notes Publication date URL / DOI
SECOMBIT (Nature Communications 2024) Metastatic, first-line sequencing Untreated metastatic BRAFV600-mutant melanoma; 209 randomized, 206 treated across 37 sites in 9 countries (ascierto2024sequentialimmunotherapyand pages 1-2) Arm A: encorafenib + binimetinib until PD → ipilimumab + nivolumab; Arm B: ipilimumab + nivolumab until PD → encorafenib + binimetinib; Arm C: 8-week encorafenib + binimetinib induction → ipilimumab + nivolumab (“sandwich”) (ascierto2024sequentialimmunotherapyand pages 1-2) 4-year OS: 46% Arm A, 64% Arm B, 59% Arm C; 4-year TPFS: 29% Arm A, 55% Arm B, 54% Arm C. Authors concluded long-term benefit with first-line immunotherapy and exploratory biomarker trends for deleterious JAK mutations / low baseline IFNγ (ascierto2024sequentialimmunotherapyand pages 1-2, ascierto2024sequentialimmunotherapyand pages 4-6) During treatment, deaths: 13 in Arm A, 11 in Arm B, 4 in Arm C; adverse events led to treatment discontinuation in 11, 10, and 11 patients in Arms A, B, and C, respectively (ascierto2024sequentialimmunotherapyand pages 1-2) 2 Jan 2024 https://doi.org/10.1038/s41467-023-44475-6
SECOMBIT brain metastases-free survival analysis (NEJM Evidence 2024) Metastatic sequencing; brain metastasis prevention analysis Unresectable metastatic BRAFV600-mutant melanoma without brain metastases at baseline; 206 treated patients from SECOMBIT (ascierto2024sequencingofcheckpoint pages 1-2, ascierto2024sequencingofcheckpoint pages 2-3) Same 3-arm SECOMBIT design: targeted→immuno, immuno→targeted, and short targeted induction→immuno→targeted (ascierto2024sequencingofcheckpoint pages 1-2) New brain metastases: 23/69 Arm A, 11/69 Arm B, 9/68 Arm C. 60-month BMFS: 56% Arm A, 80% Arm B (HR vs A 0.40, 95% CI 0.23–0.58), 85% Arm C (HR vs A 0.35, 95% CI 0.16–0.76), favoring immunotherapy-first or sandwich approaches (ascierto2024sequencingofcheckpoint pages 1-2) Safety details not the focus of this report excerpt; sequencing effect on brain metastasis-free survival was the principal finding (ascierto2024sequencingofcheckpoint pages 1-2) 24 Sep 2024 https://doi.org/10.1056/evidoa2400087
NeoTrio (Nature Medicine 2024) Neoadjuvant / perioperative Resectable stage III BRAFV600-mutant melanoma; 60 patients randomized, 42% female; 82% V600E, 15% V600K, 3% V600R (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2) Pembrolizumab alone (n=20); sequential dabrafenib + trametinib then pembrolizumab (n=20); concurrent pembrolizumab + dabrafenib + trametinib (n=20), followed by surgery and adjuvant therapy (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2) Pathological response: 55% (11/20; 6 pCRs) pembrolizumab, 50% (10/20; 3 pCRs) sequential, 80% (16/20; 10 pCRs) concurrent. 24-month EFS: 60%, 80%, 71%; 24-month RFS: 66%, 80%, 75%; 24-month OS: 76%, 89%, 95% for pembrolizumab, sequential, and concurrent arms, respectively (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2, long2024neoadjuvantpembrolizumabdabrafenib pages 5-7, long2024neoadjuvantpembrolizumabdabrafenib media 7989da9e) Neoadjuvant TRAEs affected 75–100% of patients; 9/60 discontinued early due to neoadjuvant TRAEs, including 8/20 in the concurrent arm; seven early discontinuations during neoadjuvant treatment were all in concurrent arm in abstract summary (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2) 21 Jun 2024 https://doi.org/10.1038/s41591-024-03077-5
Real-world adjuvant D/T vs anti–PD-1 (eClinicalMedicine 2023) Adjuvant Resected stage III BRAF V600-mutant melanoma; 598 patients from 15 melanoma centers; D/T n=393, PD-1 n=205 (bai2023dabrafenibplustrametinib pages 1-2) Adjuvant dabrafenib + trametinib vs adjuvant anti–PD-1 monotherapy after definitive surgery (bai2023dabrafenibplustrametinib pages 1-2) Median follow-up 33 months. Median RFS: 51.0 months for D/T vs 44.8 months for PD-1; univariate HR 0.66 (95% CI 0.50–0.87; P=0.003), multivariate HR 0.58 (95% CI 0.39–0.86; P=0.007). OS comparable: multivariate HR 0.90 (95% CI 0.48–1.70; P=0.75). Among recurrences, distant metastases were more frequent with D/T (72% vs 58%) (bai2023dabrafenibplustrametinib pages 1-2, bai2023dabrafenibplustrametinib pages 5-6) D/T had higher incidence of treatment modification due to adverse events but fewer persistent adverse events than PD-1 (bai2023dabrafenibplustrametinib pages 1-2) Nov 2023 https://doi.org/10.1016/j.eclinm.2023.102290
BRAF/MEK inhibitor AE meta-analysis (Cancers 2025) Treatment safety across advanced/unresectable disease Adults with BRAF-mutant cutaneous melanoma, predominantly unresectable locally advanced or metastatic stage IIIC–IV across included trials (belloni2025treatmentrelatedadverseevents pages 7-8, belloni2025treatmentrelatedadverseevents pages 1-2) Review/meta-analysis of approved BRAF/MEK regimens; pooled analysis feasible for vemurafenib monotherapy and dabrafenib + trametinib (belloni2025treatmentrelatedadverseevents pages 1-2) Safety-focused study; no pooled OS/PFS efficacy endpoint reported in excerpt. Quantitative toxicity findings: vemurafenib musculoskeletal/connective-tissue disorders 24% (95% CI 6–41%), arthralgia 44% (95% CI 29–59%), rash 39% (95% CI 22–56%); dabrafenib + trametinib constitutional toxicities 25% (95% CI 14–37%), fatigue 47% (95% CI 38–56%), pyrexia 40% (95% CI 26–54%) (belloni2025treatmentrelatedadverseevents pages 1-2) Grade ≥3 cutaneous AEs with vemurafenib included squamous cell carcinoma and keratoacanthoma; regimen-specific toxicity profiles emphasized for personalized care (belloni2025treatmentrelatedadverseevents pages 1-2) Sep 2025 https://doi.org/10.3390/cancers17193152

Table: This table summarizes major 2023–2024 clinical evidence and one recent safety meta-analysis relevant to BRAF V600-mutant melanoma across metastatic, adjuvant, and neoadjuvant settings. It highlights study design, populations, key efficacy numbers, and the main safety signals useful for comparative interpretation.

References

  1. (marquezrodas2024seomgemclinicalguidelines pages 1-2): Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F. Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, and Alfonso Berrocal Jaime. Seom-gem clinical guidelines for cutaneous melanoma (2023). Clinical & Translational Oncology, 26:2841-2855, May 2024. URL: https://doi.org/10.1007/s12094-024-03497-2, doi:10.1007/s12094-024-03497-2. This article has 8 citations and is from a peer-reviewed journal.

  2. (castellani2023brafmutationsin pages 1-2): Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, and Claudio Tabolacci. Braf mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers, 15:4026, Aug 2023. URL: https://doi.org/10.3390/cancers15164026, doi:10.3390/cancers15164026. This article has 206 citations.

  3. (NCT02036086 chunk 2): Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases. Sunnybrook Health Sciences Centre. 2015. ClinicalTrials.gov Identifier: NCT02036086

  4. (hoejberg2016trendsinmelanoma pages 1-3): Lise Hoejberg, Dorte Gad, Niels Gyldenkerne, and Lars Bastholt. Trends in melanoma in the elderly in denmark, 1980–2012. Acta Oncologica, 55:52-58, Jan 2016. URL: https://doi.org/10.3109/0284186x.2015.1114677, doi:10.3109/0284186x.2015.1114677. This article has 14 citations and is from a peer-reviewed journal.

  5. (ghate2018healthcareresourceutilization pages 1-5): Sameer R. Ghate, Raluca Ionescu-Ittu, Rebecca Burne, Briana Ndife, François Laliberté, Antonio Nakasato, and Mei Sheng Duh. Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy. Current Medical Research and Opinion, 34:2169-2176, Aug 2018. URL: https://doi.org/10.1080/03007995.2018.1501351, doi:10.1080/03007995.2018.1501351. This article has 10 citations and is from a peer-reviewed journal.

  6. (dixon2024primarycutaneousmelanoma—management pages 1-2): Anthony Joseph Dixon, Michael Sladden, Christos C. Zouboulis, Catalin M. Popescu, Alexander Nirenberg, Howard K. Steinman, Caterina Longo, Zoe Lee Dixon, and Joseph Meirion Thomas. Primary cutaneous melanoma—management in 2024. Journal of Clinical Medicine, 13:1607, Mar 2024. URL: https://doi.org/10.3390/jcm13061607, doi:10.3390/jcm13061607. This article has 26 citations.

  7. (dummer2026exploratoryanalysisof pages 20-21): Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J. Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Paolo A. Ascierto, Craig B. Davis, Khyati Shah, Phineas Hamilton, Alessandra di Pietro, and Keith Flaherty. Exploratory analysis of biomarkers and treatment outcomes from the columbus study in braf v600e/k–mutant advanced or metastatic melanoma. Clinical Cancer Research, 32:1266-1276, Jan 2026. URL: https://doi.org/10.1158/1078-0432.ccr-25-3262, doi:10.1158/1078-0432.ccr-25-3262. This article has 0 citations and is from a highest quality peer-reviewed journal.

  8. (belloni2025treatmentrelatedadverseevents pages 1-2): Silvia Belloni, Rosamaria Virgili, Rosario Caruso, Cristina Arrigoni, Arianna Magon, Gennaro Rocco, and Maddalena De Maria. Treatment-related adverse events in individuals with braf-mutant cutaneous melanoma treated with braf and mek inhibitors: a systematic review and meta-analysis. Cancers, 17:3152, Sep 2025. URL: https://doi.org/10.3390/cancers17193152, doi:10.3390/cancers17193152. This article has 0 citations.

  9. (frantz2020fromtankto pages 1-3): William Tyler Frantz and Craig J Ceol. From tank to treatment: modeling melanoma in zebrafish. Cells, 9:1289, May 2020. URL: https://doi.org/10.3390/cells9051289, doi:10.3390/cells9051289. This article has 41 citations.

  10. (castellani2023brafmutationsin pages 2-4): Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, and Claudio Tabolacci. Braf mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers, 15:4026, Aug 2023. URL: https://doi.org/10.3390/cancers15164026, doi:10.3390/cancers15164026. This article has 206 citations.

  11. (mohr2025updateonthe pages 2-3): Peter Mohr, Inès Nakouri, Sylvie Pfersch, François Denjean, and Celeste Lebbé. Update on the treatment of brafmut metastatic melanoma and future perspectives. JEADV Clinical Practice, Oct 2025. URL: https://doi.org/10.1002/jvc2.544, doi:10.1002/jvc2.544. This article has 0 citations and is from a peer-reviewed journal.

  12. (bai2023dabrafenibplustrametinib pages 1-2): Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty. Dabrafenib plus trametinib versus anti-pd-1 monotherapy as adjuvant therapy in braf v600-mutant stage iii melanoma after definitive surgery: a multicenter, retrospective cohort study. eClinicalMedicine, 65:102290, Nov 2023. URL: https://doi.org/10.1016/j.eclinm.2023.102290, doi:10.1016/j.eclinm.2023.102290. This article has 32 citations and is from a peer-reviewed journal.

  13. (ascierto2024sequentialimmunotherapyand pages 1-2): Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, and Giuseppe Palmieri. Sequential immunotherapy and targeted therapy for metastatic braf v600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase ii secombit trial. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44475-6, doi:10.1038/s41467-023-44475-6. This article has 99 citations and is from a highest quality peer-reviewed journal.

  14. (florent2023brafv600mutatedmetastatic pages 1-2): Laetitia Florent, Charles Saby, Florian Slimano, and Hamid Morjani. Braf v600-mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge. Cancers, 15:2607, May 2023. URL: https://doi.org/10.3390/cancers15092607, doi:10.3390/cancers15092607. This article has 44 citations.

  15. (mohr2025updateonthe pages 2-2): Peter Mohr, Inès Nakouri, Sylvie Pfersch, François Denjean, and Celeste Lebbé. Update on the treatment of brafmut metastatic melanoma and future perspectives. JEADV Clinical Practice, Oct 2025. URL: https://doi.org/10.1002/jvc2.544, doi:10.1002/jvc2.544. This article has 0 citations and is from a peer-reviewed journal.

  16. (pelosi2024brafmutantmelanomasbiology pages 4-5): Elvira Pelosi, Germana Castelli, and Ugo Testa. Braf-mutant melanomas: biology and therapy. Current Oncology, 31:7711-7737, Dec 2024. URL: https://doi.org/10.3390/curroncol31120568, doi:10.3390/curroncol31120568. This article has 12 citations.

  17. (pelosi2024brafmutantmelanomasbiology pages 2-4): Elvira Pelosi, Germana Castelli, and Ugo Testa. Braf-mutant melanomas: biology and therapy. Current Oncology, 31:7711-7737, Dec 2024. URL: https://doi.org/10.3390/curroncol31120568, doi:10.3390/curroncol31120568. This article has 12 citations.

  18. (manganelli2025skinphotodamageand pages 1-2): Michele Manganelli, Giorgio Stabile, Camila Scharf, Antonio Podo Brunetti, Giovanni Paolino, Roberta Giuffrida, Gianmarco Diego Bigotto, Giuseppe Damiano, Santo Raffaele Mercuri, Fabio Sallustio, Eleonora Mangano, Roberta Bordoni, Paola De Nardi, Gabriella Guida, Caterina Foti, Giuseppe Argenziano, Caterina Longo, Giovanni Pellacani, Nathalie Rizzo, Vincenzo Russo, Stefania Guida, and Franco Rongioletti. Skin photodamage and melanomagenesis: a comprehensive review. Cancers, 17:1784, May 2025. URL: https://doi.org/10.3390/cancers17111784, doi:10.3390/cancers17111784. This article has 15 citations.

  19. (castellani2023brafmutationsin pages 4-6): Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, and Claudio Tabolacci. Braf mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers, 15:4026, Aug 2023. URL: https://doi.org/10.3390/cancers15164026, doi:10.3390/cancers15164026. This article has 206 citations.

  20. (pelosi2024brafmutantmelanomasbiology pages 1-2): Elvira Pelosi, Germana Castelli, and Ugo Testa. Braf-mutant melanomas: biology and therapy. Current Oncology, 31:7711-7737, Dec 2024. URL: https://doi.org/10.3390/curroncol31120568, doi:10.3390/curroncol31120568. This article has 12 citations.

  21. (ascierto2024sequencingofcheckpoint pages 1-2): Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Pietro Quaglino, Céleste Lebbé, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzalez-Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Giuseppe Palmieri, Reinhard Dummer, and Vanna Chiarion Sileni. Sequencing of checkpoint or braf/mek inhibitors on brain metastases in melanoma. NEJM evidence, 3 10:EVIDoa2400087, Sep 2024. URL: https://doi.org/10.1056/evidoa2400087, doi:10.1056/evidoa2400087. This article has 12 citations and is from a peer-reviewed journal.

  22. (finke2024brafv600emetastaticmelanoma pages 1-2): Carsten Finke and Peter Mohr. Brafv600e metastatic melanoma journey: a perspective from a patient and his oncologist. Advances in Therapy, 41:2576-2585, May 2024. URL: https://doi.org/10.1007/s12325-024-02883-0, doi:10.1007/s12325-024-02883-0. This article has 2 citations and is from a peer-reviewed journal.

  23. (shang2026brafinhibitorresistance pages 2-3): Yan Shang, Tingping Cao, Junyan Li, Juan Li, Lingnan Zhang, Qiqi Ma, Lanyan Feng, and Hailong Zhao. Braf inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. Molecular Biomedicine, Mar 2026. URL: https://doi.org/10.1186/s43556-026-00425-4, doi:10.1186/s43556-026-00425-4. This article has 0 citations and is from a peer-reviewed journal.

  24. (cosci2025molecularbasisof pages 2-4): Ilaria Cosci, Valentina Salizzato, Paolo Del Fiore, Jacopo Pigozzo, Valentina Guarneri, Simone Mocellin, Alberto Ferlin, Sara Mathlouthi, Luisa Piccin, and Mariangela Garofalo. Molecular basis of braf inhibitor resistance in melanoma: a systematic review. Pharmaceuticals, 18:1235, Aug 2025. URL: https://doi.org/10.3390/ph18081235, doi:10.3390/ph18081235. This article has 10 citations.

  25. (castellani2023brafmutationsin pages 11-12): Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, and Claudio Tabolacci. Braf mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers, 15:4026, Aug 2023. URL: https://doi.org/10.3390/cancers15164026, doi:10.3390/cancers15164026. This article has 206 citations.

  26. (saeed2024cutaneousoncologystrategies pages 1-2): Wajeeha Saeed, Esha Shahbaz, Quratulain Maqsood, Shinawar Waseem Ali, and Muhammada Mahnoor. Cutaneous oncology: strategies for melanoma prevention, diagnosis, and therapy. Cancer Control : Journal of the Moffitt Cancer Center, Jan 2024. URL: https://doi.org/10.1177/10732748241274978, doi:10.1177/10732748241274978. This article has 21 citations.

  27. (garciasilva2019useofextracellular pages 1-2): Susana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, Alberto Hernández-Barranco, Pilar Ximénez-Embún, Laura Nogués, Marina S. Mazariegos, Kay Brinkmann, Ana Amor López, Lisa Meyer, Carlos Rodríguez, Carmen García-Martín, Jasminka Boskovic, Rocío Letón, Cristina Montero, Mercedes Robledo, Laura Santambrogio, Mary Sue Brady, Anna Szumera-Ciećkiewicz, Iwona Kalinowska, Johan Skog, Mikkel Noerholm, Javier Muñoz, Pablo L. Ortiz-Romero, Yolanda Ruano, José L. Rodríguez-Peralto, Piotr Rutkowski, and Héctor Peinado. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and brafv600e mutation. The Journal of Experimental Medicine, 216:1061-1070, Apr 2019. URL: https://doi.org/10.1084/jem.20181522, doi:10.1084/jem.20181522. This article has 148 citations.

  28. (imani2024theevolutionof pages 1-2): Saber Imani, Ghazaal Roozitalab, Mahdieh Emadi, Atefeh Moradi, Payam Behzadi, and Parham Jabbarzadeh Kaboli. The evolution of braf-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies. Frontiers in Oncology, Nov 2024. URL: https://doi.org/10.3389/fonc.2024.1504142, doi:10.3389/fonc.2024.1504142. This article has 45 citations.

  29. (czerw2024newscreeningmethods pages 2-3): Aleksandra Czerw, Andrzej Deptała, Olga Partyka, Monika Pajewska, Anna Badowska-Kozakiewicz, Michał Budzik, Katarzyna Sygit, Zygmunt Kopczyński, Piotr Czarnywojtek, Elżbieta Cipora, Magdalena Konieczny, Tomasz Banaś, Elżbieta Grochans, Szymon Grochans, Anna Maria Cybulska, Daria Schneider-Matyka, Ewa Bandurska, Weronika Ciećko, Jarosław Drobnik, Piotr Pobrotyn, Urszula Grata-Borkowska, Joanna Furtak-Pobrotyn, Aleksandra Sierocka, Michał Marczak, and Remigiusz Kozlowski. New screening methods in melanoma. Cancers, 16:4186, Dec 2024. URL: https://doi.org/10.3390/cancers16244186, doi:10.3390/cancers16244186. This article has 0 citations.

  30. (belloni2025treatmentrelatedadverseevents pages 7-8): Silvia Belloni, Rosamaria Virgili, Rosario Caruso, Cristina Arrigoni, Arianna Magon, Gennaro Rocco, and Maddalena De Maria. Treatment-related adverse events in individuals with braf-mutant cutaneous melanoma treated with braf and mek inhibitors: a systematic review and meta-analysis. Cancers, 17:3152, Sep 2025. URL: https://doi.org/10.3390/cancers17193152, doi:10.3390/cancers17193152. This article has 0 citations.

  31. (castellani2023brafmutationsin pages 17-18): Giorgia Castellani, Mariachiara Buccarelli, Maria Beatrice Arasi, Stefania Rossi, Maria Elena Pisanu, Maria Bellenghi, Carla Lintas, and Claudio Tabolacci. Braf mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers. Cancers, 15:4026, Aug 2023. URL: https://doi.org/10.3390/cancers15164026, doi:10.3390/cancers15164026. This article has 206 citations.

  32. (marquezrodas2024seomgemclinicalguidelines pages 4-5): Iván Márquez-Rodas, Eva Muñoz Couselo, Juan F. Rodríguez Moreno, Ana Mª Arance Fernández, Miguel Ángel Berciano Guerrero, Begoña Campos Balea, Luis de la Cruz Merino, Enrique Espinosa Arranz, Almudena García Castaño, and Alfonso Berrocal Jaime. Seom-gem clinical guidelines for cutaneous melanoma (2023). Clinical & Translational Oncology, 26:2841-2855, May 2024. URL: https://doi.org/10.1007/s12094-024-03497-2, doi:10.1007/s12094-024-03497-2. This article has 8 citations and is from a peer-reviewed journal.

  33. (long2024neoadjuvantpembrolizumabdabrafenib pages 1-2): Georgina V. Long, Matteo S. Carlino, George Au-Yeung, Andrew J. Spillane, Kerwin F. Shannon, David E. Gyorki, Edward Hsiao, Rony Kapoor, Jake R. Thompson, Iris Batula, Julie Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P. M. Saw, Thomas E. Pennington, Serigne N. Lo, Richard A. Scolyer, and Alexander M. Menzies. Neoadjuvant pembrolizumab, dabrafenib and trametinib in brafv600-mutant resectable melanoma: the randomized phase 2 neotrio trial. Nature Medicine, 30:2540-2548, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03077-5, doi:10.1038/s41591-024-03077-5. This article has 38 citations and is from a highest quality peer-reviewed journal.

  34. (long2024neoadjuvantpembrolizumabdabrafenib media 7989da9e): Georgina V. Long, Matteo S. Carlino, George Au-Yeung, Andrew J. Spillane, Kerwin F. Shannon, David E. Gyorki, Edward Hsiao, Rony Kapoor, Jake R. Thompson, Iris Batula, Julie Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P. M. Saw, Thomas E. Pennington, Serigne N. Lo, Richard A. Scolyer, and Alexander M. Menzies. Neoadjuvant pembrolizumab, dabrafenib and trametinib in brafv600-mutant resectable melanoma: the randomized phase 2 neotrio trial. Nature Medicine, 30:2540-2548, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03077-5, doi:10.1038/s41591-024-03077-5. This article has 38 citations and is from a highest quality peer-reviewed journal.

  35. (gooley2025clinicaleffectivenessof pages 1-2): Kieran Gooley, Deonna Ackermann, Ellie Medcalf, and Katy Bell. Clinical effectiveness of interventions to increase self‐surveillance in people at high risk of melanoma: a systematic review. JEADV Clinical Practice, Jun 2025. URL: https://doi.org/10.1002/jvc2.70108, doi:10.1002/jvc2.70108. This article has 3 citations and is from a peer-reviewed journal.

  36. (hooijkaas2012targetingbrafv600ein pages 1-2): Anna I. Hooijkaas, Jules Gadiot, Martin van der Valk, Wolter J. Mooi, and Christian U. Blank. Targeting brafv600e in an inducible murine model of melanoma. The American journal of pathology, 181 3:785-94, Sep 2012. URL: https://doi.org/10.1016/j.ajpath.2012.06.002, doi:10.1016/j.ajpath.2012.06.002. This article has 90 citations.

  37. (ascierto2024sequentialimmunotherapyand pages 4-6): Paolo A. Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbe, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, and Giuseppe Palmieri. Sequential immunotherapy and targeted therapy for metastatic braf v600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase ii secombit trial. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44475-6, doi:10.1038/s41467-023-44475-6. This article has 99 citations and is from a highest quality peer-reviewed journal.

  38. (ascierto2024sequencingofcheckpoint pages 2-3): Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Pietro Quaglino, Céleste Lebbé, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzalez-Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero, Antonio M. Grimaldi, Diana Giannarelli, Giuseppe Palmieri, Reinhard Dummer, and Vanna Chiarion Sileni. Sequencing of checkpoint or braf/mek inhibitors on brain metastases in melanoma. NEJM evidence, 3 10:EVIDoa2400087, Sep 2024. URL: https://doi.org/10.1056/evidoa2400087, doi:10.1056/evidoa2400087. This article has 12 citations and is from a peer-reviewed journal.

  39. (long2024neoadjuvantpembrolizumabdabrafenib pages 5-7): Georgina V. Long, Matteo S. Carlino, George Au-Yeung, Andrew J. Spillane, Kerwin F. Shannon, David E. Gyorki, Edward Hsiao, Rony Kapoor, Jake R. Thompson, Iris Batula, Julie Howle, Sydney Ch’ng, Maria Gonzalez, Robyn P. M. Saw, Thomas E. Pennington, Serigne N. Lo, Richard A. Scolyer, and Alexander M. Menzies. Neoadjuvant pembrolizumab, dabrafenib and trametinib in brafv600-mutant resectable melanoma: the randomized phase 2 neotrio trial. Nature Medicine, 30:2540-2548, Jun 2024. URL: https://doi.org/10.1038/s41591-024-03077-5, doi:10.1038/s41591-024-03077-5. This article has 38 citations and is from a highest quality peer-reviewed journal.

  40. (bai2023dabrafenibplustrametinib pages 5-6): Xue Bai, Ahmed Shaheen, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina, Juliane A. Czapla, Aleigha R. Lawless, Eleonora Bongiovanni, Umberto Santaniello, Helena Zappi, Dominika Dulak, Andrew Williamson, Rebecca Lee, Avinash Gupta, Caili Li, Lu Si, Martina Ubaldi, Naoya Yamazaki, Dai Ogata, Rebecca Johnson, Benjamin C. Park, Seungyeon Jung, Gabriele Madonna, Juliane Hochherz, Yoshiyasu Umeda, Yasuhiro Nakamura, Christoffer Gebhardt, Lucia Festino, Mariaelena Capone, Paolo Antonio Ascierto, Douglas B. Johnson, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies, Kenjiro Namikawa, Mario Mandala, Jun Guo, Paul Lorigan, Yana G. Najjar, Andrew Haydon, Pietro Quaglino, Genevieve M. Boland, Ryan J. Sullivan, Andrew J.S. Furness, Ruth Plummer, and Keith T. Flaherty. Dabrafenib plus trametinib versus anti-pd-1 monotherapy as adjuvant therapy in braf v600-mutant stage iii melanoma after definitive surgery: a multicenter, retrospective cohort study. eClinicalMedicine, 65:102290, Nov 2023. URL: https://doi.org/10.1016/j.eclinm.2023.102290, doi:10.1016/j.eclinm.2023.102290. This article has 32 citations and is from a peer-reviewed journal.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 60 citations 2026-05-05T23:45:23.079662Z

1. Disease Information

Overview

BRAF V600 Mutant Melanoma is a molecularly defined subtype of cutaneous malignant melanoma characterized by somatic gain-of-function mutations at codon 600 of the BRAF gene (7q34). BRAF is a serine/threonine protein kinase in the MAPK/ERK signaling pathway that regulates cell proliferation, differentiation, and survival. The V600E mutation (a thymine-to-adenine transversion resulting in valine-to-glutamic acid substitution) accounts for the vast majority of cases and produces a constitutively active kinase domain that drives oncogenesis independent of upstream RAS activation (PMID: 39961465).

As noted by Paluncic et al., "40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E)" (PMID: 33801689). Among BRAF V600 mutations, the distribution is: V600E (79%), V600K (12%), V600R (5%), and V600M (4%) (PMID: 22536370).

Key Identifiers

Identifier Value
OMIM #164757 (Melanoma, cutaneous malignant); BRAF gene: *164757
ICD-10 C43 (Malignant melanoma of skin)
ICD-11 2D40-2D4Z (Melanoma of skin)
MeSH D008545 (Melanoma); C562395 (BRAF gene mutation)
MONDO MONDO:0005012 (melanoma)
HGNC HGNC:1097 (BRAF)
ClinVar Variation ID 376069 (BRAF V600E)
COSMIC COSV56056643 (BRAF p.V600E)

Synonyms and Alternative Names

  • BRAF V600E-mutated melanoma
  • BRAF-mutant melanoma
  • BRAF V600E/K melanoma
  • V600E-positive melanoma
  • Melanoma with activating BRAF mutation
  • MAPK-driven melanoma (when referring to mechanism)

Information Sources

This report is derived from aggregated disease-level resources including published clinical trials, genomic databases (COSMIC, ClinVar, TCGA), epidemiological registries (SEER, GLOBOCAN), and primary research literature (PubMed). Individual patient-level data is referenced from landmark clinical trials (COMBI-d, COLUMBUS, IMspire150) and real-world registries (ADMIRE, Dutch Melanoma Treatment Registry).

2. Etiology

Disease Causal Factors

BRAF V600 Mutant Melanoma arises through a multi-step oncogenic process involving both genetic and environmental factors:

Somatic genetic origin: The BRAF V600E mutation is a somatic (acquired) missense mutation arising in melanocytes. It is not inherited in the germline but occurs during the lifetime of the individual. The mutation results in constitutive activation of the BRAF kinase, which "results in a constitutively active kinase domain, leading to dysregulated downstream signaling independent of extracellular stimuli. This sustained activation promotes cell proliferation, survival, angiogenesis, and hallmark features of the cancer cells" (PMID: 39961465).

UV radiation as initiating factor: Ultraviolet radiation, particularly UVB (280–320 nm), is the primary environmental mutagen. UV radiation induces DNA damage in melanocytes, including the characteristic thymine dimer mutations. The BRAF V600E mutation itself (T1799A) is not a classic UV signature mutation (C>T at dipyrimidine sites), suggesting that UV may act indirectly through mutagenic stress, oxidative damage, or proliferative stimulation rather than direct photoproduct formation (PMID: 27221301).

Risk Factors

Genetic Risk Factors

  • BRAF V600E somatic mutation (driver): Present in 40–50% of cutaneous melanomas; constitutive MAPK activation
  • CDKN2A (p16INK4A) germline mutations: High-penetrance melanoma susceptibility gene; loss of cell cycle control at G1/S checkpoint
  • CDK4 mutations: Rare high-penetrance susceptibility gene
  • MC1R variants: Red hair color variants (R151C, R160W, D294H) associated with fair skin, poor tanning, and increased melanoma risk
  • PTEN loss: Frequently co-occurs with BRAF V600E (seen in ~40% of BRAF-mutant melanomas); synergistic oncogenic effect through PI3K/AKT pathway activation
  • TERT promoter mutations: Common co-occurring mutations promoting telomere maintenance
  • Co-occurring NRAS mutations: Mutually exclusive with BRAF V600E in primary tumors but may arise as resistance mutations

Environmental Risk Factors

Associations with BRAF mutation were characterized by Colombino et al.: "Associations with BRAF mutation were as follows: male gender [odds ratio (OR) = 2.4], younger age (OR = 2.7), superficial spreading (OR = 15.6) and nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)" (PMID: 25357015).

  • Intermittent UV exposure: Strong association (OR = 4.6) vs. chronic sun exposure
  • Indoor tanning: "BRAF V600E genotype was more prevalent in ever-users than in nonusers (42.9% vs 28.3%, two-sided P = .04) and higher in ever-users who initiated indoor tanning prior to age 25 years compared with age 25 years or older (62.2% vs 31.1%, two-sided P = .003)" (PMID: 30923800)
  • Sunburn history: Blistering sunburns associated with increased absolute mutation incidence (1.67 vs 1.16 mutations/patient, P = 0.028) (PMID: 32445930)
  • Fair skin phenotype: Fitzpatrick skin types I and II
  • High nevus count: Multiple dysplastic nevi as a risk factor
  • Male sex: OR = 2.4 for BRAF mutation
  • Younger age: OR = 2.7 for BRAF mutation (median age younger than BRAF wild-type)
  • Residence in high-UV areas: OR = 5.54 (95% CI 1.19–25.8) for residing in states with UV index ≥7 vs ≤5 at age 30 (PMID: 25048604)

Possible Non-Traditional Risk Factors

  • Hexavalent chromium exposure: Epidemiological data suggest heavy metal exposure may contribute; UV accounts for only 40–50% of attributable melanoma risk (PMID: 21253789)

Protective Factors

Genetic Protective Factors

  • MC1R wild-type: Associated with darker skin pigmentation and improved UV protection
  • Certain HLA genotypes: Associated with improved immune surveillance
  • High MITF expression: May maintain melanocyte differentiation programs

Environmental Protective Factors

  • Sun protection behaviors: Use of sunscreen (high SPF), protective clothing, avoidance of midday sun
  • Avoidance of indoor tanning, especially before age 25
  • Regular skin self-examination and professional screening
  • Dietary factors: Some evidence for vitamin D, antioxidants, though data are inconclusive

Gene–Environment Interactions

The BRAF V600E mutation appears to arise preferentially in the context of intermittent rather than chronic UV exposure, explaining its association with trunk melanomas (usually covered, intermittently exposed) in younger patients. The B-RafV600E mutation was detected in 85% of trunk melanomas in indoor workers versus 47% in outdoor workers (P = 0.03), indicating that "the B-RafV600E mutation detected in melanoma is not associated with a chronic exposure to the sun" but rather with recreational/intermittent exposure (PMID: 24424406). MC1R variants may further modify risk by impairing DNA repair capacity in the setting of UV exposure, creating a synergistic effect.

3. Phenotypes

Clinical Signs and Symptoms

Phenotype HPO Term Type Onset Severity Frequency Progression
Cutaneous melanocytic lesion (primary tumor) HP:0012056 (Cutaneous melanoma) Physical sign Adult (median 50s) Variable 100% Progressive if untreated
Asymmetric pigmented lesion HP:0200040 (Irregular hyperpigmentation) Physical sign Adult Mild–moderate Very frequent Progressive
Ulceration of primary lesion HP:0200041 (Skin ulcer) Physical sign Later stages Moderate–severe ~40–50% Progressive
Lymphadenopathy (regional metastasis) HP:0002716 (Lymphadenopathy) Clinical sign Stage III Moderate–severe Variable Progressive
Elevated serum LDH HP:0025435 (Increased circulating lactate dehydrogenase) Laboratory abnormality Advanced disease Indicator of high tumor burden ~37.5% at presentation Progressive
Fatigue HP:0012378 (Fatigue) Symptom Advanced disease Moderate–severe Frequent Progressive
Brain metastases (neurological symptoms) HP:0002888 (Brain neoplasm) Clinical sign Stage IV Severe ~32% of advanced cases Progressive
Hepatomegaly/liver metastases HP:0002240 (Hepatomegaly) Clinical sign Stage IV Severe Common Progressive
Pulmonary symptoms (lung metastases) HP:0002094 (Dyspnea) Symptom Stage IV Moderate–severe Common Progressive

Phenotype Characteristics Specific to BRAF V600 Mutant Melanoma

  • Age of onset: Younger than BRAF wild-type melanomas (OR = 2.7 for younger age) (PMID: 25357015)
  • Histological subtypes: Strongly associated with superficial spreading melanoma (OR = 15.6) and nodular melanoma (OR = 9.5)
  • Anatomical predilection: Trunk localization (OR = 6.3); less common on chronically sun-damaged skin (head/neck)
  • Mitotic activity: BRAF-mutated melanomas tend to be more mitotically active (PMID: 28424234)

Quality of Life Impact

Advanced BRAF V600 mutant melanoma significantly impacts quality of life through: - Physical symptoms of metastatic disease (pain, fatigue, neurological deficits from brain metastases) - Psychological distress from cancer diagnosis and treatment - Treatment-related side effects (pyrexia, arthralgia, skin toxicities from targeted therapy; immune-related adverse events from immunotherapy) - Functional impairment from disease complications

4. Genetic/Molecular Information

Causal Gene

BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) - HGNC ID: HGNC:1097 - NCBI Gene ID: 673 - OMIM: 164757 - Chromosomal location: 7q34 - UniProt: P15056 - Protein*: 766 amino acid serine/threonine kinase

Pathogenic Variants

Variant HGVS Notation Type Frequency Among V600 Allele Frequency (gnomAD) Origin Functional Consequence
V600E c.1799T>A (p.Val600Glu) Missense ~79% Somatic (not in germline databases) Somatic Gain of function; ~500-fold kinase activation
V600K c.1798_1799delGTinsAA (p.Val600Lys) Dinucleotide substitution ~12% Somatic Somatic Gain of function; constitutive kinase activation
V600R c.1798_1799delGTinsAG (p.Val600Arg) Dinucleotide substitution ~5% Somatic Somatic Gain of function
V600M c.1798G>A (p.Val600Met) Missense ~4% Somatic Somatic Gain of function
V600D c.1799_1800delTGinsAT (p.Val600Asp) Dinucleotide substitution Rare Somatic Somatic Gain of function

Source for variant distribution: "Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively" (PMID: 22536370).

Variant classification: All V600 mutations listed are classified as pathogenic (oncogenic driver) in ClinVar and COSMIC.

Somatic origin: These mutations are somatic, not germline. They are acquired during the individual's lifetime and are not present in the germline. COSMIC reports BRAF V600E as one of the most frequently mutated positions across all human cancers.

V600K demographics: V600K was detected in 23% of men older than 60, compared with 6% in women older than 60 and 2% in both sexes younger than 60 (P < .001), suggesting age and sex-specific patterns (PMID: 25456393).

Modifier Genes and Co-occurring Alterations

  • PTEN (10q23.31): Loss-of-function mutations or deletions co-occur in ~40% of BRAF V600E melanomas; activates PI3K/AKT pathway synergistically
  • CDKN2A (9p21.3): Homozygous deletion or inactivating mutation; loss of p16INK4A and p14ARF tumor suppressors
  • TP53 (17p13.1): Mutations less common in melanoma than other cancers but contribute to genomic instability
  • TERT promoter (5p15.33): Activating promoter mutations (C228T, C250T) frequent in BRAF-mutant melanoma
  • APC, CTNNB1: Occasional Wnt pathway alterations
  • NF1: Generally mutually exclusive with BRAF V600E but defines a separate molecular subtype

Epigenetic Information

  • Global DNA hypomethylation: Common in melanoma progression
  • Promoter hypermethylation: Silencing of tumor suppressors (RASSF1A, MGMT, DAPK)
  • BRAF V600E suppresses MITF: Leading to reduced melanocyte differentiation gene expression
  • Histone modifications: H3K27me3 changes associated with melanoma progression; EZH2 overexpression
  • CpG island methylator phenotype (CIMP): Associated with BRAF V600E in colorectal cancer; less well-characterized in melanoma

Chromosomal Abnormalities

  • Chromosome 7 gain: Frequently observed (location of BRAF); may increase BRAF dosage
  • Chromosome 10 loss: Contains PTEN; frequently deleted in BRAF-mutant melanomas
  • 9p21 deletion: Loss of CDKN2A locus
  • 6p gain: Common in melanoma
  • Mutant allele-specific imbalance (MASI): BRAF V600E MASI predominantly present in distant organ metastases (79% vs 27% in LN metastases vs 13% in primary tumors, P < .001) (PMID: 25456393)

5. Environmental Information

Environmental Factors

  • Ultraviolet radiation (UVA/UVB): The primary environmental carcinogen. UVB (280–320 nm) directly damages DNA; UVA (320–400 nm) induces oxidative damage. "About 95% of ultraviolet A (UVA) and 5% of UVB reach the Earth's surface" (PMID: 27221301)
  • CHEBI term: CHEBI:27460 (ultraviolet radiation — as a physical agent)
  • Hexavalent chromium: Proposed as a co-carcinogen; "UV light exposure accounts for only 40-50% of the attributable risk for cutaneous melanoma" (PMID: 21253789)

Lifestyle Factors

  • Indoor tanning: Strong risk factor; BRAF V600E prevalence of 62.2% in users who started before age 25 (PMID: 30923800)
  • Intermittent recreational sun exposure: Stronger association with BRAF mutation than chronic occupational exposure (OR = 4.6) (PMID: 25357015)
  • Sunburn history: Particularly childhood/adolescent blistering sunburns

Infectious Agents

  • Beta-genus HPV: May accelerate keratinocyte carcinogenesis during BRAF inhibitor therapy. β-HPV-17, HPV-38, HPV-111 were most frequently isolated in BRAFi-associated cutaneous squamous cell carcinomas (PMID: 25724524). This is relevant to treatment-related secondary malignancies rather than melanoma etiology itself.

6. Mechanism / Pathophysiology

Molecular Pathways

RAS–RAF–MEK–ERK (MAPK) Pathway (Primary)

The central oncogenic pathway in BRAF V600 melanoma. The BRAF V600E mutation produces a constitutively active kinase that signals as a monomer (unlike wild-type BRAF which requires dimerization). This leads to sustained MEK1/2 and ERK1/2 phosphorylation, driving:

  1. Cell proliferation: Transcriptional activation of cyclin D1, c-Myc, and other cell cycle promoters
  2. Survival: Suppression of pro-apoptotic BIM, BAD; upregulation of anti-apoptotic MCL-1, BCL-2
  3. Angiogenesis: Upregulation of VEGF and other pro-angiogenic factors
  4. Invasion and metastasis: Induction of matrix metalloproteinases (MMPs), epithelial-mesenchymal transition (EMT)

KEGG pathway: hsa04010 (MAPK signaling pathway) Reactome: R-HSA-5673001 (RAF/MAP kinase cascade)

PI3K/AKT/mTOR Pathway (Cooperating)

Frequently co-activated through PTEN loss. Synergizes with MAPK pathway to promote survival and metabolic adaptation. Important in resistance to BRAF inhibitors.

KEGG pathway: hsa04151 (PI3K-Akt signaling pathway)

Wnt/β-Catenin Pathway

Contributes to melanoma cell survival, immune evasion, and resistance to immunotherapy.

Cellular Processes

  • Uncontrolled proliferation: GO:0008283 (cell population proliferation)
  • Evasion of apoptosis: GO:0043066 (negative regulation of apoptotic process)
  • Metabolic reprogramming: GO:0006096 (glycolytic process); GO:0006119 (oxidative phosphorylation)
  • Angiogenesis: GO:0001525 (angiogenesis)
  • Immune evasion: GO:0002837 (negative regulation of immune response to tumor cell)
  • Cell migration/invasion: GO:0016477 (cell migration)

Protein Dysfunction

The BRAF V600E mutation resides in the activation segment of the kinase domain. The valine-to-glutamic acid substitution mimics the phosphorylation that normally activates the kinase, locking it in a constitutively active conformation. Wild-type BRAF kinase activity is ~70-fold lower than V600E mutant BRAF. The mutant signals as a monomer, unlike wild-type BRAF which requires RAS-dependent dimerization, explaining its RAS-independence.

UniProt: P15056 (BRAF_HUMAN) PDB: 1UWH (BRAF kinase domain), 3OG7 (BRAF V600E with vemurafenib)

Metabolic Changes

BRAF V600E drives a profound metabolic reprogramming:

"BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation" (PMID: 38972133).

The mechanistic basis: "BRAF(V600E) acts to suppress expression of the melanocyte master regulator microphthalmia-associated transcription factor (MITF) and the mitochondrial biogenesis coactivator PGC1α. Accordingly, therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming in melanoma cells and elevates OXPHOS through increased MITF-PGC1α levels" (PMID: 24610826).

This metabolic plasticity is a key resistance mechanism: upon BRAF inhibitor treatment, cells shift from glycolysis to oxidative phosphorylation (OXPHOS), with increased glutamine dependence and mitochondrial biogenesis. NSAIDs (diclofenac, lumiracoxib) can counteract this metabolic reprogramming and synergize with BRAF inhibitors by preventing the shift to OXPHOS (PMID: 30481565).

KEGG pathways: hsa00010 (Glycolysis/Gluconeogenesis); hsa00190 (Oxidative phosphorylation) HMDB: HMDB0000190 (L-Lactic acid — elevated in glycolytic tumors)

Immune System Involvement

BRAF V600E melanoma has a complex relationship with the immune system:

  • Tumor immune evasion: BRAF V600E upregulates immunosuppressive cytokines (IL-6, IL-10, VEGF) and downregulates MHC class I expression
  • PD-L1 expression: Upregulated in BRAF-mutant tumors, particularly upon BRAF inhibitor treatment
  • T cell infiltration: BRAF inhibition increases intratumoral CD8+ T cell infiltrate, suggesting immune activation (PMID: 24903021)
  • B cell involvement: Tumor-infiltrating B cells may serve as a predictive biomarker; higher B cell signatures associated with better outcomes on dabrafenib + trametinib (PMID: 34108180)
  • Immune-related adverse events as biomarker: Vitiligo, panniculitis, and other immune-related skin lesions during BRAF/MEK inhibitor treatment predict better outcomes (HR 0.19 for disease progression, P = 0.043) (PMID: 30939167); immune AEs associated with mPFS of 42.8 months vs 6.1 months without (HR 0.22, P = 0.002) (PMID: 30096703)

Tissue Damage Mechanisms

  • Local invasion: Vertical growth phase melanoma invades dermis and subcutaneous tissue
  • Lymphatic spread: Regional lymph node metastasis (stage III)
  • Hematogenous spread: Distant metastasis to lung, liver, brain, bone, skin (stage IV)
  • Melanoma-induced stromal remodeling: Melanoma exosomes reprogram stromal fibroblasts via exosomal miR-155 and miR-210, increasing aerobic glycolysis and extracellular acidification to create a pre-metastatic niche (PMID: 30150674)

Resistance Mechanisms

Acquired resistance to BRAF inhibitors is multifactorial:

"Acquired resistance to vemurafenib associated with reactivation of MAPK signaling as observed by elevated ERK1/2 phosphorylation levels in progressive lesions and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations" (PMID: 23569304).

Key resistance mechanisms include: 1. MAPK reactivation: Secondary NRAS mutations, MEK mutations, BRAF amplification, BRAF splice variants 2. Alternative pathway activation: PI3K/AKT, focal adhesion kinase (FAK) signaling 3. Metabolic reprogramming: Shift from glycolysis to OXPHOS 4. Phenotype switching: Transition from proliferative to invasive state 5. Microenvironment remodeling: Stromal cell-mediated resistance 6. COP1/DET1 mutations: Acquired after BRAF inhibitor treatment, affecting oncogenic transcriptome regulation (PMID: 40643496)

Molecular Profiling

Transcriptomics

  • BRAF V600E melanomas show distinct gene expression profiles with upregulation of MAPK target genes
  • Three tumor subgroups identified by gene expression clustering including an "immune" subgroup associated with improved survival (PMID: 41537702)
  • High IFNγ gene signature scores and cytolytic scores predict better response to encorafenib + binimetinib

Proteomics

  • Plasma proteome alterations detectable by MAPKi treatment (PMID: 34246984)
  • p-ERK immunohistochemistry serves as a readout of MAPK pathway activity

Liquid Biopsy / Circulating Tumor DNA

  • BRAF V600 ctDNA detectable by droplet digital PCR (ddPCR) in 93% of pretreatment samples
  • Baseline ctDNA positivity rate was 13% in stage III resected disease
  • ctDNA detection associated with worse recurrence-free survival (median 3.71 vs 24.41 months in placebo; HR 2.91, P < 0.0001) (PMID: 40250457)
  • On-treatment ctDNA clearance predicts improved outcomes across all treatment arms (PMID: 33587894; PMID: 41537702)

7. Anatomical Structures Affected

Organ Level

Primary organ: Skin (UBERON:0002097) - Cutaneous melanoma arises from epidermal melanocytes

Secondary organ involvement (sites of metastasis): - Lymph nodes (UBERON:0000029): Regional spread; sentinel lymph node most commonly affected - Lung (UBERON:0002048): Most common site of distant metastasis - Liver (UBERON:0002107): Second most common distant site - Brain (UBERON:0000955): ~32% of advanced cases have brain metastases at presentation (PMID: 34243078) - Bone (UBERON:0002481): Common distant metastatic site - Distant skin/subcutaneous tissue: Transit metastases

Body systems: Integumentary (primary), lymphatic, respiratory, hepatobiliary, nervous, musculoskeletal

Tissue and Cell Level

  • Melanocytes (CL:0000148): Cell of origin; neural crest-derived pigment cells in the basal epidermis
  • Keratinocytes (CL:0000312): Surrounding cells affected by paracrine signaling
  • Tumor-infiltrating lymphocytes: CD8+ T cells (CL:0000625), CD4+ T cells (CL:0000624), B cells (CL:0000236), regulatory T cells (CL:0000815)
  • Dermal fibroblasts (CL:0000057): Reprogrammed by melanoma exosomes
  • Endothelial cells (CL:0000115): Involved in tumor angiogenesis

Subcellular Level

  • Cytoplasm/cytosol (GO:0005829): Location of BRAF kinase activity and MAPK cascade
  • Cell membrane (GO:0005886): RAS activation, receptor tyrosine kinase signaling
  • Nucleus (GO:0005634): ERK-mediated transcriptional activation
  • Mitochondria (GO:0005739): Site of metabolic reprogramming (OXPHOS vs glycolysis)
  • Lysosomes (GO:0005764): Autophagy involvement in resistance

Localization

  • Primary site predilection: Trunk (UBERON:0002100) — OR = 6.3 for BRAF-mutant melanoma
  • Intermittently sun-exposed skin: Back, chest, abdomen
  • Less common in chronically sun-damaged sites: Head and neck (more associated with NRAS or NF1 mutations)
  • Lateralization: Unilateral; no specific laterality preference

8. Temporal Development

Onset

  • Typical age: Adult-onset, but younger than BRAF wild-type melanomas. Median age ~50–55 years for BRAF-mutant vs ~60–65 for wild-type. BRAF V600K patients tend to be older (>60 years)
  • Onset pattern: Insidious; typically progresses from a pre-existing nevus or arises de novo over months to years
  • Precursor lesions: Dysplastic nevi; BRAF V600E is found in ~80% of benign nevi (necessary but not sufficient for melanoma development)

Progression

AJCC Staging System (8th Edition):

Stage Description 5-Year Survival
0 (in situ) Confined to epidermis ~99%
I Thin melanoma (≤2 mm), no ulceration ~92–97%
II Thicker primary or ulcerated ~53–81%
III Regional lymph node or in-transit metastasis ~40–78% (improved to ~75% with adjuvant therapy)
IV Distant metastasis ~15–20% historically; ~50% with modern therapies
  • Progression rate: Variable; can be rapid (weeks–months for nodular melanoma) or indolent (years for superficial spreading)
  • Disease course: Progressive without treatment; potential for long-term remission with modern therapy
  • Duration: Chronic; lifelong surveillance required even after complete response

Patterns

  • Remission patterns: Treatment-induced remissions with BRAF/MEK inhibitors (median duration ~9–12 months); more durable remissions with immunotherapy (years)
  • Critical periods:
  • Early intervention after diagnosis significantly impacts survival
  • Window of opportunity for adjuvant therapy in resected stage III disease
  • First 3 years post-treatment: highest risk of recurrence with targeted therapy
  • Brain metastasis development: critical period requiring prompt intervention

9. Inheritance and Population

Epidemiology

Global melanoma burden (all subtypes): "A worldwide total of 325,000 new melanoma cases (174,000 males, 151,000 females) and 57,000 deaths (32,000 males, 25,000 females) was estimated for 2020" (PMID: 35353115). "Cutaneous melanoma causes 55,500 deaths annually" and accounts for 90% of skin cancer mortality (PMID: 30238891).

BRAF V600 mutant melanoma specifically: - Represents ~40–50% of cutaneous melanomas - Estimated ~130,000–162,500 new BRAF V600 mutant melanoma cases worldwide annually - Highest absolute numbers in populations with high melanoma incidence (Australia/New Zealand, Europe, North America)

Incidence by region (all melanoma): - Australia/New Zealand: Males 42/100,000; Females 31/100,000 (highest worldwide) - Western Europe: ~19/100,000 - North America: Males 18, Females 14/100,000 - Africa and Asia: <1/100,000

Genetic Etiology Considerations

  • Not a Mendelian inherited disease: BRAF V600 mutations are somatic
  • Inheritance pattern: Multifactorial/polygenic predisposition to melanoma; the specific BRAF mutation is acquired somatically
  • Familial melanoma syndromes: CDKN2A, CDK4, BAP1, POT1 germline mutations increase melanoma susceptibility but do not guarantee BRAF mutation status
  • Penetrance: Not applicable to the somatic BRAF mutation itself; familial melanoma gene penetrance varies (CDKN2A: 58–92% by age 80)

Population Demographics

  • Sex ratio: Male predominance (OR = 2.4 for BRAF mutation); male:female ~1.15:1 for melanoma overall
  • Ethnic/racial distribution: Predominantly affects fair-skinned populations of European descent; rare in African, Asian, and Hispanic populations
  • Age distribution: BRAF-mutant melanomas are younger at diagnosis than BRAF wild-type; V600K specifically more common in older males (>60 years)
  • Geographic distribution: Higher prevalence in regions with high UV exposure and fair-skinned populations (Australia, Northern Europe, North America)
  • BRAF mutation rate varies by melanoma subtype: ~50% cutaneous, ~10–15% acral/mucosal (PMID: 37016119)

10. Diagnostics

Clinical Tests

Laboratory Tests

  • Serum lactate dehydrogenase (LDH): Prognostic biomarker; elevated LDH indicates high tumor burden and is associated with shorter PFS and OS
  • Complete blood count: Baseline and monitoring; neutrophil/lymphocyte ratio has prognostic value
  • Liver function tests: Monitoring for hepatic metastases and drug hepatotoxicity
  • Renal function: Monitoring required due to nephrotoxicity of BRAF inhibitors, especially vemurafenib (PMID: 26182194)
  • Serum S100B: Tumor marker for melanoma staging and monitoring

Biomarkers

  • BRAF V600 mutation status: Essential companion diagnostic; determines eligibility for targeted therapy
  • Circulating tumor DNA (ctDNA): BRAF V600 ctDNA by ddPCR — prognostic and predictive biomarker; detectable in 93% of pretreatment metastatic samples (PMID: 33587894); ctDNA clearance at early timepoints predicts improved survival (PMID: 40250457)
  • PD-L1 expression: Relevant for immunotherapy decisions
  • Tumor mutational burden (TMB): Higher TMB associated with better response to combination targeted therapy (PMID: 41537702)
  • IFNγ gene signature: Immune microenvironment biomarker

Imaging

  • Dermoscopy: Initial evaluation of suspicious lesions
  • CT (chest/abdomen/pelvis): Staging for distant metastases
  • PET/CT: Whole-body staging, recommended from stage IIB/C
  • MRI brain: Mandatory for staging; brain metastases present in ~32% of advanced cases
  • Ultrasound: Regional lymph node assessment; recommended from stage IB

Biopsy/Pathology

  • Excisional biopsy: Gold standard for primary diagnosis; provides Breslow depth, mitotic rate, ulceration status
  • Histopathology: Superficial spreading and nodular subtypes most common in BRAF-mutant melanoma
  • Immunohistochemistry: Anti-BRAF V600E VE1 clone antibody — sensitivity 86.1%, specificity 96.9%, concordance with PCR 95.1% (PMID: 28424234)
  • Sentinel lymph node biopsy: Staging procedure for melanomas ≥0.8 mm with risk factors or ≥1.0 mm (PMID: 35623961)

Genetic Testing

Recommended Testing Approach

BRAF mutation testing is recommended for all patients with stage IIB/C or higher melanoma, and is mandatory before initiating BRAF/MEK inhibitor therapy (PMID: 39700658).

Testing Methods

Method Turnaround Sensitivity Clinical Use
cobas® 4800 BRAF V600 Mutation Test (companion diagnostic) 1–2 days High FDA-approved CDx for vemurafenib
Idylla BRAF Mutation Test 90 minutes 98.57% concordance with sequencing Rapid automated PCR-based testing (PMID: 26921540)
Pyrosequencing 1–3 days High; can distinguish V600E/K/R/D Reference method; lookup tables assist complex result interpretation (PMID: 24713734)
Next-generation sequencing (NGS) 1–3 weeks Very high Comprehensive profiling; detects co-mutations
Sanger sequencing 3–5 days Moderate (~20% mutant allele threshold) Less commonly used now
VE1 immunohistochemistry 1–2 days 86.1% sensitivity for V600E Cost-effective screening tool
Droplet digital PCR (ddPCR) 1–2 days Very high (ctDNA detection) Liquid biopsy monitoring

Quality assurance: French national EQA achieved false response rate of only 4.8% across 46 laboratories, with improvement from 22 to 12 days turnaround over 6 months (PMID: 24119386).

Clinical Criteria

  • AJCC 8th Edition staging: Standard staging system
  • Breslow depth: Most important histological prognostic factor
  • Ulceration status: Independent prognostic factor
  • Mitotic rate: Prognostic significance
  • BRAF V600 mutation status: Determines targeted therapy eligibility

Differential Diagnosis

  • BRAF wild-type melanoma (NRAS, NF1, or triple wild-type subtypes)
  • Atypical/dysplastic nevus
  • Spitz nevus (may harbor BRAF fusions but not typically V600E)
  • Blue nevus
  • Melanoma in situ
  • Pigmented basal cell carcinoma

11. Outcome/Prognosis

Survival and Mortality

Metastatic BRAF V600 mutant melanoma (with modern therapy):

Treatment Median PFS Median OS 3-Year OS 5-Year OS
Dabrafenib + Trametinib (COMBI-d) ~11 months ~25 months 44% ~34%
Dabrafenib monotherapy (COMBI-d control) ~8 months ~18 months 32% ~27%
Encorafenib + Binimetinib (COLUMBUS) ~15 months ~34 months — —
Real-world BRAFi+MEKi (ADMIRE) 9.2 months 22.6 months — —

Source: "3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively" (PMID: 28475671).

Real-world data: ORR 57.4% for combined BRAFi+MEKi vs 39.8% BRAFi monotherapy; median PFS 9.2 months; median OS 22.6 months for first-line combination (PMID: 34064013).

BRAF mutation level as prognostic factor: High BRAF V600 mutation level (>0.44) associated with worse PFS and OS on multivariate analysis (P = 0.02 for both) (PMID: 39508497).

Prognostic Factors

Favorable: - Normal LDH - ECOG PS 0 - <3 metastatic sites - No brain metastases - Immune-related adverse events during treatment (mPFS 42.8 vs 6.1 months; HR 0.22, P = 0.002) (PMID: 30096703) - ctDNA clearance on treatment - High tumor immune infiltration and TMB

Unfavorable: - Elevated LDH - ECOG PS ≥1 - ≥3 metastatic sites - Brain metastases (introduced as major prognostic factor in real-world setting) (PMID: 34243078) - High BRAF V600 mutation level - Detectable ctDNA at baseline and on treatment

Prognostic Biomarkers

  • ctDNA: Strongest blood-based prognostic biomarker; "Baseline ctDNA was more strongly associated with survival outcomes than IFNG gene expression or tumour mutational burden" (PMID: 40250457)
  • LDH: Standard serum biomarker
  • S100B: Serum protein biomarker
  • CD8+ TILs: Higher density associated with better outcomes
  • B cell signatures: Potential predictive biomarker for targeted therapy (PMID: 34108180)

12. Treatment

Pharmacotherapy

FDA-Approved Targeted Therapy Combinations

Combination Drug Class Mechanism Approval Year
Dabrafenib + Trametinib BRAFi + MEKi BRAF V600E/K kinase inhibition + MEK1/2 inhibition 2014
Vemurafenib + Cobimetinib BRAFi + MEKi BRAF V600E kinase inhibition + MEK1/2 inhibition 2015
Encorafenib + Binimetinib BRAFi + MEKi BRAF V600E/K kinase inhibition + MEK1/2 inhibition 2018

MAXO terms: MAXO:0001084 (targeted molecular therapy); MAXO:0000058 (pharmacotherapy)

CHEBI terms: Vemurafenib (CHEBI:63637), Dabrafenib (CHEBI:75045), Trametinib (CHEBI:75998), Encorafenib (CHEBI:145372), Binimetinib (CHEBI:145371), Cobimetinib (CHEBI:145373)

Acceptability and Safety

In a network meta-analysis: "the combination of dabrafenib and trametinib is the preferred combination therapy" for BRAF V600-mutant melanoma, with better acceptability than vemurafenib + cobimetinib (RR for any-grade AEs: 0.94; CrI: 0.89–0.98) (PMID: 35530323).

Common adverse events (vemurafenib): arthralgia (37%), alopecia (25%), hyperkeratosis (23%); most common grade 3/4: cutaneous SCC (8%) and keratoacanthoma (8%) (PMID: 28501764).

Nephrotoxicity: Vemurafenib more nephrotoxic than dabrafenib; 132 cases of AKI reported with vemurafenib vs 13 with dabrafenib; predominantly tubular interstitial injury (PMID: 26182194).

Phototoxicity: Vemurafenib causes clinical photosensitivity (PMID: 24154489).

Immunotherapy

Agent Drug Class Mechanism Use in BRAF+
Nivolumab Anti-PD-1 PD-1 checkpoint blockade First or second-line
Pembrolizumab Anti-PD-1 PD-1 checkpoint blockade First or second-line
Ipilimumab Anti-CTLA-4 CTLA-4 checkpoint blockade Combination with anti-PD-1
Nivolumab + Ipilimumab Anti-PD-1 + Anti-CTLA-4 Dual checkpoint blockade First-line for aggressive disease
Atezolizumab + Vemurafenib + Cobimetinib Anti-PD-L1 + BRAFi + MEKi Triplet combination First-line (IMspire150)

MAXO terms: MAXO:0001085 (immune checkpoint inhibitor therapy)

Treatment Sequencing

European guidelines recommend: "For first-line treatment particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy" (PMID: 35623961).

Adjuvant Therapy

For resected stage III disease: - Dabrafenib + Trametinib: Approved adjuvant; 3-year RFS ~60% in COMBI-AD - Anti-PD-1 (nivolumab, pembrolizumab): Alternative adjuvant option regardless of BRAF status - Real-world data from China: D+T significantly superior to observation (P = 0.002) and potentially superior to anti-PD-1 monotherapy (P = 0.032) for RFS in BRAF-mutant stage III melanoma (PMID: 37016119)

Brain Metastases

Encorafenib + binimetinib achieves brain metastasis response rate >60% (PMID: 40503961). Real-world data shows median PFS of 5.5 months and OS of 11.9 months for BRAF V600-mutant melanoma with brain metastases (PMID: 40411977). Stereotactic radiosurgery combined with immunotherapy achieves the highest OS rates in brain metastases; BRAF mutation appears to be a favorable prognostic factor (PMID: 30739835).

Surgical Interventions

  • Wide local excision: Primary treatment; 1–2 cm margins based on Breslow depth
  • Sentinel lymph node biopsy: Staging procedure for ≥0.8 mm with risk factors
  • Complete lymph node dissection: For sentinel node-positive disease (increasingly replaced by adjuvant systemic therapy)
  • Metastasectomy: For oligometastatic disease amenable to complete resection

MAXO terms: MAXO:0000004 (surgical procedure); MAXO:0000011 (excision)

Experimental Therapies and Novel Approaches

  • PHI-501: Dual RAF/DDR1/2 inhibitor overcomes MAPK resistance (PMID: 41935307)
  • Avutometinib (RAF-MEK clamp) + FAK inhibitors: Overcomes resistance to BRAFi+MEKi and immunotherapy (PMID: 40020669)
  • Metabolic targeting: NSAIDs (diclofenac, lumiracoxib) + BRAF inhibitors delay resistance (PMID: 30481565)
  • DCA (dichloroacetate) + elesclomol: Targeting metabolic reprogramming, effective even in vemurafenib-resistant cells (PMID: 22865452)
  • Gene-edited stem cell therapy: Allogeneic twin stem cell system for brain metastatic melanoma (PMID: 37256936)

Chemotherapy

Weekly carboplatin + paclitaxel remains a palliative option after immunotherapy failure: median PFS 3.25 months, OS 7.69 months (PMID: 39354418).

13. Prevention

Primary Prevention

  • UV radiation avoidance: Limiting sun exposure, especially during peak hours (10 AM – 4 PM)
  • Sunscreen use: Broad-spectrum SPF 30+ recommended
  • Protective clothing: Hats, long sleeves, UV-protective fabrics
  • Avoidance of indoor tanning: Especially before age 25 (62.2% BRAF V600E prevalence in early initiators vs 31.1%, P = .003) (PMID: 30923800)
  • Education: USPSTF recommends counseling on UV exposure minimization, especially for patients aged 6 months to 24 years (PMID: 39418569)
  • Public health campaigns: Beach-based campaigns can identify high-risk individuals; one campaign found 8.1% suspicious skin cancer lesions and 2.9% possible melanomas among 407 beachgoers (PMID: 25069660)

MAXO terms: MAXO:0000118 (sun protection counseling); MAXO:0000002 (preventive care)

Secondary Prevention (Screening and Early Detection)

  • Skin self-examination: ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) and "ugly duckling" sign
  • Dermoscopy: Non-invasive tool enhancing clinical diagnosis; superior to naked-eye examination (PMID: 20806172)
  • Total body photography and digital dermoscopy: For high-risk patients to detect early changes
  • Confocal reflectance microscopy: Improves clinical diagnosis in special cases (PMID: 39700658)
  • Risk stratification: Identifying individuals with multiple nevi, family history, fair skin for targeted screening

Tertiary Prevention

  • Adjuvant therapy: Dabrafenib + trametinib or anti-PD-1 for resected stage III disease to prevent recurrence
  • Surveillance protocols: Stage-based follow-up with imaging and clinical examination
  • ctDNA monitoring: Emerging tool for minimal residual disease detection; patients with favorable ctDNA kinetics (durable undetectable) have markedly better outcomes (PMID: 40250457)

Genetic Counseling

  • For familial melanoma kindreds (CDKN2A, CDK4, BAP1 mutations)
  • BRAF V600E itself is somatic and does not require genetic counseling for family members
  • Identification of mole-prone phenotype in adolescents may facilitate early intervention (PMID: 28593303)

14. Other Species / Natural Disease

Taxonomy

BRAF mutations and melanoma occur across species:

Species NCBI Taxon ID BRAF Gene Melanoma Occurrence
Homo sapiens 9606 BRAF (Gene ID: 673) Primary disease
Mus musculus 10090 Braf (Gene ID: 109880) Engineered models
Danio rerio (zebrafish) 7955 braf (Gene ID: 403065) Engineered models
Canis lupus familiaris (dog) 9615 BRAF (Gene ID: 475526) Naturally occurring oral melanoma
Equus caballus (horse) 9796 BRAF Naturally occurring melanoma (grey horses)

Natural Disease in Animals

  • Dogs: Oral and cutaneous melanoma occurs naturally; BRAF mutations are rare but reported. Canine melanoma serves as a comparative oncology model
  • Horses: Grey horses develop melanoma with high frequency (>80% of grey horses >15 years); pathogenesis involves STX17 duplication rather than BRAF mutations
  • Fish: Xiphophorus (swordtail-platyfish) hybrids develop melanoma driven by xmrk oncogene, not BRAF

Comparative Biology

  • The RAS-RAF-MEK-ERK pathway is highly conserved across vertebrates
  • BRAF V600E can drive melanocyte transformation in zebrafish, demonstrating evolutionary conservation of the oncogenic mechanism
  • Zebrafish BRAF V600E melanomas "show an overall low mutation burden, which has a strong, inverse association with the number of initiating germline drivers" (PMID: 24148783)

15. Model Organisms

Mouse Models

  • BRAF(V600E)/Pten(−/−) syngeneic tumor graft model: Immunocompetent mouse model used to study BRAF inhibition and immunotherapy combination. "BRAF inhibition leads to a significant increase in the intratumoral CD8(+) T-cell density and cytokine production, similar to the effects of BRAF inhibition in patients" (PMID: 24903021)
  • ESC-GEMM platform: Rapid melanoma modeling system incorporating 12 clinically relevant genotypes from combinations of LSL-Braf(V600E) and other driver alleles (PMID: 31744817)
  • BrafCA/+; Tyr-CreERT2; Ptenfl/fl: Conditional BRAF V600E activation with PTEN deletion in melanocytes; develops melanoma with ~100% penetrance
  • Global pannexin 1 deletion model: Combined with BRAF/Pten melanoma; increased tumor-infiltrating lymphocytes (PMID: 38327091)
  • Syngeneic models: Enable immunotherapy studies; BP (BRAF V600E/PTEN−/−) model widely used

Zebrafish Models

  • Tg(mitfa:BRAF(V600E)); p53(−/−): Develops melanoma from nevi over months; relatively low mutation burden
  • Allows visualization of melanoma development in vivo
  • "Melanomas present with variable onset and pathology, implicating additional somatic mutations in a multi-hit tumorigenic process" (PMID: 24148783)
  • Recurrent amplification of protein kinase A pathway in cooperation with BRAF(V600E) and p53−/−

Cell Line Models

  • A375: Human melanoma cell line, BRAF V600E mutant; most widely used in vitro model
  • SK-MEL-28: Human melanoma cell line, BRAF V600E
  • SK-MEL-3: Used for xenograft studies of drug resistance (PMID: 41935307)
  • WM266-4, Colo829: Additional BRAF V600E lines
  • Drug-resistant derivatives generated for resistance mechanism studies

Model Limitations

  • Mouse models may not fully recapitulate human tumor microenvironment complexity
  • Syngeneic models use murine tumors that may differ in antigen presentation
  • Zebrafish lack certain mammalian immune cell populations
  • Cell lines may diverge from primary tumor biology after prolonged culture
  • Patient-derived xenografts (PDX) better represent heterogeneity but require immunodeficient hosts

CNS Tumor Models

  • Challenges in modeling heterogeneous BRAF-mutant CNS neoplasms; pediatric cancer model development lags behind adult (PMID: 37920169)

Key Findings (Evidence Summary)

Finding 1: BRAF V600E Is the Dominant Oncogenic Mutation in ~40–50% of Cutaneous Melanomas

BRAF V600E is the most frequent oncogenic BRAF mutation in melanoma, present in 40–50% of all cutaneous melanomas. Among BRAF V600 mutations specifically, V600E accounts for ~79%, V600K for ~12%, V600R for ~5%, and V600M for ~4%. The V600E substitution results in a constitutively active kinase domain with ~500-fold increased activity, leading to MAPK/ERK pathway hyperactivation independent of extracellular stimuli, driving cell proliferation, survival, angiogenesis, and other hallmark cancer features.

Key citations: - "As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E)" — PMID: 33801689 - "V600E mutation results in a constitutively active kinase domain, leading to dysregulated downstream signaling independent of extracellular stimuli" — PMID: 39961465 - "Among BRAF V600 mutations, 79%, 12%, 5%, and 4% were V600E, V600K, V600R, and V600M, respectively" — PMID: 22536370

Finding 2: BRAF V600 Melanoma Is Associated with Younger Age, Intermittent Sun Exposure, and Trunk Location

BRAF mutations are significantly associated with distinct clinicopathological features: male gender (OR = 2.4), younger age (OR = 2.7), superficial spreading melanoma (OR = 15.6), nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6). Indoor tanning users, especially those initiating before age 25, had dramatically higher BRAF V600E prevalence (62.2% vs 31.1%, P = .003).

Key citations: - "Associations with BRAF mutation were as follows: male gender [OR = 2.4], younger age (OR = 2.7), superficial spreading (OR = 15.6) and nodular melanoma (OR = 9.5), trunk localization (OR = 6.3), and intermittent sun exposure (OR = 4.6)" — PMID: 25357015 - "BRAF V600E genotype was more prevalent in ever-users than in nonusers (42.9% vs 28.3%, P = .04)" — PMID: 30923800

Finding 3: BRAF+MEK Inhibitor Combination Achieves ~60% ORR but Resistance Develops Within 6–12 Months

The combination of BRAF and MEK inhibitors achieves high initial response rates (~57–70% ORR) but acquired resistance typically develops within 6–12 months. Long-term data from COMBI-d showed 3-year PFS of 22% and 3-year OS of 44% with dabrafenib + trametinib. Resistance mechanisms involve MAPK reactivation through secondary NRAS Q61 mutations, MEK1 mutations (Q56P, E203K), BRAF amplification, and alternative pathway activation.

Key citations: - "3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively" — PMID: 28475671 - "Acquired resistance to vemurafenib associated with reactivation of MAPK signaling...and the appearance of secondary NRAS(Q61) mutations or MEK1(Q56P) or MEK1(E203K) mutations" — PMID: 23569304

Finding 4: BRAF V600E Drives Metabolic Reprogramming; Inhibition Reverses the Shift

BRAF V600E mutations augment glycolysis (Warburg effect) to support macromolecular synthesis and proliferation, while suppressing MITF and PGC1α expression to reduce mitochondrial biogenesis. BRAF inhibition reverses this metabolic program, shifting cells toward oxidative phosphorylation — a metabolic plasticity that contributes to drug resistance.

Key citations: - "BRAF mutations augment glycolysis to promote macromolecular synthesis and proliferation" — PMID: 38972133 - "BRAF(V600E) acts to suppress expression of MITF and PGC1α. Therapeutic inhibition of BRAF(V600E) reverses metabolic reprogramming and elevates OXPHOS through increased MITF-PGC1α levels" — PMID: 24610826

Finding 5: Global Melanoma Epidemiology

GLOBOCAN 2020 reported 325,000 new melanoma cases and 57,000 deaths worldwide, with highest incidence in Australia/New Zealand (males 42/100,000; females 31/100,000). BRAF V600 mutations represent 40–50% of these cutaneous melanomas.

Key citations: - "A worldwide total of 325,000 new melanoma cases (174,000 males, 151,000 females) and 57,000 deaths (32,000 males, 25,000 females) was estimated for 2020" — PMID: 35353115 - "Cutaneous melanoma causes 55,500 deaths annually" — PMID: 30238891

Mechanistic Model

The following causal chain describes the pathogenesis of BRAF V600 Mutant Melanoma:

UV Radiation (intermittent) + Genetic Susceptibility (MC1R, CDKN2A, fair skin)
    │
    ▼
    Somatic BRAF V600E Mutation in Melanocyte
    │
    ▼
    Constitutive BRAF Kinase Activation (~500x)
    │
    ├──► MEK1/2 Phosphorylation ──► ERK1/2 Activation
    │         │
    │         ├──► Cell Proliferation (Cyclin D1, c-Myc)
    │         ├──► Survival (BIM suppression, MCL-1 upregulation)
    │         ├──► Angiogenesis (VEGF)
    │         └──► Immune Evasion (PD-L1, IL-10)
    │
    ├──► MITF/PGC1α Suppression ──► Metabolic Shift to Glycolysis
    │
    └──► Cooperating Events (PTEN loss, CDKN2A deletion, TERT activation)
        │
        ▼
 Melanoma Development & Progression
        │
    ┌───────────┴───────────┐
    ▼                       ▼
    Local Invasion              Metastasis
    (Breslow depth)        (LN → Distant organs)
                    │
                    ▼
            BRAF/MEK Inhibitor Therapy
                    │
        ┌───────────┴───────────┐
        ▼                       ▼
Initial Response           Acquired Resistance
(ORR ~60-70%)         (6-12 months median)
                            │
        ┌───────────────────┼───────────────────┐
        ▼                   ▼                   ▼
MAPK Reactivation    PI3K/AKT/FAK         Metabolic Shift
(NRAS, MEK mut,      Activation            (Glycolysis → OXPHOS)
 BRAF amplification)

Evidence Base

Reference PMID Key Contribution
Paluncic et al., 2021 33801689 BRAF V600E prevalence in 40-50% of melanomas
Colombino et al., 2014 25357015 Clinicopathological associations with BRAF mutation
Ascierto et al., 2012 22536370 V600 mutation subtype distribution
Long et al., 2017 28475671 COMBI-d long-term survival data
Shi et al., 2014 23569304 Vemurafenib resistance mechanisms
Haq et al., 2014 24610826 BRAF-driven metabolic reprogramming
Garbe et al., 2022 35623961 European treatment guidelines
Arnold et al., 2022 35353115 GLOBOCAN 2020 melanoma burden
Schadendorf et al., 2018 30238891 Comprehensive melanoma review
Bhatt et al., 2020 30923800 Indoor tanning and BRAF mutation
Haq, 2024 38972133 Metabolic changes in BRAF-mutant melanoma
Kumar et al., 2025 39961465 BRAF V600E structural and pathway analysis
Saiag et al., 2021 34243078 Real-world French study of D+T
Nassi et al., 2021 34064013 ADMIRE real-world registry
Lee et al., 2026 40250457 ctDNA as prognostic biomarker

Limitations and Knowledge Gaps

  1. Optimal treatment sequencing: The ideal order of targeted therapy vs. immunotherapy for BRAF V600-mutant melanoma remains unclear; no head-to-head randomized trial comparing first-line BRAF/MEKi vs. anti-PD-1 vs. combination immunotherapy has been completed.

  2. Resistance prediction: While mechanisms of acquired resistance are increasingly understood, reliable predictive biomarkers to identify patients who will develop resistance early vs. achieve durable responses are lacking.

  3. Rare BRAF variants: Treatment evidence for V600R, V600M, V600D, and non-V600 BRAF mutations is limited to retrospective analyses. ORR for rare V600 non-E/K mutations is 45% vs 26% for non-V600 mutations (P = 0.025) (PMID: 40850313).

  4. Ethnic diversity: Most clinical trial data come from predominantly Caucasian populations. BRAF mutation rates and responses may differ in Asian, African, and other populations. A Chinese study found mutation rates of ~50% in cutaneous but only 10–15% in acral/mucosal subtypes (PMID: 37016119).

  5. Long-term survivorship: As patients increasingly achieve long-term responses, the chronic effects of prolonged targeted therapy and immunotherapy on quality of life, organ function, and secondary malignancy risk require further study.

  6. Brain metastases: While intracranial activity has been demonstrated, brain metastases remain a major prognostic challenge and the optimal management (systemic therapy, SRS, WBRT, or combinations) requires further prospective data.

  7. Minimal residual disease: ctDNA-guided interventional strategies (escalating therapy in ctDNA-positive patients, de-escalating in ctDNA-negative) are promising but unvalidated in prospective trials.

  8. Gene-environment interactions: The precise molecular mechanism by which intermittent UV exposure preferentially induces BRAF V600E mutations (vs. other mutation patterns) is not fully elucidated.

Proposed Follow-up Experiments/Actions

  1. Prospective biomarker-guided clinical trials: Design trials using baseline ctDNA and immune gene signatures to stratify patients to optimal first-line therapy (targeted vs. immunotherapy vs. combination).

  2. ctDNA-guided adjuvant therapy: Test whether ctDNA-driven escalation/de-escalation strategies improve outcomes in resected stage III BRAF-mutant melanoma.

  3. Novel combination strategies: Evaluate PHI-501 (pan-RAF/DDR inhibitor) and avutometinib + FAK inhibitor combinations in BRAF/MEK inhibitor-resistant patients.

  4. Metabolic vulnerability exploitation: Clinical trials combining BRAF/MEK inhibitors with metabolic inhibitors (e.g., OXPHOS inhibitors, glutaminase inhibitors) to prevent metabolic adaptation-based resistance.

  5. Rare BRAF variant registry: Continue global data collection through resources like the Heidelberg rare BRAF mutations database to establish evidence-based treatment guidelines for V600R, V600M, V600D, and non-V600 mutations.

  6. Single-cell and spatial transcriptomics: Apply advanced technologies to resistant tumors to understand the spatial organization of resistant clones and immune microenvironment changes.

  7. Diverse population studies: Conduct BRAF mutation screening and treatment outcome studies in underrepresented populations (African, Asian, Latin American) to ensure equitable access to precision medicine.

  8. Brain metastasis prevention: Investigate whether early use of brain-penetrant BRAF/MEK inhibitors (e.g., encorafenib) can prevent or delay brain metastasis development in high-risk patients.

Report generated: 2026-05-05 Based on analysis of 109 published papers and 5 confirmed findings Disease: BRAF V600 Mutant Melanoma (MONDO:0005012 subtype)